Methods and compositions for cosmetic applications
Patent Information
- Application Number
- PCT/US2024/027470
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-03
- Filing Date
- 2024-05-02
- Publication Date
- 2024-11-07
AI Technical Summary
There is a need for improved methods and compositions to deliver cosmetic agents below the skin surface for various cosmetic and pharmaceutical purposes, such as reducing wrinkles, where existing technologies are inadequate.
The development of lipid vesicle formulations that include anionic polymer materials like hyaluronic acid and peptides, stabilized by surfactants, which form a lipid bilayer encapsulating an oil-in-water emulsion, allowing for targeted delivery to specific skin layers like the epidermis or dermis.
These formulations enable effective delivery of cosmetic agents below the skin surface, enhancing skin appearance by providing volumization, support, and restoration of facial volume, while maintaining stability and efficacy.
Smart Images

Figure US2024027470_07112024_PF_FP_ABST
Abstract
Description
METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONSCROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 499,935, filed May 3, 2023, which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION
[0002] Certain cosmetic agents are desirably delivered below the surface of the skin. There exists a need for improved methods of delivery and compositions for such cosmetic agents for various cosmetic and pharmaceutical purposes, including the prevention, reduction, or elimination of wrinkles.SUMMARY OF THE INVENTION
[0003] The present invention relates to compositions for delivery of cosmetic agents. In some embodiments, the compositions are lipid vesicle formulations of cosmetic agents which allow the cosmetic agents to be delivered below the surface of the skin upon topical application. In some embodiments, the cosmetic agent comprises an anionic polymer material, such as hyaluronic acid, a peptide which is beneficial for the appearance of the skin, such as the skin of the lips, the face, around the eyes, or neck of a subject, or all of the above. In some embodiments, the cosmetic agents are delivered to a preferred or pre-selected layer of the skin or surrounding tissue, such as the epidermis, dermis, subcutaneous tissue, or muscle tissue.
[0004] In some aspects, the invention may be a lipid vesicle composition. In some embodiments, each vesicle may comprise a lipid bilayer comprising vesicle forming lipids and an oil-in-water emulsion entrapped in the lipid vesicles. In some embodiments, the lipid vesicle composition may be stabilized by one or more surfactants. In some embodiments, the oil-in-water emulsion may comprise one or more viscosity enhancing agents. In some embodiments, the one or more viscosity enhancing agents may comprises a fully hydrogenated oil. In some embodiments, the lipid bilayer, the oil-in-water emulsion, or a combination may comprise one or more peptides. In some embodiments, the one or more peptides may comprise an amino acid sequence:
[0005] Xaa 1 -Xaa2-Xaa3 -Xaa4-Xaa5 -Xaa6-Xaa7 -Xaa8.
[0006] In some embodiments, Xaal may be absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Gly, Lys, Pro, Tyr, or Vai. In some embodiments, Xaa2 may be absent or selected from: Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, or Vai. In some embodiments, Xaa3 may be absent or selected from: Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, or Vai. In some embodiments, Xaa4 may be absent or selected from: Ala, Arg, Glu, Gly,Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Vai. In some embodiments, Xaa5 may be absent or selected from: Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Vai. In some embodiments, Xaa6 may be absent or selected from: Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Vai and a derivative of Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Vai. In some embodiments, Xaa7 may be selected from: Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Vai. In some embodiments, Xaa8 may be selected from: Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Vai and a derivative of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Vai.
[0007] In some aspects, the invention may be a lipid vesicle composition comprising lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids. In some embodiments, it may comprise an oil-in-water emulsion entrapped in the lipid vesicles. In some embodiments, it may be stabilized by one or more surfactants. In some embodiments, the oil-in-water emulsion may comprise one or more viscosity enhancing agents. In some embodiments, the one or more viscosity enhancing agents may comprises a fully hydrogenated oil. In some embodiments, the lipid bilayer, the oil-in-water emulsion, or a combination thereof may comprise one or more peptides. In some embodiments, the one or more peptides may comprise an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to any one of SEQ ID NOs: 1-51.
[0008] In some aspects, the invention may be a lipid vesicle composition. In some embodiments the composition may comprise lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids. In some embodiments, an oil-in-water emulsion may be entrapped in the lipid vesicles. In some embodiments, the lipid vesicles may be stabilized by one or more surfactants. In some embodiments, the oil-in-water emulsion may comprise a biological extract composition in an amount of about 0.01 % to about 3 %. In some embodiments, the lipid bilayer, the oil-in- water emulsion, or a combination thereof may comprise one or more peptides. In some embodiments, the one or more peptides may comprise an amino acid sequence:
[0009] Xaa 1 -Xaa2-Xaa3 -Xaa4-Xaa5 -Xaa6-Xaa7 -Xaa8
[0010] In some embodiments, Xaal may be absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Gly, Lys, Pro, Tyr, or Vai. In some embodiments, Xaa2 may be absent or selected from: Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, or Vai. In some embodiments, Xaa3 may be absent or selected from: Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, or Vai. In some embodiments, Xaa4 may be absent or selected from: Ala, Arg, Glu, Gly,Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Vai. In some embodiments, Xaa5 may be absent or selected from: Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Vai. In some embodiments, Xaa6 may be absent or selected from: Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Vai and a derivative of Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Vai. In some embodiments, Xaa7 may be selected from: Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Vai. In some embodiments, Xaa8 may be selected from: Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Vai and a derivative of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Vai.
[0011] In some aspects, the invention may be a lipid vesicle composition. In some embodiments, the composition may comprise lipid vesicles. In some embodiments, each lipid vesicle may comprise a lipid bilayer comprising vesicle forming lipids. In some embodiments, an oil-in-water emulsion may be entrapped in the lipid vesicles. In some embodiments, the lipid vesicles may be stabilized by one or more surfactants. In some embodiments, the oil-in-water emulsion may comprise a biological extract composition in an amount of about 0.01 % to about 3 %. In some embodiments, the lipid bilayer, the oil-in-water emulsion, or a combination thereof may comprise one or more peptides. In some embodiments, the one or more peptides may comprise an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to any one of SEQ ID NOs: 1-51.
[0012] In some aspects, the invention may comprise a viscosity enhancing agent. The viscosity enhancing agent may be a fully hydrogenated oil. The fully hydrogenated oil may be jojoba wax. The fully hydrogenated oil may be candelilla wax, carnauba wax, beeswax, or petroleum-derived waxes like paraffin. The fully hydrogenated oil may be natural or synthetic.
[0013] In some aspects, the invention may comprise a biological extract. The biological extract may be Jasminum Sambac (Jasmine) flower extract. The biological extract may be Crataegus Monogyna flower extract, Jasminum Grandiflorum flower extract, Jasminum Asteroides flower extract or Jasminum Auriculatum flower extract.INCORPORATION BY REFERENCE
[0014] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0016] FIGs. 1A-1C shows physicochemical characterization of multisome formulations Fl, F2 and F3. FIG. 1A shows confocal microscopic images of multisome formulations Fl (top), F2 (middle) and F3 (bottom) containing a rhodamine red labelled HA250K and green FITC-HA10K; FI tracings show co-localization of the two labels in the vesicles. FIG. IB shows light microscopic images of multisome formulations Fl (top), F2 (middle) and F3 (bottom). FIG. 1C shows particle size distribution of multisome formulations Fl (top), F2 (middle) and F3 (bottom). The figures are labeled size distribution by intensity. The x-axis is the size (d nm) from 0.1 to 10000 labeled in increments of a factor of 10. The y-axis for Fl (top) shows the intensity (percent) from 0 to 20 labeled in increments of 5. The y-axis for F2 (middle) shows the intensity (percent) from 0 to 30 labeled in increments of 10. The y-axis for F3 (bottom) shows the intensity (percent) from 0 to 12 labeled in increments of 2.
[0017] FIG. 2 shows confocal microscopic images of human skin to which cationic multisome formulations were applied. Cationic multisome formulations were prepared with a rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K. FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. For the FI tracing for Fl (top) the x-axis is distance (nm) from 0 to 300000 labeled in increments of 50000; the y-axis is intensity from 0 to 66 in labeled increments of 10 up to 60. For the FI tracing for F2 (middle) the x-axis is distance (nm) from 0 to 198107 labeled in increments of 20000 up to 180000; the y-axis is intensity from 0 to 90 in labeled increments of 10. For the FI tracing for F3 (bottom) the x-axis is distance (nm) from 0 to 375190 labeled in increments of 50000 up to 350000; the y-axis is intensity from 0 to 65 in labeled increments of 10 up to 60. The plain of the tracing direction is shown on each micrograph.
[0018] FIGs. 3A-3C show confocal microscopic images of human skin to which multisome formulations were applied. Multisome formulations were prepared with a rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K. FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The x-axis shown are distance (nm) and the y-axis are intensity in the FI tracings. The plane of the tracing direction is shown on each micrograph. FIG. 3A shows results for El (F4HA250+10 1 mg), E4 (F4HA250+50 1 mg), E7 (F3-2HA250+50 1.5 mg), andE10 (F1-F6-COSM6BN-HA250+50 1.5 mg) from top to bottom. FIG. 3B shows results for E2 (F4HA250+10 1.5 mg), E5 (F4HA250+50 1.5 mg), E8 (F1-F6-COSM6-HA250+10 1.5 mg), and El 1 (Gel-HA250+50 1.5 mg) from top to bottom. FIG. 3C shows results for E3 (COSMF4HA250+10 1.5 mg), E6 (COSMF4HA250+50 1.5 mg), E9 (F1-F6-COSM6- HA250+50 1.5 mg), and E12 (Gel-HA250+10 1.5 mg) from top to bottom.
[0019] FIGs. 4A-4B show confocal microscopic images of human skin to which multisome formulations were applied. Multisome formulations were prepared with a rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K. FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The x-axis shown are distance (nm) and the y-axis are intensity in the FI tracings. The plane of the tracing direction is shown on each micrograph. FIG. 4A shows results for G1 (F1-F5-COSM4-HA250+10), G2 (F1-F5-COSM4+HA250+ 10+BN), G3 (F1-F6- COSM5-HA250+10), and G4 (F1-F6-COSM5-HA250+10+BN) from top to bottom. FIG. 4B shows results for G5 (F1-F5-COSM4-HA250+50), G6 (F1-F5-COSM4+HA250+50+BN), G7 (F1-F6-COSM5-HA250+50), and G8 (F1-F6-COSM5-HA250+50+BN) from top to bottom.
[0020] FIG. 5 shows an exemplary pictorial workflow for the preparation of lipid vesicles provided herein.
[0021] FIG. 6 shows an exemplary workflow for the preparation of lipid vesicles comprising hyaluronic acid (HA) as provided herein.
[0022] FIGs. 7A-7D show physicochemical characterization of multisome formulations containing various HA + functional ingredient packs (FIPs). FIG. 7A shows confocal microscopic images of multisome formulations and fluorescence intensity (FI) tracings (Panel A) and light microscopic images of the multisome formulations (Panel B). In the FI tracings, the x- axis are distance (pm) from 0 to 50 in increments of 5; the y-axis are intensity from 0 to 250 shown in increments of 50. FIG. 7B shows confocal microscopic images of further multisome formulations and FI tracings (Panel A) and corresponding light microscopic images (Panel B). In the FI tracings for F5P2.6-F6COSM5V2-H6+P2 (top), the axis is distance (pm) from 0 to 55 in increments of 5; the y-axis is intensity shows from 0 to 250 in increments of 50. In the FI tracings for F1-F6-COSM5V2-H6+P2 (bottom), the axis is distance (pm) from 0 to about 130 in increments of 20; the y-axis is intensity shows from 0 to 250 in increments of 50. FIG. 7C shows a confocal microscopic image of a selected multisome formulation and FI tracing (Panel A), as well as light microscopic images of the selected formulation for various batch sized (Panel B). In the FI tracing, the x-axis is distance (nm) from 0 to about 35000 in increments of 5000; the y-axis shows intensity from 0 to 57 in increments of 10. FIG. 7D shows a confocal microscopic image of another selected multisome formulation and FI tracing (Panel A), as well as light microscopicimages of the selected formulation before and after mixing of additional ingredients to the formulation (Panel B). In the FI tracing, the x-axis is distance (nm) from 0 to about 12000 in increments of 2000; the y-axis shows intensity from 0 to 170 in increments of 20. The confocal microscopic images in Panels A in FIGs. 7A-7D comprise a rhodamine red labelled HA250K and green FITC-HA10K and the FI tracings show co-localization of the two labels in the vesicles.
[0023] FIGs. 8A-8B show confocal microscopic images and FI tracing of human skin treated with two formulations, F5P2.6-F6COSM5V2-HA5-1+P2 (FIG. 8A) and F1-F6COSM5V2-H5- 1+P2 (FIG. 8B), at two different HA250 / 50 ratios with HA + FIP formulations: HA5-1 and 5-2. Multisome formulations were prepared with a rhodamine red labelled HA250K and green FITC- HA50K. FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plain of the tracing direction is shown on each micrograph. In the FI tracings in FIG. 8A, the x-axis is distance (nm) from 0 to 133123 in increments of 20000; the y-axis is intensity from 0 to 109 in increments of 10 for HA5-1 (top), while the x-axis is distance (nm) from 0 to 120000 in increments of 20000; the y-axis is intensity from 0 to 80 in increments of 10 for HA 5-2 (bottom). In the FI tracings in FIG. 8B, the x-axis is distance (nm) from 0 to 112730 in increments of 20000; the y-axis is intensity from 0 to 99 in increments of 10 for HA5-1 (top), while the x-axis is distance (nm) from 0 to 100000 in increments of 10000; the y-axis is intensity from 0 to 97 in increments of 10 for HA 5-2 (bottom).
[0024] FIG. 9 shows confocal microscopic images and FI tracing of human skin treated with the formulation F5P2.6-F6COSM5V2 with three different HA + FIPs formulations: HA5-1+P2 (top), HA6+P2 (middle) and HA8+P2 (bottom). Multisome formulations were prepared with a rhodamine red labelled HA250K and green FITC-HA50K.FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plain of the tracing direction is shown on each micrograph. For the FI tracings for HA5-1+P2 (top), the x-axis is distance (nm) from 0 to 133123 in increments of 20000; the y-axis is intensity from 0 to 109 in increments of 10. For the FI tracings for HA6+P2 (middle), the x-axis is distance (nm) from 0 to 130138 in increments of 20000; the y-axis is intensity from 0 to 70 in increments of 10. For the FI tracings for HA8+P2 (bottom), the x-axis is distance (nm) from 0 to 118512 in increments of 20000; the y-axis is intensity from 0 to 23 in increments of 2.
[0025] FIG. 10 shows confocal microscopic images and FI tracing of human skin treated with the formulation F5P2.6-F6COSM5V2 formulated with either propylene glycol (top) or butylene glycol (bottom). Multisome formulations were prepared with a rhodamine red labelled HA250Kand green FITC-HA50K. FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plain of the tracing direction is shown on each micrograph. For the FI tracing for F5P2.6-F6COSM5V2 formulated with propylene glycol (top), the x-axis is distance (nm) from 0 to 133123 in increments of 20000; the y-axis is intensity from 0 to 109 in increments of 10. For FI tracings for F5P2.6-F6COSM5V2 formulated with butylene glycol (bottom), the x-axis is distance (nm) from 0 to 120000 in increments of 20000; the y-axis is intensity from 0 to 17 in increments of 2.
[0026] FIGs. 11A-11C show confocal microscopic images and FI tracing of human skin treated with the formulation F1-F6COSM5NC-HA4-2P. Multisome formulations were prepared with a rhodamine red labelled HA250K and green FITC-HA50K. FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plain of the tracing direction is shown on each micrograph. Measurements shown on 12 different areas, where FIG. 11A shows areas 1, 4, 7, and 10; FIG. 11B shows areas 2, 5, 8, and 11; and FIG. 11C shows areas 3, 6, 9, and 12 (from top to bottom). For each of the FI tracings, the x-axis is distance (nm) and the y-axis is intensity. In FIG. 11 A, for area 1 the x-axis is shown from 0 to greater than 80000 in increments of 10000 and y-axis is shown from 0 to 120 in increments of 20; for area 4 the x-axis is shown from 0 to greater than 140000 in increments of 20000 and y-axis is shown from 0 to 100 in increments of 10; for area 7 the x-axis is shown from 0 to greater than 100000 in increments of 20000 and y- axis is shown from 0 to 120 in increments of 20; and for area 10 the x-axis is shown from 0 to greater than 120000 in increments of 20000 and y-axis is shown from 0 to 50 in increments of 5. In FIG. 11B, for area 2 the x-axis is shown from 0 to greater than 120000 in increments of 20000 and y-axis is shown from 0 to 110 in increments of 10; for area 5 the x-axis is shown from 0 to greater than 120000 in increments of 20000 and y-axis is shown from 0 to 75 in increments of 10; for area 8 the x-axis is shown from 0 to about 100000 in increments of 20000 and y-axis is shown from 0 to 170 in increments of 20; and for area 11 the x-axis is shown from 0 to greater than 150000 in increments of 20000 and y-axis is shown from 0 to 60 in increments of 10. In FIG. 11C, for area 3 the x-axis is shown from 0 to greater than 120000 in increments of 20000 and y-axis is shown from 0 to greater than 250 in increments of 50; for area 6 the x-axis is shown from 0 to greater than 140000 in increments of 20000 and y-axis is shown from 0 to greater than 90 in increments of 10; for area 9 the x-axis is shown from 0 to greater than 100000 in increments of 10000 and y-axis is shown from 0 to 55 in increments of 5; and for area 12 the x- axis is shown from 0 to greater than 120000 in increments of 20000 and y-axis is shown from 0 to 80 in increments of 10.
[0027] FIG. 12 shows confocal microscopic images and FI tracing of human skin treated with a gel formulation (non-vesicle formulation) as a control formulation. The gel was prepared with a rhodamine red labelled HA250K and green FITC-HA50K. FI tracing show the levels of rhodamine red labelled HA250K and green FITC-HA10K or FITC-HA50K in the skin layers from the surface of the skin to the upper dermis. The plain of the tracing direction is shown on each micrograph. Measurements shown on 2 different areas. For the FI tracing for area 1 (top), the x-axis is distance (nm) from 0 to 140000 in increments of 20000; the y-axis is intensity from 0 to 80 in increments of 10. For the FI tracing for area 2 (bottom), the x-axis is distance (nm) from 0 to 112386 in increments of 20000; the y-axis is intensity from 0 to 80 in increments of 10.DETAILED DESCRIPTION OF THE INVENTIONDefinitions
[0028] As used herein, the term “comprise” or variations thereof such as “comprises” or “comprising” are to be read to indicate the inclusion of any recited feature but not the exclusion of any other features. Thus, as used herein, the term “comprising” is inclusive and does not exclude additional, unrecited features. In some embodiments of any of the compositions and methods provided herein, “comprising” may be replaced with “consisting essentially of’ or “consisting of.” The phrase “consisting essentially of’ is used herein to require the specified feature(s) as well as those which do not materially affect the character or function of the claimed invention. As used herein, the term “consisting" is used to indicate the presence of the recited feature alone.
[0029] As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated below.
[0030] As used herein, the term “pharmaceutically acceptable salt” includes both acid and base addition salts. A pharmaceutically acceptable salt of any one of the compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0031] As used herein, the term “unmodified peptides” refers to peptides that have not been terminally modified to include additional functional groups. In some embodiments, the peptides have not been modified to include functional groups to enhance transdermal penetration, such as an octanoyl, decanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, biotinoyl, elaidoyl, oleoyl or lipoyl group. In some embodiments, the peptides have not been modified to include oleanolic acid.
[0032] As used herein, “treatment” or “treating,” or “palliating” or “ameliorating” are used interchangeably. These terms refer to an approach for obtaining beneficial or desired resultsincluding but not limited to therapeutic benefit and / or a prophylactic benefit. By “therapeutic benefit” is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient is still afflicted with the underlying disorder. For prophylactic benefit, the compositions are, in some embodiments, administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
[0033] As used herein, “conservative substitution” means an exchange of one amino acid for another amino acid with similar properties, such as size, charge, and polarity. The substitution can be for a natural or modified (e.g., unnatural amino acid). Non-limiting of examples which can be interchanged in conservative substitutions include the following groupings: Large Hydrophobics (Valine, Leucine, Isoleucine, Phenylalanine, Tryptophan, Tyrosine, Methionine), Small Non-Polar (Alanine, Glycine), Polar (Serine, Threonine, Glutamine, Asparagine, Cysteine, histidine), Positively Charged (Lysine, Arginine), and Negatively Charged (Glutamate, Aspartate).
[0034] When a % is used herein to refer to an amount of a component, unless otherwise specified, it is intended that the % be the % w / w.
[0035] The term “penetration enhancing agents” and “penetration enhancers” are used herein interchangeably. As used herein, it refers to one or more ingredients which facilitate or increase the penetration of one or more active ingredients (e.g., anionic polymeric materials such as hyaluronic acid or one or more peptides) through one or more layers of the skin of a subject. In some embodiments, the penetration enhancing agent is a surfactant, including, for example, nonionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, a cationic group, or another agent such as a terpene, alkaloid, salicylate derivative, nicotinate derivative, or any combination thereof.
[0036] The term “multisome” as used herein refers lipid vesicle (such as a biphasic lipid vesicle) which comprises one or more penetration enhancers, which in preferred embodiments include multiple penetration enhancers which work in a synergistic fashion. In some embodiments, multisomes include vesicle whose central core compartments are occupied by an oil-in-water emulsion composed of an aqueous continuous phase and a dispersed hydrophobic, hydrophilic or oil phase. In an embodiment, the spaces between adjacent bilayers of lipid vesicles may also be occupied by the emulsion.
[0037] The term “lipid vesicle composition” as used herein refers to a composition which includes one or more lipid vesicles (e.g., multisomal lipid vesicles, lipid bilayer vesicles, etc.).When a lipid vesicle composition is described as “comprising” one or more additional components (e.g., an anionic polymer material or one or more peptides provided herein), it is intended that the composition includes the additional component in any manner within the composition (e.g., encapsulated within a lipid vesicle. For example, a lipid vesicle composition comprising an anionic polymer material can include the anionic polymer material encapsulated within a lipid bilayer of the lipid vesicle composition.
[0038] The term “emulsion” as used herein refers to a mixture of two immiscible substances.
[0039] The term “bilayer” as used herein refers to a structure composed of amphiphilic lipid molecules arranged in two molecular layers, with the hydrophobic tails on the interior and the polar head groups on the exterior surfaces.
[0040] The term "topical application" or "topical delivery" as used herein means intradermal, transdermal and / or transmucosal delivery of a compound by administration of a composition comprising the compound or compounds to skin and / or a mucosal membrane.
[0041] The term “gemini surfactant” as used herein refers to a surfactant molecule which contains more than one hydrophobic tail, and each hydrophobic tail having a hydrophilic head wherein he hydrophobic tails or hydrophilic heads are linked together by a spacer moiety. The hydrophobic tails can be identical or differ. Likewise, the hydrophilic heads can be identical or differ, the hydrophilic heads may be anionic, cationic, or neutral.
[0042] The term “HLB” or “Hydrophilic-Lipophilic Balance” value refers to standard HLB according to Griffin, J. Soc. Cosm. Chem., vol. 5, 249 (1954), which indicates the degrees of hydrophilicity and lipophilicity of a surfactant.Lipid Vesicle Compositions of Anionic Polymer Materials Such as Hyaluronic Acid for Intradermal Delivery
[0043] In one aspect, provided herein, is a lipid vesicle composition comprising an anionic polymer material. In some embodiments, the lipid vesicle composition comprises lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids. In some embodiments, the lipid vesicle composition comprises an oil-in-water emulsion entrapped in the lipid vesicles. In some embodiments, the oil-in-water emulsion is stabilized by one or more surfactants. In some embodiments, the anionic polymer material is entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the anionic polymer material is hyaluronic acid.Anionic Polymer Materials
[0044] In some aspects, the lipid vesicle compositions provided herein comprise an anionic polymer material. The anionic polymer material is desirably one which is compatible withdelivery beneath the surface of the skin of a subject. In some embodiments, the anionic polymer material is one which acts as a volumizer or filler after delivery beneath the surface of the skin. In some embodiments, the anionic polymer material acts as a support for another layer of skin (e.g., the epidermis) in order to correct depressions of the skin or restore facial volume. In some embodiments, the anionic polymer material is not crosslinked. In some embodiments, the anionic polymer material is crosslinked (e.g., crosslinked hyaluronic acid, such as Hyacross™ TL100).
[0045] In some embodiments, the anionic polymer material comprises an anionic polysaccharide. In some embodiments, the anionic polysaccharide is non-sulfated glycosaminoglycan. In some embodiments, the anionic polymeric material is a naturally occurring substance. In some embodiments, the anionic polymeric material naturally occurs in a human. In some embodiments, the anionic polymer material naturally occurs in connective or epithelial tissue in a human. In some embodiments, the anionic polymeric material is hyaluronic acid, or a pharmaceutically acceptable salt thereof.
[0046] In some embodiments, the hyaluronic acid is a pharmaceutically acceptable salt of hyaluronic acid. In some embodiments, the salt is the sodium salt, the potassium salt, the magnesium salt, or any combination thereof. In some embodiments, the salt is the sodium salt. In some embodiments, the anionic polymer material comprises sodium hyaluronate. In some embodiments, the hyaluronic acid is hydrolyzed hyaluronic acid. Hydrolyzed hyaluronic, in some instances, may generally refer to hyaluronic acid having a molecular weight of about 50 kDa or less.
[0047] In some embodiments, the anionic polymer material has a molecular weight of from about 5 kDa to about 500 kDa. In some embodiments, the molecular weight is the weight average molecular weight. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 500 kDa. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa to about 10 kDa, about 5 kDa to about 20 kDa, about 5 kDa to about 50 kDa, about 5 kDa to about 100 kDa, about 5 kDa to about 200 kDa, about 5 kDa to about 250 kDa, about 5 kDa to about 300 kDa, about 5 kDa to about 400 kDa, about 5 kDa to about 500 kDa, about 10 kDa to about 20 kDa, about 10 kDa to about 50 kDa, about 10 kDa to about 100 kDa, about 10 kDa to about 200 kDa, about 10 kDa to about 250 kDa, about 10 kDa to about 300 kDa, about 10 kDa to about 400 kDa, about 10 kDa to about 500 kDa, about 20 kDa to about 50 kDa, about 20 kDa to about 100 kDa, about 20 kDa to about 200 kDa, about 20 kDa to about 250 kDa, about 20 kDa to about 300 kDa, about 20 kDa to about 400 kDa, about 20 kDa to about 500 kDa, about 50 kDa to about 100 kDa, about 50 kDa to about 200 kDa, about 50 kDa to about 250 kDa, about 50 kDa to about 300 kDa, about 50 kDa to about 400 kDa, about 50 kDa to about 500 kDa, about 100 kDa to about 200 kDa, about 100 kDa to about 250 kDa, about 100kDa to about 300 kDa, about 100 kDa to about 400 kDa, about 100 kDa to about 500 kDa, about 200 kDa to about 250 kDa, about 200 kDa to about 300 kDa, about 200 kDa to about 400 kDa, about 200 kDa to about 500 kDa, about 250 kDa to about 300 kDa, about 250 kDa to about 400 kDa, about 250 kDa to about 500 kDa, about 300 kDa to about 400 kDa, about 300 kDa to about 500 kDa, or about 400 kDa to about 500 kDa. In some embodiments, the anionic polymeric material has a molecular weight of about 5 kDa, about 10 kDa, about 20 kDa, about 50 kDa, about 100 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 400 kDa, or about 500 kDa. In some embodiments, the anionic polymeric material has a molecular weight of at least about 5 kDa, about 10 kDa, about 20 kDa, about 50 kDa, about 100 kDa, about 200 kDa, about 250 kDa, about 300 kDa, or about 400 kDa. In some embodiments, the anionic polymeric material has a molecular weight of at most about 10 kDa, about 20 kDa, about 50 kDa, about 100 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 400 kDa, or about 500 kDa.
[0048] In some embodiments, an anionic polymer material is present in an amount of about 0.01 wt% to about 1 wt%. In some embodiments, the anionic polymer material is present in an amount of about 0.01 wt% to about 0.02 wt%, about 0.01 wt% to about 0.05 wt%, about 0.01 wt% to about 0.08 wt%, about 0.01 wt% to about 0.1 wt%, about 0.01 wt% to about 0.15 wt%, about 0.01 wt% to about 0.2 wt%, about 0.01 wt% to about 0.25 wt%, about 0.01 wt% to about 0.3 wt%, about 0.01 wt% to about 0.4 wt%, about 0.01 wt% to about 0.5 wt%, about 0.01 wt% to about 1 wt%, about 0.02 wt% to about 0.05 wt%, about 0.02 wt% to about 0.08 wt%, about 0.02 wt% to about 0.1 wt%, about 0.02 wt% to about 0.15 wt%, about 0.02 wt% to about 0.2 wt%, about 0.02 wt% to about 0.25 wt%, about 0.02 wt% to about 0.3 wt%, about 0.02 wt% to about 0.4 wt%, about 0.02 wt% to about 0.5 wt%, about 0.02 wt% to about 1 wt%, about 0.05 wt% to about 0.08 wt%, about 0.05 wt% to about 0.1 wt%, about 0.05 wt% to about 0.15 wt%, about 0.05 wt% to about 0.2 wt%, about 0.05 wt% to about 0.25 wt%, about 0.05 wt% to about 0.3 wt%, about 0.05 wt% to about 0.4 wt%, about 0.05 wt% to about 0.5 wt%, about 0.05 wt% to about 1 wt%, about 0.08 wt% to about 0.1 wt%, about 0.08 wt% to about 0.15 wt%, about 0.08 wt% to about 0.2 wt%, about 0.08 wt% to about 0.25 wt%, about 0.08 wt% to about 0.3 wt%, about 0.08 wt% to about 0.4 wt%, about 0.08 wt% to about 0.5 wt%, about 0.08 wt% to about 1 wt%, about 0.1 wt% to about 0.15 wt%, about 0.1 wt% to about 0.2 wt%, about 0.1 wt% to about 0.25 wt%, about 0.1 wt% to about 0.3 wt%, about 0.1 wt% to about 0.4 wt%, about 0.1 wt% to about 0.5 wt%, about 0.1 wt% to about 1 wt%, about 0.15 wt% to about 0.2 wt%, about 0.15 wt% to about 0.25 wt%, about 0.15 wt% to about 0.3 wt%, about 0.15 wt% to about 0.4 wt%, about 0.15 wt% to about 0.5 wt%, about 0.15 wt% to about 1 wt%, about 0.2 wt% to about 0.25 wt%, about 0.2 wt% to about 0.3 wt%, about 0.2 wt% to about 0.4 wt%, about 0.2 wt% to about 0.5 wt%, about 0.2 wt% to about 1 wt%, about 0.25 wt% to about 0.3 wt%, about 0.25 wt% toabout 0.4 wt%, about 0.25 wt% to about 0.5 wt%, about 0.25 wt% to about 1 wt%, about 0.3 wt% to about 0.4 wt%, about 0.3 wt% to about 0.5 wt%, about 0.3 wt% to about 1 wt%, about 0.4 wt% to about 0.5 wt%, about 0.4 wt% to about 1 wt%, or about 0.5 wt% to about 1 wt%. In some embodiments, the anionic polymer material is present in an amount of about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or about 1 wt%. In some embodiments, the anionic polymer material is present in an amount of at least about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, or about 0.5 wt%. In some embodiments, the anionic polymer material is present in an amount of at most about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0. 1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or about 1 wt%.
[0049] In some embodiments, the lipid vesicle composition comprises a first and a second anionic polymer material. In some embodiments, the first and the second anionic polymer are a different type. In some embodiments, each of the first and the second anionic polymer material is an anionic polysaccharide of a different type. In some embodiments, the first and the second anionic polymer material are the same type. In some embodiments, each of the first and the second anionic polymer material is an anionic polysaccharide. In some embodiments, each of the first and the second anionic polymer is hyaluronic acid. In some instances, a first or a second anionic polymer is sodium hyaluronate. In some instances, a first or a second anionic polymer is hydrolyzed hyaluronic acid.
[0050] In cases where the first and second anionic polymer materials are the same type, each anionic polymer material has a different molecular weight. In some embodiments, the first anionic polymer material has a molecular weight of up to about 75 kDa and the second anionic polymer material has a molecule weight of greater than about 75 kDa. In some embodiments, the first anionic polymer material has a molecular weight of up to about 75 kDa and the second anionic polymer material has a molecular weight of greater than about 75 kDa. In some embodiments, the first anionic polymer comprises sodium hyaluronate with a molecular weight of 50 kDa and the second anionic polymer comprises sodium hyaluronate with a molecular weight of 250 kDa.
[0051] In cases where the lipid vesicle comprises a first and second anionic polymer material, each component may be included in a different amount. In some embodiments, the first and second anionic polymer material are present in about the same amount. In some embodiments, the ratios provided herein comprise weight ratios. In some embodiments, the ratio of the fist and the second anionic material is about 10: 1, 9: 1. 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1, 3:2, 2: 1, 1 : 1, 1 :2, 1 :3,1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9 or 1 : 10. In some embodiments, the weight ratio of the fist and the second anionic material is about 10: 1, 9: 1. 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1, 3:2, 2:1, 1 : 1, 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9 or 1: 10. In some embodiments, the first and the second anionic polymer comprising sodium hyaluronate with a molecular weight of 50 kDa and 250 kDa, respectively, is present at a ratio of about 1 :2. In some cases, sodium hyaluronate with a molecular weight of 250 kDa is present at 0.1 wt% and sodium hyaluronate with a molecular weight of 50 kDa is present at 0.05 wt%. In some embodiments, the first and the second anionic polymer comprising sodium hyaluronate with a molecular weight of 50 kDa and 250 kDa, respectively, is present at a ratio of about 1 : 1. In some cases, sodium hyaluronate with a molecular weight of 250 kDa is present at 0.1 wt% and sodium hyaluronate with a molecular weight of 50 kDa is present at 0.1 wt%.
[0052] In some embodiments, the combination of the first anionic polymer and the second anionic polymer is present in the amount of about 0.01 wt% to about 1 wt%. In some embodiments, the combination is present in an amount of about 0.01 wt% to about 0.02 wt%, about 0.01 wt% to about 0.05 wt%, about 0.01 wt% to about 0.08 wt%, about 0.01 wt% to about 0.1 wt%, about 0.01 wt% to about 0.15 wt%, about 0.01 wt% to about 0.2 wt%, about 0.01 wt% to about 0.25 wt%, about 0.01 wt% to about 0.3 wt%, about 0.01 wt% to about 0.4 wt%, about 0.01 wt% to about 0.5 wt%, about 0.01 wt% to about 1 wt%, about 0.02 wt% to about 0.05 wt%, about 0.02 wt% to about 0.08 wt%, about 0.02 wt% to about 0.1 wt%, about 0.02 wt% to about 0.15 wt%, about 0.02 wt% to about 0.2 wt%, about 0.02 wt% to about 0.25 wt%, about 0.02 wt% to about 0.3 wt%, about 0.02 wt% to about 0.4 wt%, about 0.02 wt% to about 0.5 wt%, about 0.02 wt% to about 1 wt%, about 0.05 wt% to about 0.08 wt%, about 0.05 wt% to about 0.1 wt%, about 0.05 wt% to about 0.15 wt%, about 0.05 wt% to about 0.2 wt%, about 0.05 wt% to about 0.25 wt%, about 0.05 wt% to about 0.3 wt%, about 0.05 wt% to about 0.4 wt%, about 0.05 wt% to about 0.5 wt%, about 0.05 wt% to about 1 wt%, about 0.08 wt% to about 0.1 wt%, about 0.08 wt% to about 0.15 wt%, about 0.08 wt% to about 0.2 wt%, about 0.08 wt% to about 0.25 wt%, about 0.08 wt% to about 0.3 wt%, about 0.08 wt% to about 0.4 wt%, about 0.08 wt% to about 0.5 wt%, about 0.08 wt% to about 1 wt%, about 0.1 wt% to about 0.15 wt%, about 0.1 wt% to about 0.2 wt%, about 0.1 wt% to about 0.25 wt%, about 0.1 wt% to about 0.3 wt%, about 0.1 wt% to about 0.4 wt%, about 0.1 wt% to about 0.5 wt%, about 0.1 wt% to about 1 wt%, about 0.15 wt% to about 0.2 wt%, about 0.15 wt% to about 0.25 wt%, about 0.15 wt% to about 0.3 wt%, about 0.15 wt% to about 0.4 wt%, about 0.15 wt% to about 0.5 wt%, about 0.15 wt% to about 1 wt%, about 0.2 wt% to about 0.25 wt%, about 0.2 wt% to about 0.3 wt%, about 0.2 wt% to about 0.4 wt%, about 0.2 wt% to about 0.5 wt%, about 0.2 wt% to about 1 wt%, about 0.25 wt% to about 0.3 wt%, about 0.25 wt% to about 0.4 wt%, about 0.25 wt% to about 0.5 wt%, about 0.25 wt% to about 1 wt%, about 0.3 wt% to about 0.4 wt%, about 0.3 wt% to about 0.5 wt%, about 0.3 wt%to about 1 wt%, about 0.4 wt% to about 0.5 wt%, about 0.4 wt% to about 1 wt%, or about 0.5 wt% to about 1 wt%. In some embodiments, the combination is present in an amount of about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or about 1 wt%. In some embodiments, the combination is present in an amount of at least about 0.01 wt%, about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, or about 0.5 wt%. In some embodiments, the combination is present in an amount of at most about 0.02 wt%, about 0.05 wt%, about 0.08 wt%, about 0.1 wt%, about 0.15 wt%, about 0.2 wt%, about 0.25 wt%, about 0.3 wt%, about 0.4 wt%, about 0.5 wt%, or about 1 wt%. For example, the first anionic polymer may be present in an amount of about 0.1 wt% and the second anionic polymer may be present in an amount of about 0.05 wt%. As a further example, the second anionic polymer may be present in an amount of about 0.1 wt% and the first anionic polymer may be present in an amount of about 0.05 wt%.
[0053] In some embodiments, the composition comprises a first, second, and third anionic polymer material. In some embodiments, the anionic polymer materials can be of the same type (e.g., three different molecular weights of hyaluronic acid). In some embodiments, two of the three anionic polymer materials are of the same type. In some embodiments, each of the anionic polymer materials are of a different type. In some embodiments, the first anionic polymer material, the second anionic polymer material, the third anionic polymer material or any combination thereof are not crosslinked. In some embodiments, the first anionic polymer material, the second anionic polymer material, or both are not crosslinked. In some embodiments, the third anionic polymer material is crosslinked. In some embodiments, the third anionic polymer material comprises a sodium hyaluronate crosspolymer. The sodium hyaluronate crosspolymer may be in a composition comprising one or more solvents, such as water and / or pentylene glycol. In some embodiments, the crosslinked polymer material is in a gel form. In some embodiments, the first anionic polymer material has a molecular weight of from about 5 kDa to about 20 kDa, the second anionic polymer has a molecular weight of from about 20 kDa to about 75 kDa, and the third anionic polymer material has a molecular weight of greater than about 75 kDa.
[0054] In some embodiments, each of the three anionic polymer materials is present in about the same amount. In some embodiments, each of the three anionic polymer materials is present in about a different amount. In some embodiments, the first anionic polymer material, the second anionic polymer material, the third anionic polymer material, or any combination thereof is each present in an amount of about 0.1 mg / g to about 10 mg / g. In some embodiments, the first anionicpolymer material, the second anionic polymer material, the third anionic polymer material, or any combination thereof is each present in an amount of about 0.01 % to about 1 %.
[0055] In some embodiments, an anionic polymer material is present in an amount of from about 0.01 mg / mL to about 10 mg / mL. In some embodiments, the anionic polymer material is present in an amount of about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 1.25 mg / mL, about 0.01 mg / mL to about 1.5 mg / mL, about 0.01 mg / mL to about 1.75 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.05 mg / mL to about 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05 mg / mL to about 1 mg / mL, about 0.05 mg / mL to about 1.25 mg / mL, about 0.05 mg / mL to about 1.5 mg / mL, about 0.05 mg / mL to about 1.75 mg / mL, about 0.05 mg / mL to about 2 mg / mL, about 0.05 mg / mL to about 5 mg / mL, about 0.05 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 1.25 mg / mL, about 0.1 mg / mL to about 1.5 mg / mL, about 0.1 mg / mL to about 1.75 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.5 mg / mL to about 1.25 mg / mL, about 0.5 mg / mL to about 1.5 mg / mL, about 0.5 mg / mL to about 1.75 mg / mL, about 0.5 mg / mL to about 2 mg / mL, about 0.5 mg / mL to about 5 mg / mL, about 0.5 mg / mL to about 10 mg / mL, about 1 mg / mL to about 1.25 mg / mL, about 1 mg / mL to about 1.5 mg / mL, about 1 mg / mL to about 1.75 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 1.25 mg / mL to about 1.5 mg / mL, about 1.25 mg / mL to about 1.75 mg / mL, about 1.25 mg / mL to about 2 mg / mL, about 1.25 mg / mL to about 5 mg / mL, about 1.25 mg / mL to about 10 mg / mL, about 1.5 mg / mL to about 1.75 mg / mL, about 1.5 mg / mL to about 2 mg / mL, about 1.5 mg / mL to about 5 mg / mL, about 1.5 mg / mL to about 10 mg / mL, about 1.75 mg / mL to about 2 mg / mL, about 1.75 mg / mL to about 5 mg / mL, about 1.75 mg / mL to about 10 mg / mL, about 2 mg / mL to about 5 mg / mL, about 2 mg / mL to about 10 mg / mL, or about 5 mg / mL to about 10 mg / mL. In some embodiments, the anionic polymer material is present in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL. In some embodiments, the anionic polymer material is present in an amount of at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, or about 5 mg / mL. In some embodiments, the anionic polymer material is present in an amount of at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL.
[0056] In some embodiments, an anionic polymer material is present in an amount of from about 0.01 mg / g to about 10 mg / g. In some embodiments, an anionic polymer material is present in an amount of from about 0.01 mg / g to about 0.05 mg / g, about 0.01 mg / g to about 0.1 mg / g, about 0.01 mg / g to about 0.5 mg / g, about 0.01 mg / g to about 1 mg / g, about 0.01 mg / g to about 2.5 mg / g, about 0.01 mg / g to about 5 mg / g, about 0.01 mg / g to about 7.5 mg / g, about 0.01 mg / g to about 10 mg / g, about 0.05 mg / g to about 0.1 mg / g, about 0.05 mg / g to about 0.5 mg / g, about 0.05 mg / g to about 1 mg / g, about 0.05 mg / g to about 2.5 mg / g, about 0.05 mg / g to about 5 mg / g, about 0.05 mg / g to about 7.5 mg / g, about 0.05 mg / g to about 10 mg / g, about 0.1 mg / g to about 0.5 mg / g, about 0.1 mg / g to about 1 mg / g, about 0.1 mg / g to about 2.5 mg / g, about 0.1 mg / g to about 5 mg / g, about 0.1 mg / g to about 7.5 mg / g, about 0.1 mg / g to about 10 mg / g, about 0.5 mg / g to about 1 mg / g, about 0.5 mg / g to about 2.5 mg / g, about 0.5 mg / g to about 5 mg / g, about 0.5 mg / g to about 7.5 mg / g, about 0.5 mg / g to about 10 mg / g, about 1 mg / g to about 2.5 mg / g, about 1 mg / g to about 5 mg / g, about 1 mg / g to about 7.5 mg / g, about 1 mg / g to about 10 mg / g, about 2.5 mg / g to about 5 mg / g, about 2.5 mg / g to about 7.5 mg / g, about 2.5 mg / g to about 10 mg / g, about 5 mg / g to about 7.5 mg / g, about 5 mg / g to about 10 mg / g, or about 7.5 mg / g to about 10 mg / g. In some embodiments, an anionic polymer material is present in an amount of from about 0.01 mg / g, about 0.05 mg / g, about 0.1 mg / g, about 0.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, about 7.5 mg / g, or about 10 mg / g. In some embodiments, an anionic polymer material is present in an amount of from at least about 0.01 mg / g, about 0.05 mg / g, about 0.1 mg / g, about 0.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, or about 7.5 mg / g. In some embodiments, an anionic polymer material is present in an amount of from at most about 0.05 mg / g, about 0.1 mg / g, about 0.5 mg / g, about 1 mg / g, about 2.5 mg / g, about 5 mg / g, about 7.5 mg / g, or about 10 mg / g. As an example, per 100 g of product, the anionic polymer material is present in an amount of from about 1 mg to about 1000 mg.
[0057] In some embodiments, a combination of the first and the second anionic polymer material is present in an amount of from about 0.01 mg / g to about 10 mg / g. In some embodiments, a combination of the first and the second anionic polymer material is present in an amount of from about 0.01 mg / mL to about 10 mg / mL. In some embodiments, a combination of the first and the second anionic polymer material is present in an amount of from about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2.5 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 7.5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.05 mg / mL to about 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05mg / mL to about 1 mg / mL, about 0.05 mg / mL to about 2.5 mg / mL, about 0.05 mg / mL to about 5 mg / mL, about 0.05 mg / mL to about 7.5 mg / mL, about 0.05 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about2.5 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 7.5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.5 mg / mL to about2.5 mg / mL, about 0.5 mg / mL to about 5 mg / mL, about 0.5 mg / mL to about 7.5 mg / mL, about 0.5 mg / mL to about 10 mg / mL, about 1 mg / mL to about 2.5 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 7.5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 2.5 mg / mL to about 5 mg / mL, about 2.5 mg / mL to about 7.5 mg / mL, about 2.5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 7.5 mg / mL, about 5 mg / mL to about 10 mg / mL, or about 7.5 mg / mL to about 10 mg / mL. In some embodiments, a combination of the first and the second anionic polymer material is present in an amount of from about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about7.5 mg / mL, or about 10 mg / mL. In some embodiments, a combination of the first and the second anionic polymer material is present in an amount of from at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL. In some embodiments, a combination of the first and the second anionic polymer material is present in an amount of from at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. As an example, per 100 g of product, the combination of the first and the second anionic polymer material is present in an amount of from about 1 mg to about 1000 mg.
[0058] In some embodiments, the first anionic polymer material is present in an amount of from about 0.01 mg / g to about 10 mg / g. In some embodiments, the first anionic polymer material is present in an amount of from about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2.5 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 7.5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.05 mg / mL to about 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05 mg / mL to about 1 mg / mL, about 0.05 mg / mL to about 2.5 mg / mL, about 0.05 mg / mL to about 5 mg / mL, about 0.05 mg / mL to about 7.5 mg / mL, about 0.05 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2.5 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 7.5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.5 mg / mL to about 2.5 mg / mL, about 0.5 mg / mL to about 5 mg / mL, about 0.5 mg / mL to about 7.5 mg / mL, about 0.5 mg / mL to about 10 mg / mL, about 1 mg / mL to about 2.5 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about7.5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 2.5 mg / mL to about 5 mg / mL, about 2.5 mg / mL to about 7.5 mg / mL, about 2.5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 7.5 mg / mL, about 5 mg / mL to about 10 mg / mL, or about 7.5 mg / mL to about 10 mg / mL. In some embodiments, the first anionic polymer material is present in an amount of from about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the first anionic polymer material is present in an amount of from at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL. In some embodiments, the first anionic polymer material is present in an amount of from at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the second anionic polymer material is present in an amount of from about 0.01 mg / g to about 10 mg / g. In some embodiments, the second anionic polymer material is present in an amount of from about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2.5 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 7.5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.05 mg / mL to about 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05 mg / mL to about 1 mg / mL, about 0.05 mg / mL to about2.5 mg / mL, about 0.05 mg / mL to about 5 mg / mL, about 0.05 mg / mL to about 7.5 mg / mL, about 0.05 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2.5 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 7.5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.5 mg / mL to about 2.5 mg / mL, about 0.5 mg / mL to about 5 mg / mL, about 0.5 mg / mL to about 7.5 mg / mL, about 0.5 mg / mL to about 10 mg / mL, about 1 mg / mL to about 2.5 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 7.5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 2.5 mg / mL to about 5 mg / mL, about 2.5 mg / mL to about 7.5 mg / mL, about 2.5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 7.5 mg / mL, about 5 mg / mL to about 10 mg / mL, or about 7.5 mg / mL to about 10 mg / mL. In some embodiments, the second anionic polymer material is present in an amount of from about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the second anionic polymer material is present in an amount of from at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL. In some embodiments, the second anionic polymer material is present in an amount of from at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some examples, the first anionic polymer is present in an amount of 0.25 mg / g and the second anionic polymer is present in an amount of about 0.5 mg / g. In some examples, the first anionic polymer is present in an amount of 0.5 mg / g and the second anionic polymer is present in an amount of about 1 mg / g. In some examples, the first anionic polymer is present in an amount of 0.5 mg / g and the second anionic polymer is present in an amount of about 0.5 mg / g. In some examples, the first anionic polymer is present in an amount of 1 mg / g and the second anionic polymer is present in an amount of about 1 mg / g. In some examples, the first anionic polymer is present in an amount of 1 mg / g and the second anionic polymer is present in an amount of about 2 mg / g. In some examples, per 100 g of product, the first anionic polymer material is present in an amount of from about 1 mg to about 500 mg. In some examples, per 100 g of product, the second anionic polymer material is present in an amount of from about 5 mg to about 1000 mg. In some embodiments, the composition further comprises the third anionic polymer that is present in an amount of from about 0.01 mg / g to about 10 mg / g. In some embodiments, the third anionic polymer material is present in an amount of from about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2.5 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 7.5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.05 mg / mL to about 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05 mg / mL to about 1 mg / mL, about 0.05 mg / mL to about 2.5 mg / mL, about 0.05 mg / mL to about 5 mg / mL, about 0.05 mg / mL to about 7.5 mg / mL, about 0.05 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2.5 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 7.5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.5 mg / mL to about 2.5 mg / mL, about 0.5 mg / mL to about 5 mg / mL, about 0.5 mg / mL to about 7.5 mg / mL, about 0.5 mg / mL to about 10 mg / mL, about 1 mg / mL to about 2.5 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 7.5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 2.5 mg / mL to about 5 mg / mL, about 2.5 mg / mL to about 7.5 mg / mL, about 2.5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 7.5 mg / mL, about 5 mg / mL to about 10 mg / mL, or about 7.5 mg / mL to about 10 mg / mL. In some embodiments, the third anionic polymer material is present in an amount of from about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some embodiments, the third anionic polymer material is present in an amount of from at least about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, or about 7.5 mg / mL. In some embodiments, the third anionic polymermaterial is present in an amount of from at most about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL. In some examples, the third anionic polymer is present in an amount of about 0.1 mg / g. In some examples, the third anionic polymer is present in an amount of about 0.2 mg / g. In some examples, the third anionic polymer is present in an amount of about 0.5 mg / g. In some examples, the third anionic polymer is present in an amount of about 1 mg / g. In some examples, the third anionic polymer is present in an amount of about 2 mg / g. In some examples, the third anionic polymer is present in an amount of about 5 mg / g. In some examples, per 100 g of product, the third anionic polymer material is present in an amount of from about 1 mg to 500 mg.Vesicle forming lipids
[0059] In some embodiments, the vesicle composition comprises one or more vesicle forming lipids. The vesicle forming lipids act to encapsulate portions of the oil-in-water emulsions. In some embodiments, this allows the oil-in-water emulsion to remain stable for a period of time.
[0060] The vesicle forming lipids may be any suitable lipids for such a purpose. In some embodiments, the vesicle forming lipids comprise phospholipids, glycolipids, lecithins, ceramides, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof. In some embodiments, the vesicle forming lipids comprise a combination of lipids. In some embodiments, the vesicle forming lipids are hydrogenated. In some examples, the vesicle forming lipids comprise hydrogenated lecithin.
[0061] In some embodiments, the vesicle forming lipids comprise phospholipids. In some embodiments, the phospholipids are naturally occurring, semi synthetic, or synthetically prepared, or a mixture thereof. In an embodiment, the phospholipids are one or more esters of glycerol with one or two (equal or different) residues of fatty adds and with phosphoric acid, wherein the phosphoric acid residue is in turn bound to a hydrophilic group, such as, for instance, choline (phosphatidylcholines— PC), serine (phosphatidylserines— PS), glycerol (phosphatidylglycerols— PG), ethanolamine (phosphatidylethanolamines— PE), or inositol (phosphatidylinositol). Esters of phospholipids with only one residue of fatty acid are generally referred to in the art as the "lyso" forms of the phospholipid or "lysophospholipids". Fatty acids residues present in the phospholipids are in general long chain aliphatic acids, typically containing 12 to 24 carbon atoms, or 14 to 22 carbon atoms; the aliphatic chain may contain one or more unsaturations or is completely saturated. Examples of suitable fatty acids included in the phospholipids are, for instance, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleicacid, linoleic acid, and linolenic acid. Saturated fatty acids such as myristic acid, palmitic acid, stearic acid and arachidic acid may be employed.
[0062] In some embodiments, the phospholipid comprises one or more natural phospholipids. In some embodiments, the phospholipid comprises one or more semisynthetic phospholipids. In some embodiments, the semisynthetic phospholipids are the partially or fully hydrogenated derivatives of the naturally occurring lecithins. In some embodiments, the phospholipids include fatty acids di-esters of phosphatidylcholine, ethylphosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine or of sphingomyelin. In some embodiments, the phospholipids include hydrogenated phosphatidylcholine (e.g., Sunlipon 90H). In some embodiments, the phospholipids are, for instance, dilauroyl-phosphatidylcholine (DLPC), dimyristoyl-phosphatidylcholine (DMPC), dipalmitoyl-phosphatidylcholine (DPPC), diarachidoyl- phosphatidylcholine (DAPC), distearoyl-phosphatidylcholine (DSPC), dioleoyl- phosphatidylcholine (DOPC), l,2Distearoyl-sn-glycero-3-Ethylphosphocholine (Ethyl-DSPC), dipentadecanoyl- phosphatidylcholine (DPDPC), l-myristoyl-2-palmitoyl-phosphatidylcholine (MPPC), 1 -palmitoyl -2- myristoyl-phosphatidylcholine (PMPC), l-palmitoyl-2-stearoyl- phosphatidylcholine (PSPC), 1- stearoyl-2-palmitoyl-phosphatidylcholine (SPPC), 1-palmitoyl- 2-oleylphosphatidylcholine (POPC), l-oleyl-2-palmitoyl-phosphatidylcholine (OPPC), dilauroylphosphatidylglycerol (DLPG) and its alkali metal salts, diarachidoylphosphatidylglycerol (DAPG) and its alkali metal salts, dimyristoylphosphatidylglycerol (DMPG) and its alkali metal salts, dipalmitoylphosphatidylglycerol (DPPG) and its alkali metal salts, distearoylphosphatidylglycerol (DSPG) and its alkali metal salts, dioleoyl-phosphatidylglycerol (DOPG) and its alkali metal salts, dimyristoyl phosphatidic acid DMPA) and its alkali metal salts, dipalmitoyl phosphatidic acid (DPP A) and its alkali metal salts, distearoyl phosphatidic acid (DSP A), diarachidoylphosphatidic acid (DAP A) and its alkali metal salts, dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoyl phosphatidyl-ethanolamine (DSPE), dioleylphosphatidylethanolamine (DOPE), diarachidoylphosphatidylethanolamine (DAPE), dilinoleylphosphatidylethanolamine (DLPE), dimyristoyl phosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS), dipalmitoyl sphingomyelin (DPSP), and di stearoyl sphingomyelin (DSSP), dilauroylphosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), dioleoyl-phosphatidylinositol (DOPI).
[0063] In some embodiments, the vesicle forming lipids are present in an amount of about 0.5 % to about 25 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of about 0.5 % to about 2 %, about 0.5 % to about 5 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 0.5 % to about 12 %, about 0.5 % to about 15 %, about 0.5 % to about 20 %, about 0.5 % to about 25 %, about 2 % to about 5 %, about 2 % to about 8 %, about 2 % to about 10 %, about 2 % to about 12 %, about 2 % to about 15 %, about 2 % to about 20 %, about 2 % to about 25 %, about 5 % to about 8 %, about 5 % to about 10 %, about 5 % to about 12 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 8 % to about 10 %, about 8 % to about 12 %, about 8 % to about 15 %, about 8 % to about 20 %, about 8 % to about 25 %, about 10 % to about 12 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 12 % to about 15 %, about 12 % to about 20 %, about 12 % to about 25 %, about 15 % to about 20 %, about 15 % to about 25 %, or about 20 % to about 25 %(w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the vesicle forming lipids are present in an amount of at least about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, or about 20 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of at most about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, about 20 %, or about 25 % (w / w) of the composition.
[0064] In some embodiments, the vesicle forming lipids are present in an amount of about 5 % to about 15 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of about 5 % to about 8 %, about 5 % to about 9 %, about 5 % to about 10 %, about 5 % to about 11 %, about 5 % to about 12 %, about 5 % to about 13 %, about 5 % to about 14 %, about 5 % to about 15 %, about 8 % to about 9 %, about 8 % to about 10 %, about 8 % to about 11 %, about 8 % to about 12 %, about 8 % to about 13 %, about 8 % to about 14 %, about 8 % to about 15 %, about 9 % to about 10 %, about 9 % to about 11 %, about 9 % to about 12 %, about 9 % to about 13 %, about 9 % to about 14 %, about 9 % to about 15 %, about 10 % to about 11 %, about 10 % to about 12 %, about 10 % to about 13 %, about 10 % to about 14 %, about 10 % to about 15 %, about 11 % to about 12 %, about 11 % to about 13 %, about 11 % to about 14 %, about 11 % to about 15 %, about 12 % to about 13 %, about 12 % to about 14 %, about 12 % to about 15 %, about 13 % to about 14 %, about 13 % to about 15 %, or about 14 % to about 15 %. In some embodiments, the vesicle forming lipids are present in an amount of about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of at least about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about12 %, about 13 %, or about 14 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of at most about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 % (w / w) of the composition.
[0065] In some embodiments, the composition comprises a short chain polyol. In some embodiments, the short chain polyol acts to enhance the stability of the resulting lipid vesicles. In some embodiments, the short chain polyol is a C2-C4 polyol comprising two or three alcohol groups. In some embodiments, the short chain polyol is propylene glycol. In some embodiments, the composition comprises propylene glycol. In some embodiments, the composition comprises butanediol (e.g., 2,3 butanediol). In some embodiments, the composition comprises propylene glycol, butanediol, or both.
[0066] In some embodiments, the propylene glycol is present in an amount of about 0.5 % to about 25 % (w / w) of the composition. In some embodiments, the propylene glycol is present in an amount of about 0.5 % to about 2 %, about 0.5 % to about 5 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 0.5 % to about 12 %, about 0.5 % to about 15 %, about 0.5 % to about 20 %, about 0.5 % to about 25 %, about 2 % to about 5 %, about 2 % to about 8 %, about 2 % to about 10 %, about 2 % to about 12 %, about 2 % to about 15 %, about 2 % to about 20 %, about 2 % to about 25 %, about 5 % to about 8 %, about 5 % to about 10 %, about 5 % to about 12 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 8 % to about 10 %, about 8 % to about 12 %, about 8 % to about 15 %, about 8 % to about 20 %, about 8 % to about 25 %, about 10 % to about 12 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 12 % to about 15 %, about 12 % to about 20 %, about 12 % to about 25 %, about 15 % to about 20 %, about 15 % to about 25 %, or about 20 % to about 25 %. In some embodiments, the propylene glycol is present in an amount of about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 10.5 %, about 12 %, about 13 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the propylene glycol is present in an amount of at least about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about13 %, about 15 %, or about 20 %. In some embodiments, the propylene glycol is present in an amount of at most about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 13 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the propylene glycol is present in an amount of about 1 % to about 10 %. In some embodiments, the propylene glycol is present in an amount of about 1 % to about 2 %, about 1 % to about 4 %, about 1 % to about 6 %, about 1 % to about 8 %, about 1 % to about 10 %, about 2 % to about 4 %, about 2 % to about 6 %, about 2 % to about 8 %, about 2 % to about 10 %, about 4 % to about 6 %, about 4 % to about 8 %, about 4 % to about 10 %, about 6 % to about 8 %, about 6 % to about 10 %, or about 8 % to about 10 %. In some embodiments, the propylene glycol is present in an amount of about 1 %, about 2 %,about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, the propylene glycol is present in an amount of at least about 1 %, about 2 %, about 4 %, about 6 %, or about 8 %. In some embodiments, the propylene glycol is present in an amount of at most about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, propylene glycol is present in about the same amount as the vesicle forming lipid. In some embodiments, the ratio of propylene glycol to vesicle forming lipid in the composition is form about 2: 1 to about 1 :2 (w / w).
[0067] In some embodiments, the butanediol (e.g., 2,3-butanediol) is present in an amount of about 0.5 % to about 25 % (w / w) of the composition. In some embodiments, the butanediol is present in an amount of about 0.5 % to about 2 %, about 0.5 % to about 5 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 0.5 % to about 12 %, about 0.5 % to about 15 %, about 0.5 % to about 20 %, about 0.5 % to about 25 %, about 2 % to about 5 %, about 2 % to about 8 %, about 2 % to about 10 %, about 2 % to about 12 %, about 2 % to about 15 %, about 2 % to about 20 %, about 2 % to about 25 %, about 5 % to about 8 %, about 5 % to about 10 %, about 5 % to about 12 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 8 % to about 10 %, about 8 % to about 12 %, about 8 % to about 15 %, about 8 % to about 20 %, about 8 % to about 25 %, about 10 % to about 12 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 12 % to about 15 %, about 12 % to about 20 %, about 12 % to about 25 %, about 15 % to about 20 %, about 15 % to about 25 %, or about 20 % to about 25 %. In some embodiments, the butanediol is present in an amount of about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 10.5 %, about 12 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the butanediol is present in an amount of at least about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, or about 20 %. In some embodiments, the butanediol is present in an amount of at most about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the butanediol is present in an amount of about 1 % to about 10 %. In some embodiments, the butanediol is present in an amount of about 1 % to about 2 %, about 1 % to about 4 %, about 1 % to about 6 %, about 1 % to about 8 %, about 1 % to about 10 %, about 2 % to about 4 %, about 2 % to about 6 %, about 2 % to about 8 %, about 2 % to about 10 %, about 4 % to about 6 %, about 4 % to about 8 %, about 4 % to about 10 %, about 6 % to about 8 %, about 6 % to about 10 %, or about 8 % to about 10 %. In some embodiments, the butanediol is present in an amount of about 1 %, about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, the butanediol is present in an amount of at least about 1 %, about 2 %, about 4 %, about 6 %, or about 8 %. In some embodiments, the butanediol is present in an amount of at most about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, butanediol is present in about the same amount as the vesicle forming lipid. In some embodiments, the ratio ofbutanediol to vesicle forming lipid in the composition is form about 2: 1 to about 1 :2 (w / w). In some embodiments, in a composition comprising butanediol and propylene glycol, the ratio of butanediol to propylene glycol is about 1 : 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1, 7: 1, 8: 1, 9: 1, 10: 1, 11 : 1, or 12: 1.Oil Phases
[0068] The lipid vesicle compositions provided herein comprise an oil-in-water emulsion. The oil component is selected such that the material is a liquid at operative temperatures (e.g., room temperature) and is non-miscible with water.
[0069] Any suitable oil may be used as the oil phase. In some embodiments, the oil comprises a naturally occurring oil. In some embodiments, the naturally occurring oil is derived from one or more plants or plant parts (e.g., seeds or nuts). In some embodiments, the oil is a naturally occurring oil such as olive oil, vegetable oil, sunflower oil, or other similar plant derived oil.
[0070] In some embodiments, the oil phase is selected from the group consisting of vegetable oils, mono-, di-, and triglycerides, silicone fluids, mineral oils, and combinations thereof.
[0071] In some embodiments, the oil comprises a silicon oil or derivative, such as dimethicone. In some embodiments, the silicon oil comprises a siloxane polymer. In some embodiments, the siloxane polymer comprises C1-C3 substituents. In some embodiments, the siloxane is polydimethylsiloxane (PDMS). In some embodiments, the silicon oil is polymethylsilsesquioxane (e.g., Botanisil™ SP-360). In some embodiments, the oil is a mixture which comprises a silicon oil (e.g., dimethicone) as a smaller component. In some embodiments, the oil is a mixture which comprises a natural emollient as a substitute for dimethicone (e.g., LexFeel™ N350 MB). In some embodiments, the silicon oil is incorporated in order to enhance the feel of the resulting composition or as a moisturizer. In some embodiments, the oil comprises a silicon oil in an amount of up to about 5 %, up to about 4%, up to about 3 %, up to about 2%, or up to about 1% (w / w) of the composition. In some embodiments, the silicon oil is present in an amount of from about 0.1 % to about 2%. In some embodiments, the silicon oil is present in an amount of from about 0.1 % to about 0.5 %, 0.1 % to about 0.7%, 0.1 % to about 1 %, 0.1 % to about 1.5%, 0.15% to about 2 %, 0.5 % to about 0.7%, 0.5 % to about 1 %, 0.5 % to about 1.5 %, 0.5 % to about 2 %, 0.7 % to about 1 %, 0.7 % to about 1.5 %, 0.7 % to about 2 %, 1 % to about 1.5 %, or 1 % to about 2 % (w / w) of the composition. In some embodiments, the silicon oil is present in an amount of about 0.1 %, 0.5 %, 0.6 %, 0.7%, 1%, 1.5%, or 2% of the composition.
[0072] In some embodiments, the oils are present in an amount of about 1 % to about 35 % (w / w) of the composition. In some embodiments, the oils are present in an amount of about 1 % to about 5 %, about 1 % to about 10 %, about 1 % to about 15 %, about 1 % to about 20 %, about 1 % to about 25 %, about 1 % to about 30 %, about 1 % to about 35 %, about 5 % to about 10 %,about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 5 % to about 30 %, about 5 % to about 35 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 10 % to about 30 %, about 10 % to about 35 %, about 15 % to about 20 %, about 15 % to about 25 %, about 15 % to about 30 %, about 15 % to about 35 %, about 20 % to about 25 %, about 20 % to about 30 %, about 20 % to about 35 %, about 25 % to about 30 %, about 25 % to about 35 %, or about 30 % to about 35 %. In some embodiments, the oils are present in an amount of about 1 %, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %. In some embodiments, the oils are present in an amount of at least about 1 %, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, or about 30 %. In some embodiments, the oils are present in an amount of at most about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %. In some embodiments, the oils are present in an amount of about 5 % to about 15 %. In some embodiments, the oils are present in an amount of about 5 % to about 8 %, about 5 % to about 9 %, about 5 % to about 10 %, about 5 % to about 11 %, about 5 % to about 12 %, about 5 % to about 13 %, about 5 % to about 14 %, about 5 % to about 15 %, about 8 % to about 9 %, about 8 % to about 10 %, about 8 % to about 11 %, about 8 % to about 12 %, about 8 % to about 13 %, about 8 % to about 14 %, about 8 % to about 15 %, about 9 % to about 10 %, about 9 % to about 11 %, about 9 % to about 12 %, about 9 % to about 13 %, about 9 % to about 14 %, about 9 % to about 15 %, about 10 % to about 11 %, about 10 % to about 12 %, about 10 % to about 13 %, about 10 % to about 14 %, about 10 % to about 15 %, about 11 % to about 12 %, about 11 % to about 13 %, about 11 % to about 14 %, about 11 % to about 15 %, about 12 % to about 13 %, about 12 % to about 14 %, about 12 % to about 15 %, about 13 % to about 14 %, about 13 % to about 15 %, or about 14 % to about 15 %. In some embodiments, the oils are present in an amount of about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 %. In some embodiments, the oils are present in an amount of at least about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, or about 14 %. In some embodiments, the oils are present in an amount of at most about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 %.
[0073] In some embodiments, the oil comprises one or more triglycerides. In some embodiments the triglyceride is a medium chain triglyceride. In some embodiments, the medium chain triglyceride comprises fatty acid esters having a chain length of Ce-Cn.
[0074] In some embodiments, the triglyceride is present in an amount of about 1 % to about 35 % (w / w) of the composition. In some embodiments, the triglyceride is present in an amount of about 1 % to about 5 %, about 1 % to about 10 %, about 1 % to about 15 %, about 1 % to about 20 %, about 1 % to about 25 %, about 1 % to about 30 %, about 1 % to about 35 %, about 5 % toabout 10 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 5 % to about 30 %, about 5 % to about 35 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 10 % to about 30 %, about 10 % to about 35 %, about 15 % to about 20 %, about 15 % to about 25 %, about 15 % to about 30 %, about 15 % to about 35 %, about 20 % to about 25 %, about 20 % to about 30 %, about 20 % to about 35 %, about 25 % to about 30 %, about 25 % to about 35 %, or about 30 % to about 35 %. In some embodiments, the triglyceride is present in an amount of about 1 %, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %. In some embodiments, the triglyceride is present in an amount of at least about 1 %, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, or about 30 %. In some embodiments, the triglyceride is present in an amount of at most about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %.
[0075] In some embodiments, the oil phase of the lipid vesicle and / or the lipid vesicle portion of the composition comprises a sterol. In some embodiments, the sterol is a naturally derived sterol. In some embodiments, the sterol is a synthetic sterol. In some embodiments, the sterol is cholesterol. In some embodiments, the cholesterol may be plant-derived cholesterol. In some embodiments, the cholesterol may be synthetic cholesterol. In some embodiments the plant- derived cholesterol may be cholest-5-en-3-ol (e.g., PhytoChoi®, SyntheChol®, Avanti#700100), or any other plant-derived cholesterol, or any combination thereof. In some embodiments, the sterol may be phytosterol or a derivative thereof. In some embodiments, the phytosterol or derivative thereof may be phytosterol MM, Advasterol™ 90 IP or 95 IP F, NET Sterol-ISO, Canola Sterols, sitosterol 700095, lanosterol-95, brassicasterol, or any combination thereof.
[0076] In some embodiments, the sterol is present in an amount of about 0.1 % to about 5 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 0.1 % to about 5 %. In some embodiments, the sterol is present in an amount of about 0.1 % to about 0.2 %, about 0.1 % to about 0.5 %, about 0.1 % to about 0.8 %, about 0.1 % to about 1 %, about 0.1 % to about 2 %, about 0.1 % to about 3 %, about 0.1 % to about 4 %, about 0.1 % to about 5 %, about 0.2 % to about 0.5 %, about 0.2 % to about 0.8 %, about 0.2 % to about 1 %, about 0.2 % to about 2 %, about 0.2 % to about 3 %, about 0.2 % to about 4 %, about 0.2 % to about 5 %, about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 0.8 % to about 1 %, about 0.8 % to about 2 %, about 0.8 % to about 3 %, about 0.8 % to about 4 %, about 0.8 % to about 5 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 %. In some embodiments, the sterol is present in an amount of about 0.1 %, about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the sterol is present in an amount of at least about 0.1 %, about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, or about 4 %. In some embodiments, the sterol is present in an amount of at most about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the sterol is present in an amount of about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, about 1.5 % to about 3 %, about 1.5 % to about 4 %, about 1.5 % to about 5 %, about 2 % to about 2.5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2.5 % to about 3 %, about 2.5 % to about 4 %, about 2.5 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 1 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 4 %, or about 5 %(w / w) of the composition. In some embodiments, the sterol is present in an amount of at least about 1 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, or about 4 %(w / w) of the composition. In some embodiments, the sterol is present in an amount of at most about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 4 %, or about 5 %(w / w) of the composition.
[0077] In some embodiments, the lipid vesicle compositions comprise one or more penetration enhancers. In some embodiments, a penetration enhancer acts to increase the amount of penetration of the anionic polymer material through one or more layers of skin when applied to the skin of an individual. In some embodiments, a penetration enhancer acts to increase the amount of penetration of one or more peptides through one or more layers of skin when applied to the skin of an individual.
[0078] In some embodiments, a composition comprising one or more penetration enhancers has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by at least 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more penetration enhancers when applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more penetration enhancers has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by greater than 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without theone or more penetration enhancers when applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more penetration enhancers has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more penetration enhancers when applied one or more layers of the skin of a similar or same skin sample or skin of an individual.
[0079] In some embodiments, a composition comprising one or more non-ionic surfactants with an HLB value of about 10 or less has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by at least 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more non-ionic surfactants with an HLB value of about 10 or less when applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more non-ionic surfactants with an HLB value of about 10 or less has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by greater than 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more non-ionic surfactants with an HLB value of about 10 or less when applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more non-ionic surfactants with an HLB value of about 10 or less has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more non-ionic surfactants with an HLB value of about 10 or less when applied one or more layers of the skin of a similar or same skin sample or skin of an individual.
[0080] In some embodiments, the penetration enhancer is included in the oil-in-water emulsion of the composition. In some embodiments, the penetration enhancer is included in the lipid bilayer of the composition.
[0081] There are many types of penetration enhancing agents that may be employed. In some embodiments, the penetration enhancing agent comprising an ionic surfactant, a nonionic surfactant, or a combination thereof. In some embodiments, an ionic surfactant, a non-ionic surfactant, or a combination thereof is not a penetration enhancing agent.
[0082] In some embodiments, the penetration enhancing agent comprises a non-ionic surfactant or a combination of non-ionic surfactants. In some embodiments, the penetration enhancing agent is a single non-ionic surfactant. In some embodiments, the penetration enhancing agent is a combination of at least 2, 3, 4, or more non-ionic surfactants. In some embodiments, the penetration enhancing agent is a combination 2 non-ionic surfactants. In some embodiments, the penetration enhancing agent is a combination 3 non-ionic surfactants.
[0083] In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters and combinations thereof.
[0084] In some embodiments, the non-ionic surfactant comprises a polyethylene glycol (PEG) ethers of a fatty alcohol. In some embodiments, the PEG ether of the fatty alcohol comprises from about 2 to about 8 PEG groups and a C12-C22 fatty alcohol. In some embodiments, the polyethylene glycol ether of a fatty alcohol comprises di ethylene glycol hexadecyl ether, 2-(2- octadecoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the polyethylene glycol ether of a fatty alcohol comprises 2-(2- octadecoxyethoxy)ethanol. In some embodiments, the PEG ether of a fatty alcohol is super refined Brij® 02 or a derivative thereof.
[0085] In some embodiments, the PEG ether of the fatty alcohol is present in an amount of from about 0.5 % to about 10 %, about 0.5 % to about 5 %, about 0.5 % to about 4 %, or about 0.05 % to about 3% (w / w) of the composition. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of about 0.5 % to about 2.5 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of at least about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of at most about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0086] In some embodiments, the non-ionic surfactant comprises a sorbitan ester. In some embodiments, the sorbitan ester is a fatty acid ester. In some embodiments, the sorbitan ester is a C12-C22 fatty acid ester. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combinations thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate. In some embodiments, the sorbitan ester comprises sorbitan monopalmitate. In some embodiments, the sorbitan ester comprises sorbitan monostearate. In some embodiments, the sorbitan ester comprises sorbitan monooleate. In some embodiments, the sorbitan ester comprises sorbitan trioleate. In some embodiments, the sorbitan ester comprises sorbitan sesquioleate. In some embodiments, the sorbitan ester comprises sorbitan isostearate.
[0087] In some embodiments, the sorbitan ester is present in an amount of up to about 5 % (w / w) of the composition. In some embodiments, the sorbitan ester is present in an amount of from about 0.5 % to about 5 %, about 0.5 % to about 4 %, or about 0.5 % to about 3 %. In some embodiments, the sorbitan ester is present in an amount of about 0.5 % to about 2.5 %. In some embodiments, the sorbitan ester is present in an amount of about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the sorbitan ester is present in an amount of about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the sorbitan ester is present in an amount of at least about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the sorbitan ester is present in an amount of at most about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0088] In some embodiments, the non-ionic surfactant comprises a polysorbate. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the polysorbate is polysorbate 20. In some embodiments, the polysorbate is added to the aqueous phase of the composition.
[0089] In some embodiments, the polysorbate is present in an amount of up to about 5 %. In some embodiments, the polysorbate is present in an amount of from about 0.5 % to about 5 %,about 0.5 % to about 4 %, or about 0.5 % to about 3 % (w / w) of the composition. In some embodiments, the polysorbate is present in an amount of about 0.5 % to about 2.5 %. In some embodiments, the polysorbate is present in an amount of about 0.2 % to about 0.5 %, about 0.2 % to about 0.8 %, about 0.2 % to about 1 %, about 0.2 % to about 1.2 %, about 0.2 % to about 1.5 %, about 0.2 % to about 2 %, about 0.2 % to about 2.5 %, about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the polysorbate is present in an amount of about 0.2 %, 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the polysorbate is present in an amount of at least about 0.2 %, 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the polysorbate is present in an amount of at most about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0090] In some embodiments, the non-ionic surfactant comprises a polyethylene glycol (PEG) fatty acid ester. In some embodiments, the PEG fatty acid ester is a PEG chain of about 2-8 subunits comprising C8-C22 fatty acids affixed to each terminal hydroxyl to form the fatty acid ester. In some embodiments, the PEG fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glycerides, or any combination thereof In some embodiments, the PEG fatty acid ester is PEG-4 dilaurate.
[0091] In some embodiments, the PEG fatty acid ester is present in an amount of up to about 5 % (w / w) of the composition. In some embodiments, the PEG fatty acid ester is present in an amount of from about 0.5 % to about 5 %, about 0.5 % to about 4 %, or about 0.5 % to about 3 %. In some embodiments, the PEG fatty ester is present in an amount of about 0.5 % to about 2.5 %. In some embodiments, the PEG fatty ester is present in an amount of about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the PEG fatty ester is present in an amount of about 0.5 %, about 0.8 %, about 1 %, about 1.2 %,about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the PEG fatty ester is present in an amount of at least about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the PEG fatty ester is present in an amount of at most about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0092] In some embodiments, the non-ionic surfactant has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the non-ionic surfactant comprises glyceryl monostearate (e.g., Cithrol GMS 40). In some embodiments, the non-ionic surfactant comprises an oleyl alcohol (e.g., Lipocol 0-95). In some embodiments, the non-ionic surfactant comprises a polyoxyethylene oleyl ether (e.g., Oleth-2). In some embodiments, the non-ionic surfactant comprises a propylene glycol monocaprylate (e.g., Capryol® 90). In some embodiments, the composition comprises a plurality of non-ionic surfactants, each having an HLB of about 10 or less. In some embodiments, the non-ionic surfactant with an HLB of 10 or less is selected from the Table 1 below, or any combination thereof.Table 1
[0093] In some embodiments, the non-ionic surfactant has a hydrophobic-lipophilic balance (HLB) of about 10 or more. In some embodiments, the composition comprises a plurality of nonionic surfactants, each having an HLB of about 10 or more.
[0094] In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.5 % to about 10 % (w / w) of the composition. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.5 % to about 1 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 0.5 % to about 6 %, about 0.5 % to about 7 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1 % to about 6 %, about 1 % to about 7 %, about 1 % to about 8 %, about 1 % to about 10 %, about 1.5 % to about 2 %, about 1.5 % to about 3 %, about 1.5 % to about 4 %, about 1.5 % to about 5 %, about 1.5 % to about 6 %, about 1.5 % to about 7 %, about 1.5 % to about 8 %, about 1.5 % to about 10 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2 % to about 6 %, about 2 % to about 7 %, about 2 % to about 8 %, about 2 % to about 10 %, about 3 % to about 4 %, about 3 % to about 5 %, about 3 % to about 6 %, about 3 % to about 7 %, about 3 % to about 8 %, about 3 % to about 10 %, about 4 % to about 5 %, about 4 % to about 6 %, about 4 % to about 7 %, about 4 % to about 8 %, about 4 % to about 10 %, about 5 % to about 6 %, about 5 % to about 7 %, about 5 % to about 8 %, about 5 % to about 10 %, about 6 % to about 7 %, about 6 % to about 8 %, about 6 % to about 10 %, about 7 % to about 8 %, about 7 % to about 10 %, or about 8 % to about 10 %. In someembodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.5 %, about 0.6 %, about 0.7 %, about 1 %, about 1.5 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, or about 10 %. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.6 % (e.g., 0.54 % to about 0.66 %). In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.7 % (e.g, 0.63 % to about 0.77 %). In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of at least about 0.5 %, about 0.7 %, about 1 %, about 1.5 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, or about 8 %. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of at most about 0.7 %, about 1 %, about 1.5 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, or about 10 %.
[0095] In some embodiments, the composition comprises a non-ionic surfactant in the oil-in- water emulsion, the lipid bilayer, or both. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion. In some embodiments, the composition comprises a non-ionic surfactant in the lipid bilayer. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion and the lipid bilayer, wherein the composition comprises two or more different non-ionic surfactants.
[0096] In some embodiments, the penetration enhancing agent comprises a salicylate ester or a nicotinate ester. In some embodiments, the ester is a Ci-Ce alkyl ester or a benzyl ester. In some embodiments, the penetration enhancing agent comprises methyl salicylate or benzyl nicotinate. In some embodiments, the penetration enhancing agent is a nicotinate ester present in an amount of up to about 0.1 %, 0.5%, 1%, 2%, or 3% (w / w) of the composition. In some embodiments, the nicotinate ester is present in an amount of from about 0.1% to about 3%, about 0.1% to about 2%, or about 0.1% to about 1%. In some embodiments, benzyl nicotinate is present at an amount of about 0.5%.Cationic Surfactants
[0097] In some embodiments, the composition comprises an ionic surfactant. In some embodiments, the ionic surfactant is a cationic surfactant. In some embodiments, the cationic surfactant is a mono-cationic surfactant, a di-cationic surfactant, or a poly-cationic surfactant.
[0098] In some embodiments, the mono-cationic surfactant is used in the composition to form a submicron emulsion prior to formation of a final lipid vesicle composition provided herein (e.g., before the lipid forming vesicles are added). In some embodiments, the mono-cationic surfactant is net-mono-cationic (e.g., a phosphate salt comprising two side chains each with a single cationic functionality, which is partially neutralized by a phosphate anion).
[0099] In some embodiments, the mono-cationic surfactant is a fatty-amide derived propylene glycol-diammonium phosphate ester. Fatty-amide derived propylene glycol-diammonium phosphate esters are phospholipids which comprise at least one propylene glycol phosphoester linked to a quaternary ammonium group, which is in turn linked with a fatty acid amide. One non-limiting example of a fatty-amide derived propylene glycol-diammonium phosphate ester is linoleamidopropyl PG-dimonium chloride phosphate. Similar compounds with different fatty acid amide groups attached are also known. In some embodiments, the fatty-amide derived propylene glycol-diammoniom phosphate ester has the structure:wherein n is an integer from 1 to 3, m is an integer from 0 to 2, wherein the sum of m and n is 3; X is a cation selected from a proton, sodium, potassium, magnesium, and calcium; and R is an acyl group of a Cs-Cso fatty acid.
[0100] In some embodiments, the fatty acid is a C12-C24 fatty acid. In some embodiments, the fatty acid is an unsaturated fatty acid. In some embodiments, the fatty acid is linoleic acid. In some embodiments, the mono-cationic penetration enhancing agent is linoleamidopropyl PG- dimonium chloride phosphate (e.g., Ariasilk™ PTM, Ariasilk™ EFA).
[0101] In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of about 1 % to about 20 % (w / w) of the composition. In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about1 % to about 5 %, about 1 % to about 6 %, about 1 % to about 7 %, about 1 % to about 8 %, about 1 % to about 9 %, about 1 % to about 10 %, about 1 % to about 12 %, about 1 % to about 15 %, about 1 % to about 20 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2 % to about 6 %, about 2 % to about 7 %, about 2 % to about 8 %, about 2 % to about 9 %, about 2 % to about 10 %, about 2 % to about 12 %, about 2 % to about 15 %, about2 % to about 20 %, about 3 % to about 4 %, about 3 % to about 5 %, about 3 % to about 6 %, about 3 % to about 7 %, about 3 % to about 8 %, about 3 % to about 9 %, about 3 % to about 10 %, about 3 % to about 12 %, about 3 % to about 15 %, about 3 % to about 20 %, about 4 % to about 5 %, about 4 % to about 6 %, about 4 % to about 7 %, about 4 % to about 8 %, about 4 % to about 9 %, about 4 % to about 10 %, about 4 % to about 12 %, about 4 % to about 15 %, about4 % to about 20 %, about 5 % to about 6 %, about 5 % to about 7 %, about 5 % to about 8 %, about 5 % to about 9 %, about 5 % to about 10 %, about 5 % to about 12 %, about 5 % to about 15 %, about 5 % to about 20 %, about 6 % to about 7 %, about 6 % to about 8 %, about 6 % to about 9 %, about 6 % to about 10 %, about 6 % to about 12 %, about 6 % to about 15 %, about 6 % to about 20 %, about 7 % to about 8 %, about 7 % to about 9 %, about 7 % to about 10 %, about 7 % to about 12 %, about 7 % to about 15 %, about 7 % to about 20 %, about 8 % to about 9 %, about 8 % to about 10 %, about 8 % to about 12 %, about 8 % to about 15 %, about 8 % to about 20 %, about 9 % to about 10 %, about 9 % to about 12 %, about 9 % to about 15 %, about 9 % to about 20 %, about 10 % to about 12 %, about 10 % to about 15 %, about 10 % to about 20 %, about 12 % to about 15 %, about 12 % to about 20 %, or about 15 % to about 20 %. In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of about 1 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 6.5 %, about 7 %, about 7.5 %, about 8 %, about 9 %, about 10 %, about 12 %, about 15 %, or about 20 %. In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of at least about 1 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 6.5 %, about 7 %, about 7.5 %, about 8 %, about 9 %, about 10 %, about 12 %, about 15 %, or about 20 %. In some embodiments, the fatty amide derived propylene glycol- diammonium phosphate ester is present in an amount of at most about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 6.5 %, about 7 %, about 7.5 %, about 8 %, about 9 %, about 10 %, about 12 %, about 15 %, or about 20 %.
[0102] In some embodiments, the cationic surfactant is a di-cationic penetration enhancing agent. In some embodiments, the di-cationic surfactant is a gemini surfactant. In some embodiments, a gemini surfactant is a surfactant comprising two quaternary amines represented by the formula A-N(R)2-B-N(R)2-C, wherein each of A and C is independently an optionally substituted C6-C24 alkyl group, each R is independently optionally substituted Ci-Ce alkyl, and B is an optionally substituted C2-C10 alkylene chain. In some embodiments, the each of A and C is a C6-C24 saturated or unsaturated hydrocarbon. In some embodiments, the each of A and C is a C6-C24 saturated hydrocarbon. In some embodiments, each R is methyl. In some embodiments, B is a saturated C2-C10 alkylene chain. In some cases, gemini surfactants follow the nomenclature X-Y- Z, wherein each of X, Y, and Z is an integer representing the number of carbon atoms of each substituent, and Y is the spacer between the two quaternary amines. Thus, for example, a 12-3-12 gemini surfactant has the formula CH3(CH2)II-[N+(CH3)2]-(CH2)3-[N+(CH3)2]- (CH2)nCH3. In some embodiments, the gemini surfactant is a 10-2-10, 12-2-12, 14-2-14, 10-3-10, 12-3-12, 14-3- 14, 10-4-10, 12-4-12, or 14-4-14 gemini surfactant. In some embodiments, the gemini surfactant is a 12-3-12 gemini surfactant.
[0103] In some embodiments, the gemini surfactant is present in an amount of about 0.1 % to about 1.5 % (w / w) of the composition. In some embodiments, the gemini surfactant is present in an amount of about 0.1 % to about 0.2 %, about 0.1 % to about 0.3 %, about 0.1 % to about 0.5 %, about 0.1 % to about 0.7 %, about 0.1 % to about 0.9 %, about 0.1 % to about 1 %, about 0.1 % to about 1.2 %, about 0.1 % to about 1.5 %, about 0.2 % to about 0.3 %, about 0.2 % to about 0.5 %, about 0.2 % to about 0.7 %, about 0.2 % to about 0.9 %, about 0.2 % to about 1 %, about 0.2 % to about 1.2 %, about 0.2 % to about 1.5 %, about 0.3 % to about 0.5 %, about 0.3 % to about 0.7 %, about 0.3 % to about 0.9 %, about 0.3 % to about 1 %, about 0.3 % to about 1.2 %, about 0.3 % to about 1.5 %, about 0.5 % to about 0.7 %, about 0.5 % to about 0.9 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.7 % to about 0.9 %, about 0.7 % to about 1 %, about 0.7 % to about 1.2 %, about 0.7 % to about 1.5 %, about 0.9 % to about 1 %, about 0.9 % to about 1.2 %, about 0.9 % to about 1.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, or about 1.2 % to about 1.5 %. In some embodiments, the gemini surfactant is present in an amount of about 0.1 %, about 0.2 %, about 0.3 %, about 0.5 %, about 0.7 %, about 0.9 %, about 1 %, about 1.2 %, or about 1.5 %. In some embodiments, the gemini surfactant is present in an amount of at least about 0.1 %, about 0.2 %, about 0.3 %, about 0.5 %, about 0.7 %, about 0.9 %, about 1 %, or about 1.2 %. In some embodiments, the gemini surfactant is present in an amount of at most about 0.2 %, about 0.3 %, about 0.5 %, about 0.7 %, about 0.9 %, about 1 %, about 1.2 %, or about 1.5 %.
[0104] In some embodiments, the cationic surfactant comprises a polycationic group. In some embodiments, the polycationic group is a polymer wherein each monomer of the polymer comprises a charged group (e.g., an amino group). In some embodiments, the polycationic group is polylysine. In some embodiments, the polycationic group is polyarginine.
[0105] In some embodiments, the polylysine has a molecular weight of from about 1 kDa to about 10 kDa, from about 1 kDa to about 5 kDa, or from about 3 kDa to about 5 kDa. In some embodiments, the polylysine is present in an amount of from about 0.01% to about 1%, from about 0.01% to about 0.5%, from about 0.01% to about 0.2%, from about 0.05% to about 1%, from about 0.05% to about 0.5%, or from about 0.05% to about 0.2% (w / w) of the composition. Additional Components
[0106] In some embodiments, the vesicle composition comprises additional components. In some embodiments, these additional components improve one or more properties of the vesicles without dramatically altering the delivery of the anionic polymer material.
[0107] In some embodiments, the vesicle composition further comprises one or more viscosity enhancing agents. In some embodiments, the viscosity enhancing agents thicken the composition for increased stability and / or feel to a user of the vesicle composition. In some embodiments, theviscosity enhancing agents also act as surfactants. In some embodiments, the viscosity enhancing agent comprises one or more of a fatty alcohol, an oil, a wax, a fatty ester of glycerol, or any combination thereof. In some embodiments, the fatty alcohol is a C8-C20 fatty alcohol. In some embodiments, the fatty alcohol is cetyl alcohol. In some embodiments, the wax is a naturally occurring or synthetic wax. In some embodiments, the wax is beeswax. In some embodiment, the wax is synthetic beeswax. In some embodiments, the synthetic beeswax is syncrowax™ BB4. In some embodiments, the synthetic beeswax is non-animal derived beeswax. In some embodiments, the non-animal derived beeswax is syncrowax™ SB1. In some embodiments, the wax is jojoba wax. In some instances, the jojoba wax comprises jojoba wax flakes. In some instances, the wax / oil is hydrogenated wax / oil (e.g., hydrogenated jojoba oil). In some instances, the wax / oil is fully hydrogenated. In some embodiments, the fatty ester of glycerol is a monoester. In some embodiments, the monoester is an ester of a C8-C24 fatty acid. In some embodiments, the fatty ester of glycerol is glycerol monostearate.
[0108] In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.1% to about 10% (w / w) of the composition. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.1 % to about 5 %. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.1 % to about 0.3 %, about 0.1 % to about 0.5 %, about 0.1 % to about 1 %, about 0.1 % to about 1 %, about 0.1 % to about 2 %, about 0.1 % to about 3 %, about 0.1 % to about 4 %, about 0.1 % to about 5 %, about 0.3 % to about 0.5 %, about 0.3 % to about 1 %, about 0.3 % to about 1 %, about 0.3 % to about 2 %, about 0.3 % to about 3 %, about 0.3 % to about 4 %, about 0.3 % to about 5 %, about 0.5 % to about 1 %, about 0.5 % to about 1 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 1 % to about 1 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 %. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.1 %, about 0.3 %, about 0.5 %, about 1 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the viscosity enhancing agents are present in an amount of from at least about 0.1 %, about 0.3 %, about 0.5 %, about 1 %, about 1 %, about 2 %, about 3 %, or about 4 %. In some embodiments, the viscosity enhancing agents are present in an amount of from at most about 0.3 %, about 0.5 %, about 1 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the viscosity enhancing agents comprise a fatty alcohol in an amount of up to about 2 %, a wax in an amount of up to about 2%, and a fatty ester of glycerol in an amount of upto about 5 %. In some embodiments, the fatty alcohol is present in an amount of from about 0.1 to about 1.5%. In some embodiments, the fatty alcohol is present in an amount of about 0.4 % (e.g., 0.36 % to about 0.44 %). In some embodiments, the fatty alcohol is present in an amount of about 0.6%. In some embodiments, the wax is present in an amount of from about 0.1% to about 1%. In some embodiments, the wax is present in an amount of about 0.2% (e.g., about 0.18 % to about 0.22 %). In some embodiments, the wax is present in an amount of about 0.3% (e.g., about 0.27 % to about 0.33 %). In some embodiments, the fatty ester of glycerol is present in an amount of from about 0.5 % to about 2 %. In some embodiments, the fatty ester of glycerol is present in an amount of about 0.8 % (e.g., 0.72 % to about 0.88 %). In some embodiments, the fatty ester of glycerol is present in an amount of about 0.9%. In some embodiments, the fatty ester of glycerol is present in an amount of about 1%. In some embodiments, the fatty ester of glycerol is present in an amount of about 1.2%.
[0109] In some embodiments, the vesicle composition further comprises one or more of a thickener, a preservative, a moisturizer, an emollient, a humectant, or any combination thereof. In some embodiments, the vesicle composition further comprises a thickener. In some embodiments, the vesicle composition further comprises a preservative. In some embodiments, the vesicle composition further comprises a moisturizer. In some embodiments, the vesicle composition further comprises an emollient. In some embodiments, the vesicle composition further comprises a humectant. In some embodiments, the vesicle composition further comprises a fragrance (e.g., Mentha piperita). In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.01% to about 0.1%. In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.05%.
[0110] In some embodiments, the vesicle composition further comprises an antimicrobial. In some embodiments, the antimicrobial is a paraben ester. In some embodiments, the antimicrobial is methylparaben or propylparaben, or a combination thereof. In some embodiments, the antimicrobial is present in an amount of up to about 1%, up to about 0.9%, up to about 0.8%, up to about 0.7%, up to about 0.6%, up to about 0.5%, up to about 0.4%, up to about 0.3%, up to about 0.2% (w / w) of the composition.[OHl] In some embodiments, the vesicle composition further comprises a thickener. In some embodiments, the thickener is an inert polymer material. In some embodiments, the thickener is a siloxane polymer. In some embodiments, the thickener polydimethyl siloxane (PDMS). In some embodiments, the PDMS is present in an amount of up to about 5%, up to about 4%, up to about 3%, up to about 2%, or up to about 1%. In some embodiments, the PDMS is present in an amount of from about 0.1% to about 2% (w / w) of the composition.
[0112] In some embodiments, the composition further comprises a humectant. In some embodiments, the composition comprises glycerol. In some embodiments, the glycerol is present in an amount of from about 0.5 % to about 25 %, about 0.5 % to about 20%, about 0.5 % to about 15 %, or about 0.5 % to about 10 %. In some embodiments, the glycerol is present in an amount of about 1 % to about 10 %. In some embodiments, the glycerol is present in an amount of about 0.1 % to about 0.5 %, about 0.1 % to about 1 %, about 0.5 % to about 1 %, about 0.5% to about 1.5 %, about 1 % to about 2 %, about 1 % to about 4 %, about 1 % to about 6 %, about 1 % to about 8 %, about 1 % to about 10 %, about 2 % to about 4 %, about 2 % to about 6 %, about 2 % to about 8 %, about 2 % to about 10 %, about 4 % to about 6 %, about 4 % to about 8 %, about 4 % to about 10 %, about 6 % to about 8 %, about 6 % to about 10 %, or about 8 % to about 10 %. In some embodiments, the glycerol is present in an amount of about 0.1%, about 0.5%, about 1 %, about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, the glycerol is present in an amount of at least about 0.1 %, about 0.5%, about 1 %, about 2 %, about 4 %, about 6 %, or about 8 %. In some embodiments, the glycerol is present in an amount of at most about 1%, about 2 %, about 4 %, about 6 %, about 8 %, or about 10 % (w / w) of the composition.
[0113] In some embodiments, the vesicle composition comprises a preservative. In some embodiments, the preservative is a cosmetic preservative, such as Euxyl® PE 9010 or Spectrastat®. In some embodiments, the preservative comprises a phenoxyethanol / ethylhexylglycerin mixture. In some embodiments, the preservative comprises a blend of caprylhydroxamic acid, caprylyl glycol, glycerin, or any combination thereof. In some embodiments, the preservative or each of the components of a preservative provided herein is present in an amount of up to about 2%, up to about 1.5 %, or up to about 1% (w / w) of the composition. In some embodiments, the preservative or each of the components of a preservative is present in an amount of from about 0.1% to about 2%, from about 0.1% to about 1.5%, from about 0.1% to about 1%, from about 0.01% to 0.05%, from about 0.01% to 0.1%, from about 0.05% to 0.1%, or from about 0.05% to 0.5%. In some embodiments, the preservative or each of the components of a preservative is present in an amount of about 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1%, 1.05%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, or 2%.
[0114] In some embodiments, the composition further comprises material to promote a desirable change in the skin, such as smoothing wrinkles. In some embodiments, the composition comprises a carbohydrate or an acceptable salt thereof. In some embodiments, the carbohydrate is a monosaccharide, disaccharide, or polysaccharide. In some embodiments, the carbohydrate or acceptable salt thereof comprises N-Acetyl-a-D-glucosamine 6-phosphate disodium salt(NovHyal™). In some embodiments, carbohydrate comprises a saccharide isomerate (e.g., Hyanify™). In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of from about 0.1% to about 0.5 %. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of from about 0.1 % to about 0.2 %, about 0.1 % to about 0.3 %, about 0.1 % to about 0.4 %, about 0.1 % to about 0.5 %, about 0.2 % to about 0.3 %, about 0.2 % to about 0.4 %, about 0.2 % to about 0.5 %, about 0.3 % to about 0.4 %, about 0.3 % to about 0.5 %, or about 0.4 % to about 0.5 %. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of about 0.1 %, 0.2 %, 0.3 %, 0.4 %, or 0.5 %. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of at least about 0.1 %, 0.2 %, 0.3 %, 0.4 %, or 0.5 %. In some embodiments, the carbohydrate or an acceptable salt thereof is present in the composition in an amount of at most about 0.1 %, 0.2 %, 0.3 %, 0.4 %, or 0.5 %.
[0115] In some embodiments, the composition comprises a polymer of an amino acid. In some embodiments, the polymer of an amino acid comprises a high molecular weight (MW) polymer of the amino acid, a low MW polymer of the amino acid, or both. In some embodiments, the polymer of an amino acid comprises polyglutamate. In some cases, the polyglutamate comprises low MW polyglutamate (e.g., Hyafactor™ PGA LM), high MW polyglutamate (e.g., Hyafactor™ PGA HM), or both. In some embodiments, the polymer of the amino acid comprises sodium polyglutamate.
[0116] In some embodiments, the ratio of high MW polymer of the amino acid and low MW polymer of the amino acid is about 10: 1, 9: 1. 8: 1, 7: 1, 6: 1, 5: 1, 4: 1, 3: 1, 3:2, 2: 1, 1 : 1, 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9 or 1 : 10.
[0117] In some embodiments, the polymer of an amino acid is present in an amount from about 0.01 % to about 0.2 %. In some embodiments, the polymer of an amino acid is present in an amount from about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the polymer of an amino acid is present in an amount of about 0.01 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the polymer of an amino acid is present in an amount of at least about 0.01 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, the polymer of an amino acid is present in an amount of at most about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %.
[0118] In some embodiments, the combination of the high MW polymer and the low MW polymer is present in an amount from about 0.01 % to about 0.2 %. In some embodiments, thecombination is present in an amount from about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the combination is present in an amount of about 0.01 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the combination is present in an amount of at least about 0.01 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, the combination is present in an amount of at most about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %.
[0119] In some embodiments, the high MW polymer of the amino acid is present in an amount of about 0.01 % to about 0.2 %. In some embodiments, the high MW polymer is present in an amount from about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the high MW polymer is present in an amount of about 0.01 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the high MW polymer is present in an amount of at least about 0.01 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, the high MW polymer is present in an amount of at most about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the low MW polymer of the amino acid is present in an amount of about 0.01 % to about 0.2 %. In some embodiments, the low MW polymer of the amino acid is present in an amount from about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the low MW polymer of the amino acid is present in an amount of about 0.01 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the low MW polymer of the amino acid is present in an amount of at least about 0.01 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, the low MW polymer of the amino acid is present in an amount of at most about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some examples, the high MW polymer is present in an amount of about 0.01 % and the low MW polymer is present in an amount of about 0.01 %. In some examples, the high MW polymer is present in an amount of about 0.02 % and the low MW polymer is present in an amount of about 0.01 %. In some examples, the high MW polymer is present in an amount of about 0.05 % and the low MW polymer is present in an amount of about 0.025 %. In some examples, the high MW polymer is present in an amount of about 0.05 %. In some embodiments, the low MW polymer is present in an amount of about 0.05 %. In someexamples, the high MW polymer is present in an amount of about 0.05 % and the low MW polymer is present in an amount of about 0.05 %. In some examples, the high MW polymer is present in an amount of about 0.1 % and the low MW polymer is present in an amount of about 0.1 %. In some examples, the high MW polymer is present in an amount of about 0.2 % and the low MW polymer is present in an amount of about 0.1 %. In some examples, the high MW polymer is present in an amount of about 0.2 % and the low MW polymer is present in an amount of about 0.2 %.
[0120] In some embodiments, the composition further comprises collagen. In some cases, the collagen in human collagen or vegan human collagen (e.g., HumaColl21®). In some cases, the molecular weight is about 15 kDa, 18 kDa, 20 kDa, 25 kDa, or 30 kDa. In some embodiments, the collagen in present in an amount from about 0.01 % to about 0.2 %. In some embodiments, the collagen is present in an amount from about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the collagen is present in an amount of about 0.01 %, about 0.02 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the collagen is present in an amount of at least about 0.01 %, about 0.02 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, the collagen is present in an amount of at most about 0.2%, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %.
[0121] In some embodiments, the composition further comprises material to promote a desirable change in the skin, such as reducing darkness in one or more areas of the skin. In some embodiments, the material comprises one or more biological extracts. The one or more biological extracts, each or in total, may be present in an amount of from about 0.01 % to about 0.2 %. In some instances, one or more biological extracts may be present in an amount of from about 0.01 % to about 0.02 %, about 0.01 % to about 0.04 %, about 0.01 % to about 0.06 %, about 0.01 % to about 0.08 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.12 %, about 0.01 % to about 0.14 %, about 0.01 % to about 0.16 %, about 0.01 % to about 0.18 %, about 0.01 % to about 0.2 %, about 0.02 % to about 0.04 %, about 0.02 % to about 0.06 %, about 0.02 % to about 0.08 %, about 0.02 % to about 0.1 %, about 0.02 % to about 0.12 %, about 0.02 % to about 0.14 %, about 0.02 % to about 0.16 %, about 0.02 % to about 0.18 %, about 0.02 % to about 0.2 %, about 0.04 % to about 0.06 %, about 0.04 % to about 0.08 %, about 0.04 % to about 0.1 %, about 0.04 % to about 0.12 %, about 0.04 % to about 0.14 %, about 0.04 % to about 0.16 %, about 0.04 % to about 0.18 %, about 0.04 % to about 0.2 %, about 0.06 % to about 0.08 %, about 0.06 % to about 0.1 %, about 0.06 % to about 0.12 %, about 0.06 % to about 0.14 %, about 0.06 % to about 0.16%, about 0.06 % to about 0.18 %, about 0.06 % to about 0.2 %, about 0.08 % to about 0.1 %, about 0.08 % to about 0.12 %, about 0.08 % to about 0.14 %, about 0.08 % to about 0.16 %, about 0.08 % to about 0.18 %, about 0.08 % to about 0.2 %, about 0.1 % to about 0.12 %, about 0.1 % to about 0.14 %, about 0.1 % to about 0.16 %, about 0.1 % to about 0.18 %, about 0.1 % to about 0.2 %, about 0.12 % to about 0.14 %, about 0.12 % to about 0.16 %, about 0.12 % to about 0.18 %, about 0.12 % to about 0.2 %, about 0.14 % to about 0.16 %, about 0.14 % to about 0.18 %, about 0.14 % to about 0.2 %, about 0.16 % to about 0.18 %, about 0.16 % to about 0.2 %, or about 0.18 % to about 0.2 %. In some instances, one or more biological extracts, each or in total, may be present in an amount of from about 0.01 %, about 0.02 %, about 0.04 %, about 0.06 %, about 0.08 %, about 0.1 %, about 0.12 %, about 0.14 %, about 0.16 %, about 0.18 %, or about 0.2 %. In some instances, one or more biological extracts, each or in total, may be present in an amount of from at least about 0.01 %, about 0.02 %, about 0.04 %, about 0.06 %, about 0.08 %, about 0.1 %, about 0.12 %, about 0.14 %, about 0.16 %, or about 0.18 %. In some instances, one or more biological extracts, each or in total, may be present in an amount of from at most about 0.02 %, about 0.04 %, about 0.06 %, about 0.08 %, about 0.1 %, about 0.12 %, about 0.14 %, about 0.16 %, about 0.18 %, or about 0.2 %.
[0122] In some embodiments, the one or more biological extracts are natural extracts or synthetic extracts. In some embodiments, the one or more biological extracts comprises a carbohydrate. In some embodiments, the carbohydrate comprises fucoidan. Examples of biological extracts comprise, but are not limited to, an algae extract, a marine extract, a biotechnology extract, root extract, or a flower extract (e.g., Seanactiv, Shadownyl Clear, Eyedeline, Eye’fective, Meiview, Rootness Awake, etc.). In some examples, the flower extract comprises a Jasminum Sambac flower extract (e.g., jasmine flower extract). In some examples, the flower extract comprises a Crataegus Monogyna flower extract (e.g., Hawthorn flower extract). In some examples, the extract is obtained by fermentation of bacteria. As an example, Bacillus ferment may be obtained by fermentation of Bacillus subtilis. In some examples, the root extract is from a plant belonging to the family Convolvulaceae. As an example, the root extract may be obtained from the roots of Ipomoea batatas. Each of the algae extract, marine extract, biotechnology extract, root extract, or flower extract may be present in in a biological extract composition added to the formulation in an amount of about 0.01 %, 0.02 %, 0.03 %, 0.04 %, 0.05 %, 0.06 %, 0.07 %, 0.08 %, 0.09 %, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, or 0.8 %, 0.9 %, or 1 %. Each of the algae extract, marine extract, biotechnology extract, root extract, or flower extract may be present in in a biological extract composition added to the formulation in an amount of at most about 0.01 %, 0.02 %, 0.03 %, 0.04 %, 0.05 %, 0.06 %, 0.07 %, 0.08 %, 0.09 %, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, or 0.8 %, 0.9 %, or 1 %. Each of the algae extract, marine extract,biotechnology extract, root extract, or flower extract may be present in in a biological extract composition added to the formulation in an amount of at least about 0.01 %, 0.02 %, 0.03 %,0.04 %, 0.05 %, 0.06 %, 0.07 %, 0.08 %, 0.09 %, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7%, or 0.8 %, 0.9 %, or 1 %. Each of the algae extract, marine extract, biotechnology extract, root extract, or flower extract may be present in in a biological extract composition added to the formulation in an amount of about 0.1 % to 0.2 %, 0.1 % to 0.5 %, 0.1 % to 0.8 %, 0.1 % to 1 %,0.2 % to 0.5 %, 0.2 % to 0.8 %, 0.2 % to 1 %, 0.5 % to 0.8 %, 0.5 % to 1 %, or 0.8 % to 1 %. In some embodiments, the biological extract composition is present in the formulation from about0.1 % to 0.2 %, 0.1 % to 0.5 %, 0.1 % to 0.8 %, 0.1 % to 1 %, 0.1 % to 1.2 %, 0.1 % to 1.5 %,0.1 % to 2 %, 0.1 % to 2.5 %, 0.1 % to 3 %, 0.2 % to 0.5 %, 0.2 % to 0.8 %, 0.2 % to 1 %, 0.2 % to 1.2 %, 0.2 % to 1.5 %, 0.2 % to 2 %, 0.2 % to 2.5 %, 0.2 % to 3 %, 0.5 % to 0.8 %, 0.5 % to 1%, 0.5 % to 1.2 %, 0.5 % to 1.5 %, 0.5 % to 2 %, 0.5 % to 2.5 %, 0.5 % to 3 %, or 0.8 % to 1 %,0.8 % to 1.2 %, 0.8 % to 1.5 %, 0.8 % to 2 %, 0.8 % to 2.5 %, 0.8 % to 3 %, 1 % to 1.2 %, 1 % to1.5 %, 1 % to 2 %, 1 % to 2.5 %, 1 % to 3 %, 1.2 % to 1.5 %, 1.2 % to 2 %, 1.2 % to 2.5 %, 1.2% to 3 %, 1.5 % to 2 %, 1.5 % to 2.5 %, 1.5 % to 3 %, 2 % to 2.5 %, 2 % to 3 %, or 2.5 % to 3%. In some embodiments, the biological extract composition is present in the formulation in an amount of about 0.01 %, 0.02 %, 0.03 %, 0.04 %, 0.05 %, 0.06 %, 0.07 %, 0.08 %, 0.09 %, 0.1%, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, or 0.8 %, 0.9 %, 1 %, 1.2 %, 1.5 %, 2 %, 2.5 %, or3 %. In some embodiments, the biological extract composition is present in the formulation in an amount of at least about 0.01 %, 0.02 %, 0.03 %, 0.04 %, 0.05 %, 0.06 %, 0.07 %, 0.08 %, 0.09%, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, or 0.8 %, 0.9 %, 1 %, 1.2 %, 1.5 %, 2 %, or2.5 %. In some embodiments, the biological extract composition is present in the formulation in an amount of at most about 0.01 %, 0.02 %, 0.03 %, 0.04 %, 0.05 %, 0.06 %, 0.07 %, 0.08 %,0.09 %, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, or 0.8 %, 0.9 %, 1 %, 1.2 %, 1.5 %, 2 %, 2.5 %, or 3 %.
[0123] A biological extract composition added to the formulation provided herein may further comprise additional ingredients such as, for example, water, propanediol, xanthum gum, sodium sulfate, glycerin, glyceryl caprylate, or another other suitable solvent, or any combination thereof. In some instances, an additional ingredient (e.g., propanediol, xanthum gum, sodium sulfate, glycerin, glyceryl caprylate, etc.) is present in an amount of about 1% to about 10 %. In some instances, an additional ingredient is present in an amount of about 1 %, 2 %, 3 %, 4 %, 5%, 8%, or 10 %. In some instances, an additional ingredient is present in an amount of at least about 1 %, 2 %, 3 %, 4 %, 5%, or 8%. In some instances, an additional ingredient is present in an amount of at most about 2 %, 3 %, 4 %, 5%, 8%, or 10 %. In some instances, an additional ingredient is present in an amount from about 1% to 2%, 1% to 3%, 1% to 4%, 1% to 5%, 1% to8%, 1% to 10%, 2% to 3%, 2% to 4%, 2% to 5%, 2% to 8%, 2% to 10%, 3% to 4%, 3% to 5%, 3% to 8%, 3% to 10%, 4% to 5%, 4% to 8%, 4% to 10%, 5% to 8%, 5% to 10%, or 8% to 10%.
[0124] In some embodiments, an additional component may comprise one or more vitamins or derivatives thereof. In some cases, the one or more vitamins or derivatives thereof may provide one or more desired effects (e.g., smoothing, toning, moisturizing, brightening, reducing acne, eczema, wrinkles, etc.) when applied to the skin or epidermis. In some instances, the additional component may comprise vitamin B, vitamin C (ascorbic acid), vitamin A (retinol), vitamin E (tocopherol), vitamin D, vitamin F, vitamin K or any derivative thereof. In some examples, the additional component may comprise vitamin B3 (niacin). In some instances, a vitamin B3 derivative may comprise niacinamide. In some examples, the additional component may comprise vitamin E (tocopherol). In some instances, a vitamin E derivative may comprise tocopherol acetate. In some instances, a vitamin C derivative may comprise aminopropyl ascorbyl phosphate. In some examples, the additional component may comprise provitamin B5 (panthenol). In some embodiments, the one or more vitamins or derivatives thereof are each or collectively present in the composition in an about from about 0.1 % to about 4 % (w / w). In some embodiments, the one or more vitamins or derivatives thereof are each or collectively present in an amount of about 0.01% to about 0.05%, about 0.01% to about 0.1%, about 0.05% to about 0.1%, about 0.1 % to about 0.2%, about 0.1 % to about 0.3 %, about 0.1 % to about 0.5 %, about 0.1 % to about 0.8 %, about 0.1 % to about 1 %, about 0.1 % to about 1.2 %, about 0.1 % to about 1.5 %, about 0.1 % to about 2 %, about 0.1 % to about 2.5 %, about 0.1 % to about 3 %, about 0.1 % to about 3.5 %, about 0.1 % to about 4 %, about 0.2 % to about 0.3 %, about 0.2 % to about 0.5 %, about 0.2 % to about 0.8 %, about 0.2 % to about 1 %, about 0.2 % to about 1.2 %, about 0.2 % to about 1.5 %, about 0.2 % to about 2 %, about 0.2 % to about 2.5 %, about 0.2 % to about 3 %, about 0.2 % to about 3.5 %, about 0.2 % to about 4 %, about 0.3 % to about 0.5 %, about 0.3 % to about 0.8 %, about 0.3 % to about 1 %, about 0.3 % to about 1.2 %, about 0.3 % to about 1.5 %, about 0.3 % to about 2 %, about 0.3 % to about 2.5 %, about 0.3 % to about 3 %, about 0.3 % to about 3.5 %, about 0.3 % to about 4 %, about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.5 % to about 3 %, about 0.5 % to about 3.5 %, about 0.5 % to about 4 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 0.8 % to about 3 %, about 0.8 % to about 3.5 %, about 0.8 % to about 4 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1 % to about 3 %, about 1 % to about 3.5 %, about 1 % to about 4 %, about 1.2 % to about 1.5 %,about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.2 % to about 3 %, about 1.2 % to about 3.5 %, about 1.2 % to about 4 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, about 1.5 % to about 3 %, about 1.5 % to about 3.5 %, about 1.5 % to about 4 %, about 2 % to about 2.5 %, about 2 % to about 3 %, about 2 % to about 3.5 %, about 2 % to about 4 %, about 2.5 % to about 3 %, about 2.5 % to about 3.5 %, about 2.5 % to about 4 %, about 3 % to about 3.5 %, about 3 % to about 4 %, or about 3.5 % to about 4 %. In some embodiments, the one or more vitamins or derivatives thereof is each or collectively present in an amount of about 0.01%, about 0.05%, about 0.1 %, about 0.2 %, about 0.3%, about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, about 2.05 %, about 2.5 %, about 3 %, about 3.5 %, or about 4%. In some embodiments, the one or more vitamins or derivatives thereof is each or collectively present in an amount of at least about 0.01%, about 0.05%, about 0.1 %, about 0.2 %, about 0.3%, about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 3.5 %, or about 4%. In some embodiments, the one or more vitamins or derivatives thereof is each or collectively present in an amount of at most about 0.01%, about 0.05%, about 0.1 %, about 0.2 %, about 0.3%, about 0.5%, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 3.5 %, or about 4%.
[0125] In some embodiments, an additional component in the lipid vesicle composition may comprise an antioxidant. In some cases, the antioxidant may comprise vitamin C or a derivative thereof. In some instances, the antioxidant may comprise ascorbic acid, citric acid, ascorbyl palmitate, sodium ascorbyl phosphate, magnesium ascorbyl phosphate, retinyl ascorbate, aminopropyl ascorbyl phosphate (K3 Vita-C), tetrahexyl decyl ascorbate, ascorbyl methylsilanol pectinate (ascorbosilane SP), or a combination thereof. In some embodiments, the antioxidant, such as a vitamin C or derivative thereof, may also aid in collagen synthesis. In some embodiments, the additional component may comprise resorcinol (e.g., 4-butyl resorcinol). In some embodiments, antioxidant is present in the composition in an amount of from about 0.005 % to about 1 %. In some embodiments, antioxidant is present in the composition in an amount of from about 0.005 % to about 0.01 %, about 0.005 % to about 0.02 %, about 0.005 % to about 0.05 %, about 0.005 % to about 0.07 %, about 0.005 % to about 0.1 %, about 0.005 % to about 0.3 %, about 0.005 % to about 0.5 %, about 0.005 % to about 0.8 %, about 0.005 % to about 1 %, about 0.01 % to about 0.02 %, about 0.01 % to about 0.05 %, about 0.01 % to about 0.07 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.3 %, about 0.01 % to about 0.5 %, about 0.01 % to about 0.8 %, about 0.01 % to about 1 %, about 0.02 % to about 0.05 %, about 0.02 % to about 0.07 %, about 0.02 % to about 0.1 %, about 0.02 % to about 0.3 %, about 0.02 % to about 0.5 %, about 0.02 % to about 0.8 %, about 0.02 % to about 1 %, about 0.05 % to about0.07 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.3 %, about 0.05 % to about 0.5 %, about 0.05 % to about 0.8 %, about 0.05 % to about 1 %, about 0.07 % to about 0.1 %, about 0.07 % to about 0.3 %, about 0.07 % to about 0.5 %, about 0.07 % to about 0.8 %, about 0.07 % to about 1 %, about 0.1 % to about 0.3 %, about 0.1 % to about 0.5 %, about 0.1 % to about 0.8 %, about 0.1 % to about 1 %, about 0.3 % to about 0.5 %, about 0.3 % to about 0.8 %, about 0.3 % to about 1 %, about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, or about 0.8 % to about 1 %. In some embodiments, antioxidant is present in the composition in an amount of about 0.005 %, about 0.01 %, about 0.02 %, about 0.05 %, about 0.07 %, about 0.1 %, about 0.3 %, about 0.5 %, about 0.51 %, about 0.8 %, or about 1 %. In some embodiments, antioxidant is present in the composition in an amount of at least about 0.005 %, about 0.01 %, about 0.02 %, about 0.05 %, about 0.07 %, about 0.1 %, about 0.3 %, about 0.5 %, about 0.8 %, or about 1 %. In some embodiments, antioxidant is present in the composition in an amount of at most about 0.01 %, about 0.02 %, about 0.05 %, about 0.07 %, about 0.1 %, about 0.3 %, about 0.5 %, about 0.8 %, or about 1 %.
[0126] In some embodiments, an additional component comprises one or more trace amounts of benzyl salicylate, linalool, benzyl alcohol, or limonene. In some embodiments, one or more trace ingredients is present in the composition in less than 0.001 %, 0.0005%, 0.0001%.
[0127] In some embodiments, the composition comprises a silicon oil or derivative, such as dimethicone. In some embodiments, the oil silicon oil comprises a siloxane polymer. In some embodiments, the siloxane polymer comprises C1-C3 substituents. In some embodiments, the siloxane is polydimethylsiloxane (PDMS). In some embodiments, the silicon oil is polymethylsilsesquioxane (e.g., Botanisil™ SP-360). In some embodiments, the oil is a mixture which comprises a silicon oil (e.g., dimethicone) as a smaller component. In some embodiments, the silicon oil is incorporated in order to enhance the feel of the resulting composition or as a moisturizer. In some embodiments, the oil comprises a silicon oil in an amount of up to about 5 %, up to about 4%, up to about 3 %, up to about 2%, or up to about 1%. In some embodiments, the silicon oil is present in an amount of from about 0.1 % to about 2% (w / w) of the composition. In some embodiments, the silicon oil is present in an amount of from about 0.1 % to about 0.5 %, 0.1 % to about 0.7%, 0.1 % to about 1 %, 0.1 % to about 1.5%, 0.15% to about 2 %, 0.5 % to about 0.7%, 0.5 % to about 1 %, 0.5 % to about 1.5 %, 0.5 % to about 2 %, 0.7 % to about 1 %, 0.7 % to about 1.5 %, 0.7 % to about 2 %, 1 % to about 1.5 %, or 1 % to about 2 % (w / w) of the composition. In some embodiments, the silicon oil is present in an amount of about 0.1 %, 0.5 %, 0.6 %, 0.7%, 1%, 1.5%, or 2% of the composition.
[0128] In some embodiments, the composition comprises an emollient. In some embodiments, the emollient comprises caprylic and / or capric triglycerides (e.g., Labrafac CC). In someembodiments, caprylic and / or capric triglycerides is present in an amount of about 1 % to about 10 %. In some embodiments, caprylic and / or capric triglycerides is present in an amount of about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1 % to about 6 %, about 1 % to about 7 %, about 1 % to about 8 %, about 1 % to about 9 %, about 1 % to about 10 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2 % to about 6 %, about 2 % to about 7 %, about 2 % to about 8 %, about 2 % to about 9 %, about 2 % to about 10 %, about 3 % to about 4 %, about 3 % to about 5 %, about 3 % to about 6 %, about 3 % to about 7 %, about 3 % to about 8 %, about 3 % to about 9 %, about 3 % to about 10 %, about 4 % to about 5 %, about 4 % to about 6 %, about 4 % to about 7 %, about 4 % to about 8 %, about 4 % to about 9 %, about 4 % to about 10 %, about 5 % to about 6 %, about 5 % to about 7 %, about 5 % to about 8 %, about 5 % to about 9 %, about 5 % to about 10 %, about 6 % to about 7 %, about 6 % to about 8 %, about 6 % to about 9 %, about 6 % to about 10 %, about 7 % to about 8 %, about 7 % to about 9 %, about 7 % to about 10 %, about 8 % to about 9 %, about 8 % to about 10 %, or about 9 % to about 10 %. In some embodiments, caprylic and / or capric triglycerides is present in an amount of about 1 %, about 2 %, about 3 %, about 3.5 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, about 9 %, or about 10 %. In some embodiments, caprylic and / or capric triglycerides is present in an amount of at least about 1 %, about 2 %, about 3 %, about 3.5 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, or about 9 %. In some embodiments, caprylic and / or capric triglycerides is present in an amount of at most about 2 %, about 3 %, about 3.5 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, about 9 %, or about 10 %.
[0129] In some embodiments, the additional components comprise purified water. In some embodiments, purified water is present in an amount of about 50% to 80% (w / w). In some embodiments, purified water is present in an amount of about 50 % to about 55 %, about 50 % to about 60 %, about 50 % to about 65 %, about 50 % to about 70 %, about 50 % to about 75 %, about 50 % to about 80 %, about 55 % to about 60 %, about 55 % to about 65 %, about 55 % to about 70 %, about 55 % to about 75 %, about 55 % to about 80 %, about 60 % to about 65 %, about 60 % to about 70 %, about 60 % to about 75 %, about 60 % to about 80 %, about 65 % to about 70 %, about 65 % to about 75 %, about 65 % to about 80 %, about 70 % to about 75 %, about 70 % to about 80 %, or about 75 % to about 80 %. In some embodiments, purified water is present in an amount of about 50 %, about 55 %, about 60 %, about 65 %, about 70 %, about 75 %, or about 80 %. In some embodiments, purified water is present in an amount of at least about 50 %, about 55 %, about 60 %, about 65 %, about 70 %, or about 75 %. In some embodiments, purified water is present in an amount of at most about 55 %, about 60 %, about 65 %, about 70 %, about 75 %, or about 80 %.Exemplary Compositions for Delivery of Anionic Polymer Materials
[0130] Provided below are exemplary compositions for the delivery of anionic polymer materials. The embodiments below may additionally comprise any of the other ingredients or components provided herein. In some embodiments, the other ingredients or components may be one or more peptides provided herein. In some embodiments, the one or more peptides can be dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, heptapeptides, octapeptides, or a combination thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides are entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof.
[0131] Hyaluronic Acid Composition 1: In one aspect, provided herein, is a lipid vesicle composition comprising(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids, wherein the vesicle forming lipids are present in an amount of from about 5% to about 20%;(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants, wherein the one or more surfactants comprises a cationic surfactant;(c) hyaluronic acid in an amount of from about 0.01 mg / mL to about 10 mg / mL entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof; and(d) one or more peptides in an amount of from about 0.1 mg / mL to about 50 mg / mL entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof.
[0132] In some embodiments, the oil component is present in an amount of from about 2.5% to about 20 %.
[0133] In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 1.25 mg / mL, about 0.01 mg / mL to about 1.5 mg / mL, about 0.01 mg / mL to about 1.75 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 1.25 mg / mL, about 0.1 mg / mL to about 1.5 mg / mL, about 0.1 mg / mL to about 1.75 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 1 mg / mL to about 1.5 mg / mL, about 1 mg / mL to about 1.75 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 10 mg / mL. In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL.
[0134] In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL. In some embodiments the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0135] In some embodiments, the lipid vesicle composition further comprises viscosity enhancing agents in an amount of from about 0.5% to about 5%. In some embodiments, the viscosity enhancing agents comprise one or more of a fatty alcohol, a wax, a fatty ester of glycerol, or any combination thereof.
[0136] In some embodiments, the lipid vesicle composition further comprises a non-ionic surfactant in an amount of from about 0.1% to about 3%. In some embodiments, the non-ionic surfactant is a PEG ether of a fatty alcohol.
[0137] In some embodiments, the one or more peptides of (d) comprise a tetrapeptide, pentapeptide, a hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 31, 36, or 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of any one of SEQ ID NO: 31, 36, or 37. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of SEQ ID NO: 37.
[0138] In some embodiments, the cationic surfactant is a fatty amide derived propylene glycoldiammonium phosphate ester. In some embodiments, the cationic surfactant is present in an amount of from about 1 % to about 10 %.
[0139] Hyaluronic Acid Composition 2: In one aspect, provided herein, is a lipid vesicle composition comprising(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids, wherein the vesicle forming lipids are present in an amount of from about 2% to about 20%;(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants;(c) hyaluronic acid in an amount of from about 0.01 mg / mL to about 10 mg / mL entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof, wherein the composition further comprises: a gemini surfactant in an amount of from about 0.01% to about 0.5%; and a polysorbate in an amount of from about 0.1 % to about 2%; and(d) one or more peptides in an amount of from about 0.1 mg / mL to about 50 mg / mL entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof.
[0140] In some embodiments, the oil component is present in an amount of from about 2.5% to about 20 %.
[0141] In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 1.25 mg / mL, about 0.01 mg / mL to about 1.5 mg / mL, about 0.01 mg / mL to about 1.75 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 1.25 mg / mL, about 0.1 mg / mL to about 1.5 mg / mL, about 0.1 mg / mL to about 1.75 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 1 mg / mL to about 1.5 mg / mL, about 1 mg / mL to about 1.75 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 10 mg / mL. In some embodiments, the lipid vesicle composition comprises hyaluronic acid in an amount of about 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 1.25 mg / mL, about 1.5 mg / mL, about 1.75 mg / mL, about 2 mg / mL, about 5 mg / mL, or about 10 mg / mL.
[0142] In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL. In some embodiments thelipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0143] In some embodiments, the lipid vesicle composition further comprises viscosity enhancing agents in an amount of from about 0.5% to about 5%. In some embodiments, the viscosity enhancing agents comprise one or more of a fatty alcohol, a wax, a fatty ester of glycerol, or any combination thereof.
[0144] In some embodiments, the one or more peptides of (d) comprise a tetrapeptide, pentapeptide, hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 31, 36, or 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of any one of SEQ ID NO: 31, 36, or 37. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of SEQ ID NO: 37.
[0145] In some embodiments, the polysorbate is polysorbate 80.Lipid Vesicle Compositions of One or More Peptides for Intradermal Delivery
[0146] In one aspect, provided herein, is a lipid vesicle composition comprising one or more peptides. In some embodiments, the one or more peptides can be dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, heptapeptides, octapeptides or a combination thereof. In some embodiments, the one or more peptides are unmodified. In some embodiments, the lipid vesicle composition comprises lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids. In some embodiments, the lipid vesicle composition comprises an oil-in-water emulsion entrapped in the lipid vesicles. In some embodiments, the oil-in-water emulsion is stabilized by one or more surfactants. In some embodiments, the one or more peptides are entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the lipid vesicle may further comprise other ingredients or components. In someembodiments, the other ingredients or components may be an anionic polymer material. In some embodiments, the anionic polymer material may be entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof. In some embodiments, the anionic polymer material is hyaluronic acid. In some embodiments, the hyaluronic acid is hydrolyzed hyaluronic acid.
[0147] In one aspect, the present disclosure relates to a lipid vesicle composition comprising one or more peptides, which may provide biological activity. Peptides which may provide biological activity may be referred to as bioactive peptides. In some embodiments, bioactive peptides may play a role in biological processes related to skin care, including, but not limited to, modulation of cell proliferation, inflammation, angiogenesis, melanogenesis, extracellular matrix synthesis, etc. See e.g., Falla, et. al., 2009, “Cosmeceuticals and peptides,” Clinics in Dermatology 27:485- 494, which is incorporated herein by reference in its entirety.Peptides in a Lipid Vesicle Composition
[0148] The present disclosure provides lipid vesicle compositions comprising one or more peptides in a lipid vesicle composition. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides comprise dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, heptapeptides, octapeptides, or a combination thereof. In some embodiments, the one or more peptides are tetrapeptides, pentapeptides, hexapeptides, or a combination thereof. In some embodiments, the one or more tetrapeptides, pentapeptides, hexapeptides, or a combination thereof, may be in a lipid vesicle composition comprising an anionic polymer material (e.g., hyaluronic acid). In some embodiments, the one or more peptides may exhibit a high affinity to a metal to form a complex. In some embodiments, the metal may be copper.
[0149] In some embodiments, the one or more peptides in the lipid vesicle composition provided herein has a desirable property, or an improved property relative to peptides known in the art. Such a property can include, e.g., a pharmacokinetic property (including but not limited to absorption, bioavailability, distribution, metabolism, and excretion), a pharmacodynamic property (including but not limited to: receptor binding characteristics, e.g., binding half-life; postreceptor effects; and chemical interactions), enhanced activity (e.g., represented by IC50), stability (e.g., represented by half-life), solubility (e.g., in a formulation), or permeability (e.g., permeability of the skin by a formulation containing the one or more peptides). In some embodiments, a formulation of the lipid vesicle containing one or more peptides of the disclosure has a desirable property, or an improved property relative to a formulation known in the art. In some embodiments, a desirable or improved property of a formulation of the disclosure is a property relating to the use of the formulation for an indication as described elsewhere herein, e.g., use for reducing or improving the appearance of skin wrinkles.Peptides
[0150] In some embodiments, the one or more peptides of the lipid vesicle composition comprises dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, heptapeptides, octapeptides, or a combination thereof. In some embodiments, the one or more peptides comprises a tetrapeptide. In some embodiments, the one or more peptides comprises a pentapeptide. In some embodiments, the one or more peptides comprises a hexapeptide. In some embodiments, the one or more peptides comprises a pentapeptide and a hexapeptide. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides comprises an amino acid sequence which has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides comprise one or more amino acid substitutions relative to any one SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprise 1, 2, or 3, 4 amino acid substitutions relative any one of SEQ ID NO: 1-51. In some embodiments, at least 1 of the 1, 2, or 3 amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides comprise an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51. In some embodiments, the one or more peptides have an amino acid sequence consisting of an identical sequence of any one of SEQ ID NOs: 1-51.
[0151] In some embodiments, the one or more peptides comprise an amino acid sequence which has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence SEQ ID NO: 13. In some embodiments, the one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 13. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaal-Xaa3. In some embodiments, the one or more peptides comprise 1 or 2 amino acid substitutions relative to SEQ ID NO: 13. In some embodiments, at least 1 of the 1 or 2 amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides have an amino acid sequence consisting of an identical sequence of SEQ ID NO: 13.
[0152] In some embodiments, the one or more peptides comprise an amino acid sequence which has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence SEQ ID NO: 21. In some embodiments, the one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 21. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaal-Xaa5. In some embodiments, the one or more peptides comprise 1, or 2 amino acid substitutions relative to SEQ ID NO: 21. In some embodiments, atleast 1 of the 1 or 2 amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides have an amino acid sequence consisting of an identical sequence of SEQ ID NO: 21.
[0153] In some embodiments, the one or more peptides comprise an amino acid sequence which has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence SEQ ID NO: 31. In some embodiments, the one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 31. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaal-Xaa5. In some embodiments, the one or more peptides comprise 1, or 2 amino acid substitutions relative to SEQ ID NO: 31. In some embodiments, at least 1 of the 1 or 2 amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides have an amino acid sequence consisting of an identical sequence of SEQ ID NO: 31.
[0154] In some embodiments, the one or more peptides comprise an amino acid sequence which has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 36. In some embodiments, the one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 36. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaal-Xaa6. In some embodiments, the one or more peptides comprise 1, 2, or 3amino acid substitutions relative to SEQ ID NO: 36. In some embodiments, at least lof the 1, 2, or 3 amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides have an amino acid sequence consisting of an identical sequence of SEQ ID NO: 36.
[0155] In some embodiments, the one or more peptides comprise an amino acid sequence which has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 37. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaal-Xaa6. In some embodiments, the one or more peptides comprise 1, 2, or 3 amino acid substitutions relative to SEQ ID NO: 37. In some embodiments, at least 1 of the 1, 2, or 3 amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides have an amino acid sequence consisting of an identical sequence of SEQ ID NO: 37.
[0156] In some embodiments, the one or more peptides comprise an amino acid sequence which has at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at leastabout 90% sequence homology to the amino acid sequence of SEQ ID NO: 40. In some embodiments, the one or more peptides comprise one or more amino acid substitutions relative to SEQ ID NO: 37. In some embodiments, the one or more amino acid substitutions are selected from the amino acids defined as Xaal-Xaa6. In some embodiments, the one or more peptides comprise 1, 2, or 3 amino acid substitutions relative to SEQ ID NO: 40. In some embodiments, at least 1 of the 1, 2, or 3 amino acid substitutions is a conservative substitution. In some embodiments, the one or more peptides have an amino acid sequence consisting of an identical sequence of SEQ ID NO: 40.
[0157] In some embodiments, the one or more peptides comprises up to about 8 amino acids up to about 7 amino acids, up to 6 amino acids, up to 5 amino acids, up to 4 amino acids, up to 3 amino acids, or up to 2 amino acids. In some embodiments, the one or more peptides has a molecular weight of up to about 1500 Da, up to about 1100 Da, up to about 950 Da, up to about 800 Da, up to about 650 Da, up to about 500 Da, up to about to about 350 Da, or up to about 250 Da.
[0158] In some embodiments, one or more peptides of the lipid vesicle composition has 2-8 residues. In some embodiments, one or more peptides of the lipid vesicle comprises the amino acid sequence:
[0159] Xaa 1 -Xaa2-Xaa3 -Xaa4-Xaa5 -Xaa6-Xaa7 -Xaa8 wherein:
[0160] Xaal is absent or selected from Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;
[0161] Xaa2 is absent or selected from: Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;
[0162] Xaa3 is absent or selected from: Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;
[0163] Xaa4 is absent or selected from: Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;
[0164] Xaa5 is absent or selected from: Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;Xaa6 is absent or selected from: Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;
[0165] Xaa7 is selected from: Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;;
[0166] Xaa8 is selected from: Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, He and a derivative of Ala, Gly, Gin, Glu, Vai, Leu, Cys, Met, Sec, Ser, Thr, Tyr, Trp, Arg, Asn, Asp, His, Pro, Phe, Lys, or He;
[0167] the N-terminus is unmodified; and
[0168] the C-terminus is unmodified.
[0169] In some embodiments, one or more peptides of the lipid vesicle composition has 2-8 residues. In some embodiments, one or more peptides of the lipid vesicle comprises the amino acid sequence:
[0170] Xaa 1 -Xaa2-Xaa3 -Xaa4-Xaa5 -Xaa6-Xaa7 -Xaa8 wherein:
[0171] Xaal is absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Gly, Lys, Pro, Tyr, or Vai;
[0172] Xaa2 is absent or selected from: Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, or Vai;
[0173] Xaa3 is absent or selected from: Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, or Vai;
[0174] Xaa4 is absent or selected from: Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Vai;
[0175] Xaa5 is absent or selected from: Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Vai;
[0176] Xaa6 is absent or selected from: Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Vai and a derivative of Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Vai;
[0177] Xaa7 is selected from: Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Vai;
[0178] Xaa8 is selected from: Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Vai and a derivative of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Vai;
[0179] the N-terminus is unmodified; and
[0180] the C-terminus is unmodified.
[0181] Non-limiting examples of one or more peptides of the disclosure are shown in Table 2.Table 2. Peptide Examples
[0182] Unless otherwise indicated in the table, peptides listed in Table 2 can comprise all L- amino acids or all D-amino acids. In some embodiments, peptides listed in Table 2 are unmodified. In some embodiments, peptides listed in Table 2 are synthetic human peptides (e.g., sh-polypeptide). In some embodiments, peptides listed in Table 2 are recombinant human peptides (e.g., rh-polypeptide). In some embodiments, the peptides listed in Table 2 comprise a counter ion (e.g., acetate). In some embodiments, the peptides listed in Table 2 are modified with an acetyl group (e.g., Ac).Amino Acid Derivatives
[0183] The present disclosure contemplates the use of an amino acid derivative or analog of any amino acid in any of the one or more peptides of the disclosure, such as those listed in Table 2. In some embodiments, amino acid modifications can be made chemically using any known method. Selective protein modifications are described in the literature, e.g., by Spicer and Davis, 2014, “Selective chemical protein modification,” Nature Communications 5: 4740, incorporated herein by reference.
[0184] In some embodiments, an amino acid derivative is a non-canonical amino acid. In some embodiments, a non-canonical amino acid has an (S) configuration at the alpha position. In some embodiments, a non-canonical amino acid has an (R) configuration at the alpha position. In some embodiments, a non-canonical amino acid is an alpha amino acid. In some embodiments, a non- canonical amino acid is a beta or gamma amino acid (e.g., beta-alanine). In some embodiments, a non-canonical amino acid is selected from the group consisting of an aromatic side chain amino acid; a non-aromatic side chain amino acid; an aliphatic side chain amino acid; a side chain amide amino acid; a side chain ester amino acid; a heteroaromatic side chain amino acid; a side chain thiol amino acid; a beta amino acid; and a backbone-modified amino acid. In some embodiments, a non-canonical amino acid is a derivative of tyrosine, histidine, tryptophan, or phenylalanine. In some embodiments, a derivative of an amino acid comprises an ester, amide, disulfide, carbamate, urea, phosphate, ether of the amino acid. In some embodiments, a non- aromatic side chain amino acid is a derivative of serine, threonine, cysteine, methionine, arginine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, proline, glycine, alanine, valine, isoleucine, or leucine. In some embodiments, a non-canonical amino acid is selected from the group consisting of 2-aminoadipic acid; 3-aminoadipic acid; beta-alanine; beta-aminoproprionicacid; 2-aminobutyric acid; 4-aminobutyric acid; piperidinic acid; 6-aminocaproic acid; 2- aminoheptanoic acid; 2-aminoisobutyric acid; 3 -aminoisobutyric acid; 2-aminopimelic acid; 2,4- diaminobutyric acid; desmosine; 2,2'-diaminopimelic acid; 2,3-diaminoproprionic acid; N- ethylglycine; N-ethylasparagine; hydroxylysine; allo-hydroxylysine; 3-hydroxyproline; 4- hydroxyproline; isodesmosine; allo-isoleucine; N-methylglycine; sarcosine; n-methylisoleucine; 6-N-methyllysine; N-methylvaline; norvaline; norleucine; and ornithine. In some embodiments, a non-canonical amino acid is a proline derivative. In some embodiments, a proline derivative is 3 -fluoroproline, 4-fluoroproline, 3-hydroxyproline, 4-hydroxyproline, 3 -aminoproline, 4- aminoproline, 3,4-dehydroproline, aziridine-2-carboxylic acid, azetidine-2-carboxylic acid, pipecolic acid, 4-oxa-proline, 3 -thiaproline, or 4-thiaproline. In some embodiments, a non- canonical amino acid comprises a lipid.
[0185] In some embodiments, one or more peptides of the disclosure comprises one or more amino acid derivative or analog, e.g., as known to those of skill in the art and described in the literature or herein. In some embodiments, one or more peptides of the disclosure comprises 2, 3, 4, 5, 6, 7, 8, 2-3, 2-4, 2-5, 2-6, 2-7, or 2-8 amino acid derivatives. In some embodiments, the one or more peptides are unmodified.
[0186] In some embodiments, each amino acid derivative present in the one or more peptides of the disclosure is a non-canonical amino acid independently selected from the group consisting of: an aromatic side chain amino acid; a non-aromatic side chain amino acid; an aliphatic side chain amino acid; a side chain amide amino acid; a side chain ester amino acid; a heteroaromatic side chain amino acid; a side chain thiol amino acid; a beta amino acid; and a backbone-modified amino acid, selected from e.g., the non-canonical amino acids described herein or known in the art and described in the published literature.
[0187] In some embodiments, the one or more peptides comprises one or more amino acids that have the D-amino acid configuration, and the remaining amino acids in the peptide have the L- amino acid configuration.
[0188] In some embodiments, a non-canonical amino acid is a proline derivative. In some embodiments, a proline derivative comprises one or more substitutions on the pyrrolidine ring. In some embodiments, a proline derivative comprises one or more substitutions on the pyrrolidine ring, wherein the substitutions comprise halogen, alkoxy, amino, hydroxyl, alkyl (methyl, ethyl), thiol, or alkylthio. In some embodiments, a proline derivative comprises one or more substitutions on the pyrrolidine ring, wherein the substitutions comprise halogen, or alkyl (methyl, ethyl). In some embodiments, a proline derivative comprises one or more substitutions on the pyrrolidine ring, wherein the substitutions comprise halogen. In some embodiments, a proline derivative comprises one or more substitutions on the pyrrolidine ring, wherein thesubstitutions comprise alkoxy, hydroxyl, amino. In some embodiments, a proline derivative comprises one or more substitutions on the pyrrolidine ring, wherein the substitutions comprise halogen, alkoxy, alkyl (methyl, ethyl), thiol, or alkylthio.Concentrations of Peptides in the Composition
[0189] The composition can comprise one or more peptides. In some embodiments, the one or more peptides comprise one or more peptides provided in Table 2. In some embodiments, the one or more peptides are present in the vesicle composition in an amount of about 0.01 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides is present in the vesicle composition in an amount of about 0.005 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 3 mg / mL, about 0.01 mg / mL to about 4 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.01 mg / mL to about 20 mg / mL, about 0.01 mg / mL to about 50 mg / mL, about 0.05 mg / mL to about 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05 mg / mL to about1 mg / mL, about 0.05 mg / mL to about 2 mg / mL, about 0.05 mg / mL to about 3 mg / mL, about 0.05 mg / mL to about 4 mg / mL, about 0.05 mg / mL to about 5 mg / mL, about 0.05 mg / mL to about 10 mg / mL, about 0.01 mg / mL to about 20 mg / mL, about 0.05 mg / mL to about 50 mg / mL, 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.5 mg / mL to about 2 mg / mL, about 0.5 mg / mL to about 3 mg / mL, about 0.5 mg / mL to about 4 mg / mL, about 0.5 mg / mL to about 5 mg / mL, about 0.5 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 20 mg / mL, about 0.5 mg / mL to about 50 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 3 mg / mL, about 1 mg / mL to about 4 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 1 mg / mL to about 20 mg / mL, about 1 mg / mL to about 50 mg / mL, about 2 mg / mL to about 3 mg / mL, about 2 mg / mL to about 4 mg / mL, about 2 mg / mL to about 5 mg / mL, about 2 mg / mL to about 10 mg / mL, about 2 mg / mL to about 20 mg / mL, about 2 mg / mL to about 50 mg / mL, about 3 mg / mL to about 4 mg / mL, about 3 mg / mL to about 5 mg / mL, about 3 mg / mL to about 10 mg / mL, about 3 mg / mL to about 20 mg / mL, about 3 mg / mL to about 50 mg / mL, about 4 mg / mL to about 5 mg / mL, about 4 mg / mL to about 10 mg / mL, about 4 mg / mL to about 20 mg / mL, about 4 mg / mL to about 50 mg / mL, about 5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 20 mg / mL, about 5 mg / mL to about 50 mg / mL, about 10 mg / mL to about 20 mg / mL, about 10 mg / mL to about 50 mg / mL, or about 20 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides ispresent in the vesicle composition in an amount of about 0.005 mg / mL, 0.01 mg / mL, 0.02 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the one or more peptides is present in the vesicle composition in an amount of at least about 0.005 mg / mL, 0.01 mg / mL, 0.02 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, or about 20 mg / mL. In some embodiments, the one or more peptides is present in the vesicle composition in an amount of at most about 0.01 mg / mL, 0.02 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the one or more peptides is present in the composition in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0190] In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of about 0.001 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides is present in the vesicle composition in an amount of about 0.01 mg / mL to about 0.05 mg / mL, about 0.01 mg / mL to about 0.1 mg / mL, about 0.01 mg / mL to about 0.5 mg / mL, about 0.01 mg / mL to about 1 mg / mL, about 0.01 mg / mL to about 2 mg / mL, about 0.01 mg / mL to about 3 mg / mL, about 0.01 mg / mL to about 4 mg / mL, about 0.01 mg / mL to about 5 mg / mL, about 0.01 mg / mL to about 10 mg / mL, about 0.01 mg / mL to about 20 mg / mL, about 0.01 mg / mL to about 50 mg / mL, about 0.05 mg / mL to about 0.1 mg / mL, about 0.05 mg / mL to about 0.5 mg / mL, about 0.05 mg / mL to about 1 mg / mL, about 0.05 mg / mL to about 2 mg / mL, about 0.05 mg / mL to about 3 mg / mL, about 0.05 mg / mL to about 4 mg / mL, about 0.05 mg / mL to about 5 mg / mL, about 0.05 mg / mL to about 10 mg / mL, about 0.01 mg / mL to about 20 mg / mL, about 0.05 mg / mL to about 50 mg / mL, about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.5 mg / mL to about 2 mg / mL, about 0.5 mg / mL to about 3 mg / mL, about 0.5 mg / mL to about 4 mg / mL, about 0.5 mg / mL to about 5 mg / mL, about 0.5 mg / mL to about 10 mg / mL, about 0.5 mg / mL to about 20 mg / mL, about 0.5 mg / mL to about 50 mg / mL, about 1 mg / mL to about 2 mg / mL, about 1 mg / mL to about 3 mg / mL, about 1 mg / mL to about 4 mg / mL, about 1 mg / mL to about 5 mg / mL, about 1 mg / mL to about 10 mg / mL, about 1 mg / mL to about 20 mg / mL, about 1 mg / mL to about 50 mg / mL, about 2 mg / mL to about 3 mg / mL, about 2 mg / mL to about 4 mg / mL, about 2 mg / mL to about 5mg / mL, about 2 mg / mL to about 10 mg / mL, about 2 mg / mL to about 20 mg / mL, about 2 mg / mL to about 50 mg / mL, about 3 mg / mL to about 4 mg / mL, about 3 mg / mL to about 5 mg / mL, about 3 mg / mL to about 10 mg / mL, about 3 mg / mL to about 20 mg / mL, about 3 mg / mL to about 50 mg / mL, about 4 mg / mL to about 5 mg / mL, about 4 mg / mL to about 10 mg / mL, about 4 mg / mL to about 20 mg / mL, about 4 mg / mL to about 50 mg / mL, about 5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 20 mg / mL, about 5 mg / mL to about 50 mg / mL, about 10 mg / mL to about 20 mg / mL, about 10 mg / mL to about 50 mg / mL, or about 20 mg / mL to about 50 mg / mL. In some embodiments, the one or more peptides is present in the vesicle composition in an amount of about 0.001 mg / mL, 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, 0.02 mg / mL, 0.03 mg / mL, 0.05 mg / mL, 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of at least about 0.001 mg / mL, 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, or about 20 mg / mL. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of at most about 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, each of the one or more peptides is present in the composition in an amount of about 0.001 mg / mL, 0.002 mg / mL, 0.005 mg / mL, 0.01 mg / mL, about 0.05 mg / mL, about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0191] In some embodiments, the one or more peptides are present in the vesicle composition in a total amount of about 0.005 % to about 0.2 %. In some embodiments, the one or more peptides is present in the vesicle composition in a total amount of about 0.005 % to about 0.01 %, about 0.005 % to about 0.05 %, about 0.005 % to about 0.1 %, about 0.005 % to about 0.15 %, about 0.005 % to about 0.2 %, about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.02% to about 0.03 %, about 0.02 % to about 0.05 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the one or more peptides is present in the vesicle composition in a total amount of about 0.01 %, about 0.02%, about 0.021 %, about 0.022 %, about 0.023 %, about 0.024 %, about 0.025 %, about 0.026 %, about 0.028%, about 0.03%, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the one or more peptides is present in the vesicle composition in a total amount of at least about 0.005 %, 0.01 %, about 0.05 %, about 0.1%, or about 0.15 %. In some embodiments, the one or more peptides is present in the vesicle composition in a total amount of at most about 0.01 %, 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %.
[0192] In some embodiments, each of the one or more peptides are present in the vesicle composition in an amount of about 0.001 % to about 0.2 %. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of about 0.001 % to about 0.002%, about 0.001 % to about 0.005%, about 0.001 % to about 0.01 %, about 0.001 % to about 0.05 %, about 0.001 % to about 0.1 %, about 0.001 % to about 0.15 %, about 0.001 % to about 0.2 %, about 0.002 % to about 0.005%, about 0.002 % to about 0.01 %, about 0.002 % to about 0.05 %, about 0.002 % to about 0.1 %, about 0.002 % to about 0.15 %, about 0.002 % to about 0.2 %, about 0.005 % to about 0.01 %, about 0.005 % to about 0.05 %, about 0.005 % to about 0.1 %, about 0.005 % to about 0.15 %, about 0.005 % to about 0.2 %, about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of about 0.001%, 0.002%, 0.005%, 0.01 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of at least about 0.001%, 0.002%, 0.005%, 0.01 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, each of the one or more peptides is present in the vesicle composition in an amount of at most about 0.002%, 0.005%, 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %.Vesicle forming lipids
[0193] In some embodiments, the vesicle composition comprises one or more vesicle forming lipids. The vesicle forming lipids act to encapsulate portions of the oil-in-water emulsions. In some embodiments, this allows the oil-in-water emulsion to remain stable for a period of time.
[0194] The vesicle forming lipids may be any suitable lipids for such a purpose. In some embodiments, the vesicle forming lipids comprise phospholipids, glycolipids, lecithins, ceramides, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof. In some embodiments, the vesicle forming lipids comprise a combination of lipids. In some embodiments, the vesicle forming lipids are hydrogenated. In some examples, the vesicle forming lipids comprise hydrogenated lecithin.
[0195] In some embodiments, the vesicle forming lipids comprise phospholipids. In some embodiments, the phospholipids are naturally occurring, semi synthetic, or synthetically prepared,or a mixture thereof. In an embodiment, the phospholipids are one or more esters of glycerol with one or two (equal or different) residues of fatty adds and with phosphoric acid, wherein the phosphoric acid residue is in turn bound to a hydrophilic group, such as, for instance, choline (phosphatidylcholines— PC), serine (phosphatidylserines— PS), glycerol (phosphatidylglycerols— PG), ethanolamine (phosphatidylethanolamines— PE), or inositol (phosphatidylinositol). Esters of phospholipids with only one residue of fatty acid are generally referred to in the art as the "lyso" forms of the phospholipid or "lysophospholipids". Fatty acids residues present in the phospholipids are in general long chain aliphatic acids, typically containing 12 to 24 carbon atoms, or 14 to 22 carbon atoms; the aliphatic chain may contain one or more unsaturations or is completely saturated. Examples of suitable fatty acids included in the phospholipids are, for instance, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, and linolenic acid. Saturated fatty acids such as myristic acid, palmitic acid, stearic acid and arachidic acid may be employed.
[0196] In some embodiments, the phospholipid comprises one or more natural phospholipids. In some embodiments, the phospholipid comprises one or more semisynthetic phospholipids. In some embodiments, the semisynthetic phospholipids are the partially or fully hydrogenated derivatives of the naturally occurring lecithins. In some embodiments, the phospholipids include fatty acids di-esters of phosphatidylcholine, ethylphosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine or of sphingomyelin. In some embodiments, the phospholipids include hydrogenated phosphatidylcholine (e.g., Sunlipon 90H). In some embodiments, the phospholipids are, for instance, dilauroyl-phosphatidylcholine (DLPC), dimyristoyl-phosphatidylcholine (DMPC), dipalmitoyl-phosphatidylcholine (DPPC), diarachidoyl- phosphatidylcholine (DAPC), distearoyl-phosphatidylcholine (DSPC), dioleoyl- phosphatidylcholine (DOPC), l,2Distearoyl-sn-glycero-3-Ethylphosphocholine (Ethyl-DSPC), dipentadecanoyl- phosphatidylcholine (DPDPC), l-myristoyl-2-palmitoyl-phosphatidylcholine (MPPC), 1 -palmitoyl -2- myristoyl-phosphatidylcholine (PMPC), l-palmitoyl-2-stearoyl- phosphatidylcholine (PSPC), 1- stearoyl-2-palmitoyl-phosphatidylcholine (SPPC), 1-palmitoyl- 2-oleylphosphatidylcholine (POPC), l-oleyl-2-palmitoyl-phosphatidylcholine (OPPC), dilauroylphosphatidylglycerol (DLPG) and its alkali metal salts, diarachidoylphosphatidylglycerol (DAPG) and its alkali metal salts, dimyristoylphosphatidylglycerol (DMPG) and its alkali metal salts, dipalmitoylphosphatidylglycerol (DPPG) and its alkali metal salts, distearoylphosphatidylglycerol (DSPG) and its alkali metal salts, dioleoyl-phosphatidylglycerol (DOPG) and its alkali metal salts, dimyristoyl phosphatidic acid DMPA) and its alkali metal salts, dipalmitoyl phosphatidic acid (DPP A) and its alkali metal salts, distearoyl phosphatidicacid (DSP A), diarachidoylphosphatidic acid (DAP A) and its alkali metal salts, dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), distearoyl phosphatidyl-ethanolamine (DSPE), dioleylphosphatidylethanolamine (DOPE), diarachidoylphosphatidylethanolamine (DAPE), dilinoleylphosphatidylethanolamine (DLPE), dimyristoyl phosphatidylserine (DMPS), diarachidoyl phosphatidylserine (DAPS), dipalmitoyl phosphatidylserine (DPPS), distearoylphosphatidylserine (DSPS), dioleoylphosphatidylserine (DOPS), dipalmitoyl sphingomyelin (DPSP), and di stearoyl sphingomyelin (DSSP), dilauroylphosphatidylinositol (DLPI), diarachidoylphosphatidylinositol (DAPI), dimyristoylphosphatidylinositol (DMPI), dipalmitoylphosphatidylinositol (DPPI), distearoylphosphatidylinositol (DSPI), dioleoyl-phosphatidylinositol (DOPI).
[0197] In some embodiments, the vesicle forming lipids are present in an amount of about 0.5 % to about 25 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of about 0.5 % to about 2 %, about 0.5 % to about 5 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 0.5 % to about 12 %, about 0.5 % to about 15 %, about 0.5 % to about 20 %, about 0.5 % to about 25 %, about 2 % to about 5 %, about 2 % to about 8 %, about 2 % to about 10 %, about 2 % to about 12 %, about 2 % to about 15 %, about 2 % to about 20 %, about 2 % to about 25 %, about 5 % to about 8 %, about 5 % to about 10 %, about 5 % to about 12 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 8 % to about 10 %, about 8 % to about 12 %, about 8 % to about 15 %, about 8 % to about 20 %, about 8 % to about 25 %, about 10 % to about 12 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 12 % to about 15 %, about 12 % to about 20 %, about 12 % to about 25 %, about 15 % to about 20 %, about 15 % to about 25 %, or about 20 % to about 25 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the vesicle forming lipids are present in an amount of at least about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, or about 20 %(w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of at most about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, about 20 %, or about 25 % (w / w) of the composition.
[0198] In some embodiments, the vesicle forming lipids are present in an amount of about 5 % to about 15 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of about 5 % to about 8 %, about 5 % to about 9 %, about 5 % to about 10 %, about 5 % to about 11 %, about 5 % to about 12 %, about 5 % to about 13 %, about 5 % to about 14 %, about 5 % to about 15 %, about 8 % to about 9 %, about 8 % to about 10 %, about 8 % to about 11 %, about 8 % to about 12 %, about 8 % to about 13 %, about 8 % to about 14 %,about 8 % to about 15 %, about 9 % to about 10 %, about 9 % to about 11 %, about 9 % to about 12 %, about 9 % to about 13 %, about 9 % to about 14 %, about 9 % to about 15 %, about 10 % to about 11 %, about 10 % to about 12 %, about 10 % to about 13 %, about 10 % to about 14 %, about 10 % to about 15 %, about 11 % to about 12 %, about 11 % to about 13 %, about 11 % to about 14 %, about 11 % to about 15 %, about 12 % to about 13 %, about 12 % to about 14 %, about 12 % to about 15 %, about 13 % to about 14 %, about 13 % to about 15 %, or about 14 % to about 15 %. In some embodiments, the vesicle forming lipids are present in an amount of about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 %(w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of at least about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, or about 14 % (w / w) of the composition. In some embodiments, the vesicle forming lipids are present in an amount of at most about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 % (w / w) of the composition.
[0199] In some embodiments, the composition comprises a short chain polyol. In some embodiments, the short chain polyol acts to enhance the stability of the resulting lipid vesicles. In some embodiments, the short chain polyol is a C2-C4 polyol comprising two or three alcohol groups. In some embodiments, the short chain polyol is propylene glycol. In some embodiments, the composition comprises propylene glycol. In some embodiments, the composition comprises a butanediol. In some embodiments, the butanediol is 1,3 -butanediol. In some embodiments, the butanediol is 2,3-butanediol. In some embodiments, the composition comprises propylene glycol, butanediol (e.g., 2,3-butanediol), or both.
[0200] In some embodiments, the propylene glycol is present in an amount of about 0.5 % to about 25 % (w / w) of the composition. In some embodiments, the propylene glycol is present in an amount of about 0.5 % to about 2 %, about 0.5 % to about 5 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 0.5 % to about 12 %, about 0.5 % to about 15 %, about 0.5 % to about 20 %, about 0.5 % to about 25 %, about 2 % to about 5 %, about 2 % to about 8 %, about 2 % to about 10 %, about 2 % to about 12 %, about 2 % to about 15 %, about 2 % to about 20 %, about 2 % to about 25 %, about 5 % to about 8 %, about 5 % to about 10 %, about 5 % to about 12 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 8 % to about 10 %, about 8 % to about 12 %, about 8 % to about 15 %, about 8 % to about 20 %, about 8 % to about 25 %, about 10 % to about 12 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 12 % to about 15 %, about 12 % to about 20 %, about 12 % to about 25 %, about 15 % to about 20 %, about 15 % to about 25 %, or about 20 % to about 25 %. In some embodiments, the propylene glycol is present in an amount of about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 10.5 %, about 12 %, about 13 %, about15 %, about 20 %, or about 25 %. In some embodiments, the propylene glycol is present in an amount of at least about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 13 %, about 15 %, or about 20 %. In some embodiments, the propylene glycol is present in an amount of at most about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 13 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the propylene glycol is present in an amount of about 1 % to about 10 %. In some embodiments, the propylene glycol is present in an amount of about 1 % to about 2 %, about 1 % to about 4 %, about 1 % to about 6 %, about 1 % to about 8 %, about 1 % to about 10 %, about 2 % to about 4 %, about 2 % to about 6 %, about 2 % to about 8 %, about 2 % to about 10 %, about 4 % to about 6 %, about 4 % to about 8 %, about 4 % to about 10 %, about 6 % to about 8 %, about 6 % to about 10 %, or about 8 % to about 10 %. In some embodiments, the propylene glycol is present in an amount of about 1 %, about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, the propylene glycol is present in an amount of at least about 1 %, about 2 %, about 4 %, about 6 %, or about 8 %. In some embodiments, the propylene glycol is present in an amount of at most about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, propylene glycol is present in about the same amount as the vesicle forming lipid. In some embodiments, the ratio of propylene glycol to vesicle forming lipid in the composition is form about 2: 1 to about 1 :2 (w / w).
[0201] In some embodiments, the butanediol (e.g., 2,3 -butanediol) is present in an amount of about 0.5 % to about 25 % (w / w) of the composition. In some embodiments, the butanediol is present in an amount of about 0.5 % to about 2 %, about 0.5 % to about 5 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 0.5 % to about 12 %, about 0.5 % to about 15 %, about 0.5 % to about 20 %, about 0.5 % to about 25 %, about 2 % to about 5 %, about 2 % to about 8 %, about 2 % to about 10 %, about 2 % to about 12 %, about 2 % to about 15 %, about 2 % to about 20 %, about 2 % to about 25 %, about 5 % to about 8 %, about 5 % to about 10 %, about 5 % to about 12 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 8 % to about 10 %, about 8 % to about 12 %, about 8 % to about 15 %, about 8 % to about 20 %, about 8 % to about 25 %, about 10 % to about 12 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 12 % to about 15 %, about 12 % to about 20 %, about 12 % to about 25 %, about 15 % to about 20 %, about 15 % to about 25 %, or about 20 % to about 25 %. In some embodiments, the butanediol is present in an amount of about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 10.5 %, about 12 %, about 15 %, about 20 %, or about 25 %. In some embodiments, the butanediol is present in an amount of at least about 0.5 %, about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, or about 20 %. In some embodiments, the butanediol is present in an amount of at most about 2 %, about 5 %, about 8 %, about 10 %, about 12 %, about 15 %, about 20 %, or about 25 %. In someembodiments, the butanediol is present in an amount of about 1 % to about 10 %. In some embodiments, the butanediol is present in an amount of about 1 % to about 2 %, about 1 % to about 4 %, about 1 % to about 6 %, about 1 % to about 8 %, about 1 % to about 10 %, about 2 % to about 4 %, about 2 % to about 6 %, about 2 % to about 8 %, about 2 % to about 10 %, about 4 % to about 6 %, about 4 % to about 8 %, about 4 % to about 10 %, about 6 % to about 8 %, about 6 % to about 10 %, or about 8 % to about 10 %. In some embodiments, the butanediol is present in an amount of about 1 %, about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, the butanediol is present in an amount of at least about 1 %, about 2 %, about 4 %, about 6 %, or about 8 %. In some embodiments, the butanediol is present in an amount of at most about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %. In some embodiments, butanediol is present in about the same amount as the vesicle forming lipid. In some embodiments, the ratio of butanediol to vesicle forming lipid in the composition is form about 2: 1 to about 1 :2 (w / w).
[0202] In some embodiments, the oil phase of the lipid vesicle and / or the lipid vesicle portion of the composition comprises a sterol. In some embodiments, the sterol is a naturally derived sterol. In some embodiments, the sterol is a synthetic sterol. In some embodiments, the sterol is cholesterol. In some embodiments, the cholesterol may be plant-derived cholesterol. In some embodiments, the cholesterol may be synthetic cholesterol. In some embodiments the plant- derived cholesterol may be cholest-5-en-3-ol (e.g., PhytoChoi®, SyntheChol®, Avanti#700100), or any other plant-derived cholesterol, or any combination thereof. In some embodiments, the sterol may be phytosterol or a derivative thereof. In some embodiments, the phytosterol or derivative thereof may be phytosterol MM, Advasterol™ 90 IP or 95 IP F, NET Sterol-ISO, Canola Sterols, sitosterol 700095, lanosterol-95, brassicasterol, or any combination thereof.
[0203] In some embodiments, the sterol is present in an amount of about 0.1 % to about 5 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 0.1 % to about 5 %. In some embodiments, the sterol is present in an amount of about 0.1 % to about 0.2 %, about 0.1 % to about 0.5 %, about 0.1 % to about 0.8 %, about 0.1 % to about 1 %, about 0.1 % to about 2 %, about 0.1 % to about 3 %, about 0.1 % to about 4 %, about 0.1 % to about 5 %, about 0.2 % to about 0.5 %, about 0.2 % to about 0.8 %, about 0.2 % to about 1 %, about 0.2 % to about 2 %, about 0.2 % to about 3 %, about 0.2 % to about 4 %, about 0.2 % to about 5 %, about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 0.8 % to about 1 %, about 0.8 % to about 2 %, about 0.8 % to about 3 %, about 0.8 % to about 4 %, about 0.8 % to about 5 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 %. In some embodiments, the sterolis present in an amount of about 0.1 %, about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the sterol is present in an amount of at least about 0.1 %, about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, or about 4 %. In some embodiments, the sterol is present in an amount of at most about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the sterol is present in an amount of about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, about 1.5 % to about 3 %, about 1.5 % to about 4 %, about 1.5 % to about 5 %, about 2 % to about 2.5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2.5 % to about 3 %, about 2.5 % to about 4 %, about 2.5 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 1 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 4 %, or about 5 %(w / w) of the composition. In some embodiments, the sterol is present in an amount of at least about 1 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, or about 4 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of at most about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 4 %, or about 5 % (w / w) of the composition.Oil Phases
[0204] The lipid vesicle compositions provided herein comprise an oil-in-water emulsion. The oil component is selected such that the material is a liquid at operative temperatures (e.g., room temperature) and is non-miscible with water.
[0205] Any suitable oil may be used as the oil phase. In some embodiments, the oil comprises a naturally occurring oil. In some embodiments, the naturally occurring oil is derived from one or more plants or plant parts (e.g., seeds or nuts). In some embodiments, the oil is a naturally occurring oil such as olive oil, vegetable oil, sunflower oil, or other similar plant derived oil.
[0206] In some embodiments, the oil phase is selected from the group consisting of vegetable oils, mono-, di-, and triglycerides, silicone fluids, mineral oils, and combinations thereof. In some embodiments, the oil phase comprises an emollient. In some embodiments, the emollient comprises caprylic and / or capric triglycerides (e.g., Labrafac CC). In some embodiments, the emollient comprises a natural oil-soluble emollient, such an oil-soluble plant extracts, essential oils, vegetable oils, vegetable butters, or any combination thereof. In some embodiments, the natural oil-soluble emollient comprise oils from sunflowers. In some embodiments, the natural oil-soluble emollient comprise oils from avocados.
[0207] In some embodiments, the oil comprises a silicon oil or derivative, such as dimethicone. In some embodiments, the oil silicon oil comprises a siloxane polymer. In some embodiments,the siloxane polymer comprises C1-C3 substituents. In some embodiments, the siloxane is polydimethylsiloxane (PDMS). In some embodiments, the silicon oil is polymethylsilsesquioxane (e.g., Botanisil™ SP-360). In some embodiments, the oil is a mixture which comprises a silicon oil (e.g., dimethicone) as a smaller component. In some embodiments, the silicon oil is incorporated in order to enhance the feel of the resulting composition or as a moisturizer. In some embodiments, the oil comprises a silicon oil in an amount of up to about 5 %, up to about 4%, up to about 3 %, up to about 2%, or up to about 1%. In some embodiments, the silicon oil is present in an amount of from about 0.1 % to about 2% (w / w) of the composition. In some embodiments, the silicon oil is present in an amount of from about 0.1 % to about 0.5 %, 0.1 % to about 0.7%, 0.1 % to about 1 %, 0.1 % to about 1.5%, 0.15% to about 2 %, 0.5 % to about 0.7%, 0.5 % to about 1 %, 0.5 % to about 1.5 %, 0.5 % to about 2 %, 0.7 % to about 1 %, 0.7 % to about 1.5 %, 0.7 % to about 2 %, 1 % to about 1.5 %, or 1 % to about 2 % (w / w) of the composition. In some embodiments, the silicon oil is present in an amount of about 0.1 %, 0.5 %, 0.6 %, 0.7%, 1%, 1.5%, or 2% of the composition.
[0208] In some embodiments, the oils are present in an amount of about 1 % to about 35 % (w / w) of the composition. In some embodiments, the oils are present in an amount of about 1 % to about 5 %, about 1 % to about 10 %, about 1 % to about 15 %, about 1 % to about 20 %, aboutI % to about 25 %, about 1 % to about 30 %, about 1 % to about 35 %, about 5 % to about 10 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 5 % to about 30 %, about 5 % to about 35 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 10 % to about 30 %, about 10 % to about 35 %, about 15 % to about 20 %, about 15 % to about 25 %, about 15 % to about 30 %, about 15 % to about 35 %, about 20 % to about 25 %, about 20 % to about 30 %, about 20 % to about 35 %, about 25 % to about 30 %, about 25 % to about 35 %, or about 30 % to about 35 %. In some embodiments, the oils are present in an amount of about 1 %, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %. In some embodiments, the oils are present in an amount of at least about 1 %, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, or about 30 %. In some embodiments, the oils are present in an amount of at most about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %. In some embodiments, the oils are present in an amount of about 5 % to about 15 %. In some embodiments, the oils are present in an amount of about 5 % to about 8 %, about 5 % to about 9 %, about 5 % to about 10 %, about 5 % to about 11 %, about 5 % to about 12 %, about 5 % to about 13 %, about 5 % to about 14 %, about 5 % to about 15 %, about 8 % to about 9 %, about 8 % to about 10 %, about 8 % to aboutI I %, about 8 % to about 12 %, about 8 % to about 13 %, about 8 % to about 14 %, about 8 % to about 15 %, about 9 % to about 10 %, about 9 % to about 11 %, about 9 % to about 12 %, about9 % to about 13 %, about 9 % to about 14 %, about 9 % to about 15 %, about 10 % to about 11 %, about 10 % to about 12 %, about 10 % to about 13 %, about 10 % to about 14 %, about 10 % to about 15 %, about 11 % to about 12 %, about 11 % to about 13 %, about 11 % to about 14 %, about 11 % to about 15 %, about 12 % to about 13 %, about 12 % to about 14 %, about 12 % to about 15 %, about 13 % to about 14 %, about 13 % to about 15 %, or about 14 % to about 15 %. In some embodiments, the oils are present in an amount of about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 %. In some embodiments, the oils are present in an amount of at least about 5 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, or about 14 %. In some embodiments, the oils are present in an amount of at most about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, or about 15 %.
[0209] In some embodiments, the oil comprises one or more triglycerides. In some embodiments the triglyceride is a medium chain triglyceride. In some embodiments, the medium chain triglyceride comprises fatty acid esters having a chain length of Ce-Cn.
[0210] In some embodiments, the triglyceride is present in an amount of about 1 % to about 35 % (w / w) of the composition. In some embodiments, the triglyceride is present in an amount of about 1 % to about 5 %, about 1 % to about 10 %, about 1 % to about 15 %, about 1 % to about 20 %, about 1 % to about 25 %, about 1 % to about 30 %, about 1 % to about 35 %, about 5 % to about 10 %, about 5 % to about 15 %, about 5 % to about 20 %, about 5 % to about 25 %, about 5 % to about 30 %, about 5 % to about 35 %, about 10 % to about 15 %, about 10 % to about 20 %, about 10 % to about 25 %, about 10 % to about 30 %, about 10 % to about 35 %, about 15 % to about 20 %, about 15 % to about 25 %, about 15 % to about 30 %, about 15 % to about 35 %, about 20 % to about 25 %, about 20 % to about 30 %, about 20 % to about 35 %, about 25 % to about 30 %, about 25 % to about 35 %, or about 30 % to about 35 %. In some embodiments, the triglyceride is present in an amount of about 1 %, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %. In some embodiments, the triglyceride is present in an amount of at least about 1 %, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, or about 30 %. In some embodiments, the triglyceride is present in an amount of at most about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about 4%, about 4.5%, about 5 %, about 10 %, about 15 %, about 20 %, about 25 %, about 30 %, or about 35 %.
[0211] In some embodiments, the oil phase of the lipid vesicle and / or the lipid vesicle portion of the composition comprises a sterol. In some embodiments, the sterol is cholesterol. In some embodiments, the cholesterol may be plant-derived cholesterol. In some embodiments, the plant-derived cholesterol may be PhytoChoi®, SyntheChol®, or any other plant-derived cholesterol (e.g., Avanti#700100), or any combination thereof. In some embodiments, the sterol may be phytosterol or a derivative thereof. In some embodiments, the phytosterol or derivative thereof may be phytosterol MM, Advasterol™ 90 IP or 95 IP F, NET Sterol-ISO, canola sterols, sitosterol 700095, lanosterol-95, brassicasterol, or any combination thereof.
[0212] In some embodiments, the sterol is present in an amount of about 0.1 % to about 5 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 0.1 % to about 5 %. In some embodiments, the sterol is present in an amount of about 0.1 % to about 0.2 %, about 0.1 % to about 0.5 %, about 0.1 % to about 0.8 %, about 0.1 % to about 1 %, about 0.1 % to about 2 %, about 0.1 % to about 3 %, about 0.1 % to about 4 %, about 0.1 % to about 5 %, about 0.2 % to about 0.5 %, about 0.2 % to about 0.8 %, about 0.2 % to about 1 %, about 0.2 % to about 2 %, about 0.2 % to about 3 %, about 0.2 % to about 4 %, about 0.2 % to about 5 %, about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 0.8 % to about 1 %, about 0.8 % to about 2 %, about 0.8 % to about 3 %, about 0.8 % to about 4 %, about 0.8 % to about 5 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 %. In some embodiments, the sterol is present in an amount of about 0.1 %, about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the sterol is present in an amount of at least about 0.1 %, about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, or about 4 %. In some embodiments, the sterol is present in an amount of at most about 0.2 %, about 0.5 %, about 0.8 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the sterol is present in an amount of about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, about 1.5 % to about 3 %, about 1.5 % to about 4 %, about 1.5 % to about 5 %, about 2 % to about 2.5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2.5 % to about 3 %, about 2.5 % to about 4 %, about 2.5 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of about 1 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 4 %, or about 5 %(w / w) of the composition. In some embodiments, the sterol is present in an amount of at least about 1 %, about 1.5 %, about 2 %, about 2.5 %, about 3 %, or about 4 % (w / w) of the composition. In some embodiments, the sterol is present in an amount of at most about 1.5 %, about 2 %, about 2.5 %, about 3 %, about 4 %, or about 5 % (w / w) of the composition.
[0213] In some embodiments, the lipid vesicle compositions comprise one or more penetration enhancers. In some embodiments, a penetration enhancer acts to increase the amount of penetration of the anionic polymer material through one or more layers of skin when applied to the skin of an individual. In some embodiments, a penetration enhancer acts to increase the amount of penetration of one or more peptides through one or more layers of skin when applied to the skin of an individual.
[0214] In some embodiments, a composition comprising one or more penetration enhancers has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by at least 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more penetration enhancers when applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more penetration enhancers has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by greater than 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more penetration enhancers when applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more penetration enhancers has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more penetration enhancers when applied one or more layers of the skin of a similar or same skin sample or skin of an individual.
[0215] In some embodiments, a composition comprising one or more non-ionic surfactants with an HLB value of about 10 or less has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by at least 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more non-ionic surfactants with an HLB value of about 10 or less when applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more non-ionic surfactants with an HLB value of about 10 or less has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by greater than 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more non-ionic surfactants with an HLB value of about 10 or less when-n-applied one or more layers of the skin of a similar or same skin sample or skin of an individual. In some embodiments, a composition comprising one or more non-ionic surfactants with an HLB value of about 10 or less has an increase in penetration through one or more layers of the skin when applied to a skin sample or the skin of an individual by about 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 %, 90 %, 100 %, 120 %, 150%, or 200 % compared to an otherwise same or similar composition without the one or more non-ionic surfactants with an HLB value of about 10 or less when applied one or more layers of the skin of a similar or same skin sample or skin of an individual.
[0216] In some embodiments, the penetration enhancer is included in the oil-in-water emulsion of the composition. In some embodiments, the penetration enhancer is included in the lipid bilayer of the composition.
[0217] There are many types of penetration enhancing agents that may be employed. In some embodiments, the penetration enhancing agent comprising an ionic surfactant, a nonionic surfactant, or a combination thereof. In some embodiments, an ionic surfactant, a non-ionic surfactant, or a combination thereof is not a penetration enhancing agent.
[0218] In some embodiments, the penetration enhancing agent comprises a non-ionic surfactant or a combination of non-ionic surfactants. In some embodiments, the penetration enhancing agent is a single non-ionic surfactant. In some embodiments, the penetration enhancing agent is a combination of at least 2, 3, 4, or more non-ionic surfactants. In some embodiments, the penetration enhancing agent is a combination 2 non-ionic surfactants. In some embodiments, the penetration enhancing agent is a combination 3 non-ionic surfactants.
[0219] In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, and polyethylene glycol fatty acid esters, glycerol stearate and combinations thereof.
[0220] In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol ether of a fatty alcohol and a sorbitan ester. In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol ethers of fatty alcohol and a polysorbate. In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol ethers of fatty alcohol and a sorbitan ester. In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol ethers of fatty alcohol and a polyethylene glycol fatty acid ester. In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol ether of a fatty alcohol, a sorbitan ester, and a polysorbate. In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol ether of a fatty alcohol, a sorbitan ester, and a polyethylene glycol fatty acid ester. In some embodiments, the combination of non-ionicsurfactants is a combination of a polyethylene glycol ether of a fatty alcohol, a polysorbate, and a polyethylene glycol fatty acid ester. In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol ether of a fatty alcohol, a polysorbate, and glycerol stearate.
[0221] In some embodiments, the combination of non-ionic surfactants comprises a polyethylene glycol fatty acid ester and a sorbitan ester. In some embodiments, the combination of non-ionic surfactants comprises a polyethylene glycol fatty acid ester and a polysorbate. In some embodiments, the combination of non-ionic surfactants is a combination of a polyethylene glycol fatty acid ester, a polysorbate, and a sorbitan ester.
[0222] In some embodiments, the non-ionic surfactant comprises a polyethylene glycol (PEG) ether of a fatty alcohol. In some embodiments, the PEG ether of the fatty alcohol comprises from about 2 to about 8 PEG groups and a C12-C22 fatty alcohol. In some embodiments, the polyethylene glycol ether of a fatty alcohol comprises di ethylene glycol hexadecyl ether, 2-(2- octadecoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof. In some embodiments, the polyethylene glycol ether of a fatty alcohol comprises 2-(2- octadecoxyethoxy)ethanol. In some embodiments, the PEG ether of a fatty alcohol is super refined Brij® 02, or a derivative thereof. In some embodiments, the non-ionic surfactant is added to the aqueous phase of the composition.
[0223] In some embodiments, the PEG ether of the fatty alcohol is present in an amount of from about 0.5 % to about 10 % (w / w) of the composition. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of about 0.5 % to about 2.5 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of at least about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the PEG ether of the fatty alcohol is present in an amount of at most about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0224] In some embodiments, the non-ionic surfactant comprises a sorbitan ester. In some embodiments, the sorbitan ester is a fatty acid ester. In some embodiments, the sorbitan ester is a C12-C22 fatty acid ester. In some embodiments, the sorbitan ester comprises sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combinations thereof. In some embodiments, the sorbitan ester comprises sorbitan monolaurate. In some embodiments, the sorbitan ester comprises sorbitan monopalmitate. In some embodiments, the sorbitan ester comprises sorbitan monostearate. In some embodiments, the sorbitan ester comprises sorbitan monooleate. In some embodiments, the sorbitan ester comprises sorbitan trioleate. In some embodiments, the sorbitan ester comprises sorbitan sesquioleate. In some embodiments, the sorbitan ester comprises sorbitan isostearate.
[0225] In some embodiments, the sorbitan ester is present in an amount of about 0.5 % to about 2.5 % (w / w) of the composition. In some embodiments, the sorbitan ester is present in an amount of about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the sorbitan ester is present in an amount of about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the sorbitan ester is present in an amount of at least about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the sorbitan ester is present in an amount of at most about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0226] In some embodiments, the non-ionic surfactant comprises a polysorbate. In some embodiments, the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof. In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the polysorbate is polysorbate 20.
[0227] In some embodiments, the polysorbate is present in an amount of about 0.5 % to about 2.5 % (w / w) of the composition. In some embodiments, the polysorbate is present in an amount of about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %,about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the polysorbate is present in an amount of about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the polysorbate is present in an amount of at least about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the polysorbate is present in an amount of at most about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0228] In some embodiments, the non-ionic surfactant comprises a polyethylene glycol (PEG) fatty acid ester. In some embodiments, the PEG fatty acid ester is a PEG chain of about 2-8 subunits comprising C8-C22 fatty acids affixed to each terminal hydroxyl to form the fatty acid ester. In some embodiments, the PEG fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glycerides, or any combination thereof. In some embodiments, the PEG fatty acid ester is PEG-4 dilaurate.
[0229] In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5 % to about 2.5 % (w / w) of the composition. In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5 % to about 0.8 %, about 0.5 % to about 1 %, about 0.5 % to about 1.2 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 2.5 %, about 0.8 % to about 1 %, about 0.8 % to about 1.2 %, about 0.8 % to about 1.5 %, about 0.8 % to about 2 %, about 0.8 % to about 2.5 %, about 1 % to about 1.2 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 2.5 %, about 1.2 % to about 1.5 %, about 1.2 % to about 2 %, about 1.2 % to about 2.5 %, about 1.5 % to about 2 %, about 1.5 % to about 2.5 %, or about 2 % to about 2.5 %. In some embodiments, the PEG fatty acid ester is present in an amount of about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %. In some embodiments, the PEG fatty ester is present in an amount of at least about 0.5 %, about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, or about 2 %. In some embodiments, the PEG fatty acid ester is present in an amount of at most about 0.8 %, about 1 %, about 1.2 %, about 1.5 %, about 2 %, or about 2.5 %.
[0230] In some embodiments, the non-ionic surfactant has a hydrophobic-lipophilic balance (HLB) of about 10 or less. In some embodiments, the composition comprises a plurality of non- ionic surfactants, each having an HLB of about 10 or less. In some embodiments, the non-ionic surfactant with an HLB of 10 or less is selected from the Table 1, or any combination thereof.
[0231] In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.5 % to about 10 % (w / w) of the composition. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in anamount of about 0.5 % to about 1 %, about 0.5 % to about 1.5 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 0.5 % to about 6 %, about 0.5 % to about 7 %, about 0.5 % to about 8 %, about 0.5 % to about 10 %, about 1 % to about 1.5 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1 % to about 6 %, about 1 % to about 7 %, about 1 % to about 8 %, about 1 % to about 10 %, about 1.5 % to about 2 %, about 1.5 % to about 3 %, about 1.5 % to about 4 %, about 1.5 % to about 5 %, about 1.5 % to about 6 %, about 1.5 % to about 7 %, about 1.5 % to about 8 %, about 1.5 % to about 10 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2 % to about 6 %, about 2 % to about 7 %, about 2 % to about 8 %, about 2 % to about 10 %, about 3 % to about 4 %, about 3 % to about 5 %, about 3 % to about 6 %, about 3 % to about 7 %, about 3 % to about 8 %, about 3 % to about 10 %, about4 % to about 5 %, about 4 % to about 6 %, about 4 % to about 7 %, about 4 % to about 8 %, about 4 % to about 10 %, about 5 % to about 6 %, about 5 % to about 7 %, about 5 % to about 8 %, about 5 % to about 10 %, about 6 % to about 7 %, about 6 % to about 8 %, about 6 % to about 10 %, about 7 % to about 8 %, about 7 % to about 10 %, or about 8 % to about 10 %. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.5 %, about 0.6 %, about 0.7 %, about 1 %, about 1.5 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, or about 10 %. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.6 % (e.g., 0.54 % to about 0.66 %). In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of about 0.7 % (e.g, 0.63 % to about 0.77 %). In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of at least about 0.5 %, about 0.7 %, about 1 %, about 1.5 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, or about 8 %. In some embodiments, the non-ionic surfactant or combination of non-ionic surfactants are present in an amount of at most about 0.7 %, about 1 %, about 1.5 %, about 2 %, about 3 %, about 4 %, about5 %, about 6 %, about 7 %, about 8 %, or about 10 %.
[0232] In some embodiments, the composition comprises a non-ionic surfactant in the oil-in- water emulsion, the lipid bilayer, or both. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion. In some embodiments, the composition comprises a non-ionic surfactant in the lipid bilayer. In some embodiments, the composition comprises a non-ionic surfactant in the oil-in-water emulsion and the lipid bilayer, wherein the composition comprises two or more different non-ionic surfactants.
[0233] In some embodiments, the penetration enhancing agent comprises a salicylate ester or a nicotinate ester. In some embodiments, the ester is a Ci-Ce alkyl ester or a benzyl ester. In someembodiments, the penetration enhancing agent may be a vasodilator. In some embodiments, the penetration enhancing agent comprises methyl salicylate or benzyl nicotinate. In some embodiments, the penetration enhancing agent is a nicotinate ester present in an amount of up to about 0.1 %, 0.5%, 1%, 2%, or 3% (w / w) of the composition. In some embodiments, the nicotinate ester is present in an amount of from about 0.1% to about 3%, about 0.1% to about 2%, or about 0.1% to about 1%. In some embodiments, benzyl nicotinate is present at an amount of about 0.5%.
[0234] In some embodiments, the penetration enhancing agent comprises a fatty acid acylated amino acid. In some embodiments, the fatty acid acylated amino acid is lysine. In some embodiments, the lysine is mono-acylated with a fatty acid. In some embodiments, the penetration enhancing agent is monoloauryl lysine. In some embodiments, the lysine is diacylated. In some embodiments, the penetration enhancing agent is dipalmitoyllysine. In some embodiments, the fatty acylated amino acid is present in an amount of up to about 1%, up to about 2%, up to about 3%, up to about 4%, or up to about 5% (w / w) of the composition. In some embodiments, the fatty acylated amino acid is present in an amount of from about 0.1% to about 5%, from about 0.1% to about 4%, from about 0.1% to about 3%, from about 0.1% to about 2%, from about 0.5% to about 5%, from about 0.5% to about 4%, from about 0.5% to about 3%, from about 0.5% to about 2%, from about 1% to about 5%, from about 1% to about 4%, from about 1% to about 3%, from about 1% to about 2%, or from about 1.5% to about 2.5%.Cationic Surfactants
[0235] In some embodiments, the composition further comprises a cationic surfactant. In some embodiments, the cationic surfactant is used to stabilize the water-in-oil emulsion (e.g., at the submicron emulsion stage prior to lipid vesicle formation). In some embodiments, the cationic surfactant is a mono-cationic surfactant. In some embodiments, the mono-cationic surfactant is net-mono-cationic (e.g., a phosphate salt comprising two side chains each with a single cationic functionality, which is partially neutralized by a phosphate anion).
[0236] In some embodiments, the mono-cationic surfactant is a fatty-amide derived propylene glycol-diammonium phosphate ester. In some embodiments, the mono-cationic surfactant is linoleamidopropyl PG-dimonium chloride phosphate (e.g., Ariasilk™ PTM, Ariasilk™ EFA).
[0237] In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of about 1 % to about 20 % (w / w) of the composition. In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1 % to about 6 %, about 1 % to about 7 %, about 1 % to about 8 %, about 1 % to about 9 %, about 1 % to about 10 %, about 1 % to about 11 %, about 1 % to about12 %, about 1 % to about 13 %, about 1 % to about 14 %, about 1 % to about 15 %, about 1 % to about 16 %, about 1 % to about 17 %, about 1 % to about 18 %, about 1 % to about 19 %, about1 % to about 20 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 2 % to about 6 %, about 2 % to about 7 %, about 2 % to about 8 %, about 2 % to about 9 %, about 2 % to about 10 %, about 2 % to about 11 %, about 2 % to about 12 %, about 2 % to about 13 %, about 2 % to about 14 %, about 2 % to about 15 %, about 2 % to about 16 %, about2 % to about 17 %, about 2 % to about 18 %, about 2 % to about 19 %, about 2 % to about 20 %, about 3 % to about 4 %, about 3 % to about 5 %, about 3 % to about 6 %, about 3 % to about 7 %, about 3 % to about 8 %, about 3 % to about 9 %, about 3 % to about 10 %, about 3 % to about 11 %, about 3 % to about 12 %, about 3 % to about 13 %, about 3 % to about 14 %, about 3 % to about 15 %, about 3 % to about 16 %, about 3 % to about 17 %, about 3 % to about 18 %, about3 % to about 19 %, about 3 % to about 20 %, about 4 % to about 5 %, about 4 % to about 6 %, about 4 % to about 7 %, about 4 % to about 8 %, about 4 % to about 9 %, about 4 % to about 10 %, about 4 % to about 11 %, about 4 % to about 12 %, about 4 % to about 13 %, about 4 % to about 14 %, about 4 % to about 15 %, about 4 % to about 16 %, about 4 % to about 17 %, about4 % to about 18 %, about 4 % to about 19 %, about 4 % to about 20 %, about 5 % to about 6 %, about 5 % to about 7 %, about 5 % to about 8 %, about 5 % to about 9 %, about 5 % to about 10 %, about 5 % to about 11 %, about 5 % to about 12 %, about 5 % to about 13 %, about 5 % to about 14 %, about 5 % to about 15 %, about 5 % to about 16 %, about 5 % to about 17 %, about5 % to about 18 %, about 5 % to about 19 %, about 5 % to about 20 %, about 6 % to about 7 %, about 6 % to about 8 %, about 6 % to about 9 %, about 6 % to about 10 %, about 6 % to about 11 %, about 6 % to about 12 %, about 6 % to about 13 %, about 6 % to about 14 %, about 6 % to about 15 %, about 6 % to about 16 %, about 6 % to about 17 %, about 6 % to about 18 %, about6 % to about 19 %, about 6 % to about 20 %, about 7 % to about 8 %, about 7 % to about 9 %, about 7 % to about 10 %, about 7 % to about 11 %, about 7 % to about 12 %, about 7 % to about13 %, about 7 % to about 14 %, about 7 % to about 15 %, about 7 % to about 16 %, about 7 % to about 17 %, about 7 % to about 18 %, about 7 % to about 19 %, about 7 % to about 20 %, about8 % to about 9 %, about 8 % to about 10 %, about 8 % to about 11 %, about 8 % to about 12 %, about 8 % to about 13 %, about 8 % to about 14 %, about 8 % to about 15 %, about 8 % to about 16 %, about 8 % to about 17 %, about 8 % to about 18 %, about 8 % to about 19 %, about 8 % to about 20 %, about 9 % to about 10 %, about 9 % to about 11 %, about 9 % to about 12 %, about9 % to about 13 %, about 9 % to about 14 %, about 9 % to about 15 %, about 9 % to about 16 %, about 9 % to about 17 %, about 9 % to about 18 %, about 9 % to about 19 %, about 9 % to about 20 %, about 10 % to about 11 %, about 10 % to about 12 %, about 10 % to about 13 %, about 10 % to about 14 %, about 10 % to about 15 %, about 10 % to about 16 %, about 10 % to about 17%, about 10 % to about 18 %, about 10 % to about 19 %, about 10 % to about 20 %, about 11 % to about 12 %, about 11 % to about 13 %, about 11 % to about 14 %, about 11 % to about 15 %, about 11 % to about 16 %, about 11 % to about 17 %, about 11 % to about 18 %, about 11 % to about 19 %, about 11 % to about 20 %, about 12 % to about 13 %, about 12 % to about 14 %, about 12 % to about 15 %, about 12 % to about 16 %, about 12 % to about 17 %, about 12 % to about 18 %, about 12 % to about 19 %, about 12 % to about 20 %, about 13 % to about 14 %, about 13 % to about 15 %, about 13 % to about 16 %, about 13 % to about 17 %, about 13 % to about 18 %, about 13 % to about 19 %, about 13 % to about 20 %, about 14 % to about 15 %, about 14 % to about 16 %, about 14 % to about 17 %, about 14 % to about 18 %, about 14 % to about 19 %, about 14 % to about 20 %, about 15 % to about 16 %, about 15 % to about 17 %, about 15 % to about 18 %, about 15 % to about 19 %, about 15 % to about 20 %, about 16 % to about 17 %, about 16 % to about 18 %, about 16 % to about 19 %, about 16 % to about 20 %, about 17 % to about 18 %, about 17 % to about 19 %, about 17 % to about 20 %, about 18 % to about 19 %, about 18 % to about 20 %, or about 19 % to about 20 %. In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of about 1 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, about 15 %, about 16 %, about 17 %, about 18 %, about 19 %, or about 20 % (w / w) of the composition. In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of at least about 1 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, about 15 %, about 16 %, about 17 %, about 18 %, about 19 %, or about 20 %. In some embodiments, the fatty amide derived propylene glycol-diammonium phosphate ester is present in an amount of at most about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, about 9 %, about 10 %, about 11 %, about 12 %, about 13 %, about 14 %, about 15 %, about 16 %, about 17 %, about 18 %, about 19 %, or about 20 %.Additional Components
[0238] In some embodiments, the vesicle composition comprises additional components. In some embodiments, these additional components improve one or more properties of the vesicles without dramatically altering the delivery of an anionic polymer material, peptide, or a combination thereof.
[0239] In some embodiments, the vesicle composition further comprises one or more viscosity enhancing agents. In some embodiments, the viscosity enhancing agents thicken the composition for increased stability and / or feel to a user of the vesicle composition. In some embodiments, the viscosity enhancing agents also act as surfactants. In some embodiments, the viscosity enhancingagent comprises one or more of a fatty alcohol, a wax, a fatty ester of glycerol, or any combination thereof. In some embodiments, the fatty alcohol is a C8-C20 fatty alcohol. In some embodiments, the fatty alcohol is cetyl alcohol (e.g., Crodacol C95). In some embodiments, the wax is a naturally occurring or synthetic wax. In some embodiments, the wax is beeswax. In some embodiment, the wax is synthetic beeswax. In some embodiments, the synethetic beeswax is syncrowax™ BB4. In some embodiments, the synthetic beeswax is non-animal derived beeswax. In some embodiments, the non-animal derived beeswax is syncrowax™ SB1. In some embodiments, the wax is jojoba wax. In some instances, the jojoba wax comprises jojoba wax flakes. In some instances, the wax / oil is hydrogenated wax / oil (e.g., hydrogenated jojoba oil). In some instances, the wax / oil is fully hydrogenated. In some embodiments, the fatty ester of glycerol is a monoester. In some embodiments, the monoester is an ester of a C8-C24 fatty acid. In some embodiments, the fatty ester of glycerol is glycerol monostearate.
[0240] In some embodiments, the one or more viscosity enhancing agents are present in an amount of from about 0.1% to about 10% (w / w) of the composition. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.1 % to about 5 %. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.1 % to about 0.3 %, about 0.1 % to about 0.5 %, about 0.1 % to about 1 %, about 0.1 % to about 1 %, about 0.1 % to about 2 %, about 0.1 % to about 3 %, about 0.1 % to about 4 %, about 0.1 % to about 5 %, about 0.3 % to about 0.5 %, about 0.3 % to about 1 %, about 0.3 % to about 1 %, about 0.3 % to about 2 %, about 0.3 % to about 3 %, about 0.3 % to about 4 %, about 0.3 % to about 5 %, about 0.5 % to about 1 %, about 0.5 % to about 1 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 1 % to about 1 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 2 % to about 3 %, about 2 % to about 4 %, about 2 % to about 5 %, about 3 % to about 4 %, about 3 % to about 5 %, or about 4 % to about 5 %. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.1 %, about 0.3 %, about 0.5 %, about 1 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the viscosity enhancing agents are present in an amount of from at least about 0.1 %, about 0.3 %, about 0.5 %, about 1 %, about 1 %, about 2 %, about 3 %, or about 4 %. In some embodiments, the viscosity enhancing agents are present in an amount of from at most about 0.3 %, about 0.5 %, about 1 %, about 1 %, about 2 %, about 3 %, about 4 %, or about 5 %. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.5% to about 10% (w / w) of the composition. In some embodiments, the viscosity enhancing agents are present in an amount of from about 0.5% to about 5%, about 0.5 % to about 5%, about 0.5 % toabout 4%, about 0.5 % to about 3%, or from about 0.5% to about 2% (w / w) of the composition. In some embodiments, the viscosity enhancing agents comprise a fatty alcohol in an amount of up to about 2 %, a wax in an amount of up to about 2%, and a fatty ester of glycerol in an amount of up to about 5 %. In some embodiments, the fatty alcohol is present in an amount of from about 0.1 to about 1.5%. In some embodiments, the fatty alcohol is present in an amount of about 0.4 % (e.g., 0.36 % to about 0.44 %). In some embodiments, the wax (e.g., hydrogenated jojoba oil) is present in an amount of from about 0.1% to about 1%. In some embodiments, the wax is present in an amount of about 0.2 % (e.g., about 0.18 % to about 0.22 %). In some embodiments, the wax is present in an amount of about 0.3% (e.g., about 0.27 % to about 0.33 %). In some embodiments, the fatty ester of glycerol is present in an amount of from about 0.5 % to about 2 %. In some embodiments, the fatty ester of glycerol is present in an amount of about 0.8 % (e.g., 0.72 % to about 0.88 %). In some embodiments, the fatty ester of glycerol is present in an amount of about 0.9%.
[0241] In some embodiments, the vesicle composition further comprises one or more of a thickener, a preservative, a moisturizer, an emollient, a humectant, or any combination thereof. In some embodiments, the vesicle composition further comprises a thickener. In some embodiments, the vesicle composition further comprises a preservative. In some embodiments, the vesicle composition further comprises a moisturizer. In some embodiments, the vesicle composition further comprises an emollient. In some embodiments, the vesicle composition further comprises a humectant. In some embodiments, the vesicle composition further comprises a fragrance (e.g., Mentha piperita). In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.01% to about 0.1%. In some embodiments, the fragrance (e.g., Mentha piperita) is present in an amount of about 0.05%.
[0242] In some embodiments, the vesicle composition further comprises a humectant. In some embodiments, the composition comprises glycerol. In some embodiments, the glycerol is present in an amount of from about 0.5 % to about 25 %, about 0.5 % to about 20%, about 0.5 % to about 15 %, or about 0.5 % to about 10 % (w / w) of the composition. In some embodiments, the glycerol is present in an amount of about 1 % to about 10 %. In some embodiments, the glycerol is present in an amount of about 0.1 % to about 0.5 %, about 0.1 % to about 1 %, about 0.5 % to about 1 %, about 0.5% to about 1.5 %, about 1 % to about 2 %, about 1 % to about 4 %, about 1 % to about 6 %, about 1 % to about 8 %, about 1 % to about 10 %, about 2 % to about 4 %, about 2 % to about 6 %, about 2 % to about 8 %, about 2 % to about 10 %, about 4 % to about 6 %, about 4 % to about 8 %, about 4 % to about 10 %, about 6 % to about 8 %, about 6 % to about 10 %, or about 8 % to about 10 %. In some embodiments, the glycerol is present in an amount of about 0.1%, about 0.5%, about 1 %, about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %.In some embodiments, the glycerol is present in an amount of at least about 0.1%, about 0.5%, about 1 %, about 2 %, about 4 %, about 6 %, or about 8 %. In some embodiments, the glycerol is present in an amount of at most about 1 %, about 2 %, about 4 %, about 6 %, about 8 %, or about 10 %.
[0243] In some embodiments, the vesicle composition further comprises a preservative. In some embodiments, the preservative is a paraben ester. In some embodiments, the preservative is methylparaben or propylparaben, or a combination thereof. In some embodiments, the preservative is a cosmetic preservative, such as Euxyl® PE 9010 or Spectrastat®. In some embodiments, the preservative comprises a phenoxyethanol / ethylhexylglycerin mixture. In some embodiments, the preservative comprises a blend of caprylhydroxamic acid, caprylyl glycol, glycerin, or any combination thereof. In some embodiments, the preservative is present in an amount of up to about 2%, up to about 1.5 %, up to about 1%, up to about 0.9%, up to about 0.8%, up to about 0.7%, up to about 0.6%, up to about 0.5%, up to about 0.4%, up to about 0.3%, up to about 0.2% (w / w) of the composition. In some embodiments, the preservative or each of the components of a preservative is present in an amount of from about 0.1% to about 2%, from about 0.1% to about 1.5%, from about 0.1% to about 1%, from about 0.01% to 0.05%, from about 0.01% to 0.1%, from about 0.05% to 0.1%, or from about 0.05% to 0.5%. In some embodiments, the preservative or each of the components of a preservative is present in an amount of about 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1%, 1.05%, 1.1%, 1.2%, 1.3%, 1.4%, or 1.5%.
[0244] In some embodiments, the composition further comprises material to promote a desirable change in the skin, such as smoothing wrinkles. In some embodiments, the composition comprises one or more carbohydrates or an acceptable salts thereof. In some embodiments, the one or more carbohydrates is a monosaccharide, disaccharide, or polysaccharide. In some embodiments, a carbohydrate or acceptable salt thereof comprises a glucosamine phosphate. In some embodiments, the glucosamine phosphate comprises disodium acetyl glucosamine phosphate, such as acetyl N-Acetyl-a-D-glucosamine 6-phosphate disodium salt (NovHyal™). In some embodiments, a carbohydrate comprises a saccharide isomerate (e.g., Hyanify™). In some embodiments, the one or more carbohydrates or acceptable salts thereof is in a liquid form. In some embodiments, the one or more carbohydrates or acceptable salts thereof is in a gel form. In some embodiments, the one or more carbohydrates or acceptable salts thereof is in a solid form. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of from about 0.001 % to about 1 %. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of from about 0.001% to 0.01%, 0.005%, 0.01%, 0.008%, 0.01%, 0.005% to 0.05%,0.01% to 0.1%, 0.05% to 0.1%, 0.05% to 0.15%, about 0.1 % to about 0.2 %, about 0.1 % to about 0.3 %, about 0.1 % to about 0.4 %, about 0.1 % to about 0.5 %, about 0.1 % to about 0.6 %, about 0.1 % to about 0.7 %, about 0.1 % to about 0.8 %, about 0.1 % to about 0.9 %, about 0.1 % to about 1 %, about 0.2 % to about 0.3 %, about 0.2 % to about 0.4 %, about 0.2 % to about 0.5 %, about 0.2 % to about 0.6 %, about 0.2 % to about 0.7 %, about 0.2 % to about 0.8 %, about 0.2 % to about 0.9 %, about 0.2 % to about 1 %, about 0.3 % to about 0.4 %, about 0.3 % to about 0.5 %, about 0.3 % to about 0.6 %, about 0.3 % to about 0.7 %, about 0.3 % to about 0.8 %, about 0.3 % to about 0.9 %, about 0.3 % to about 1 %, about 0.4 % to about 0.5 %, about 0.4 % to about 0.6 %, about 0.4 % to about 0.7 %, about 0.4 % to about 0.8 %, about 0.4 % to about 0.9 %, about 0.4 % to about 1 %, about 0.5 % to about 0.6 %, about 0.5 % to about 0.7 %, about 0.5 % to about 0.8 %, about 0.5 % to about 0.9 %, about 0.5 % to about 1 %, about 0.6 % to about 0.7 %, about 0.6 % to about 0.8 %, about 0.6 % to about 0.9 %, about 0.6 % to about 1 %, about 0.7 % to about 0.8 %, about 0.7 % to about 0.9 %, about 0.7 % to about 1 %, about 0.8 % to about 0.9 %, about 0.8 % to about 1 %, or about 0.9 % to about 1 %. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of from about 0.1 %, about 0.2 %, about 0.3 %, about 0.4 %, about 0.5 %, about 0.6 %, about 0.7 %, about 0.8 %, about 0.9 %, or about 1 %. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of from at least about 0.1 %, about 0.2 %, about 0.3 %, about 0.4 %, about 0.5 %, about 0.6 %, about 0.7 %, about 0.8 %, or about 0.9 %. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of from at most about 0.2 %, about 0.3 %, about 0.4 %, about 0.5 %, about 0.6 %, about 0.7 %, about 0.8 %, about 0.9 %, or about 1 %. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of about 0.001%, 0.002%, 0.004%, 0.005%, 0.008%, 0.01%, 0.05%, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, 0.8 %, 0.9 %, and 1 %. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of at least about 0.001%, 0.002%, 0.004%, 0.005%, 0.008%, 0.01%, 0.05%, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, 0.8 %, 0.9 %, and 1 %. In some embodiments, the one or more carbohydrates or an acceptable salts thereof is present in the composition in an amount of at most about 0.001%, 0.002%, 0.004%, 0.005%, 0.008%, 0.01%, 0.05%, 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 0.6 %, 0.7 %, 0.8 %, 0.9 %, and 1 %.
[0245] In some embodiments, the composition comprises a polymer of an amino acid. In some embodiments, the polymer of an amino acid comprises a high MW and a low MW polymer of the amino acid. In some embodiments, the polymer of an amino acid comprises polyglutamate. In some cases, the polyglutamate comprises low MW polyglutamate (e.g., Hyfactor™ PGA LM)and / or high MW polyglutamate (e.g., Hyfactor™ PGA HM). In some embodiments, the polymer of the amino acid comprises sodium polyglutamate. In some embodiments, the polymer of an amino acid is present in an amount from about 0.01 % to about 0.2 %. In some embodiments, the polymer of an amino acid is present in an amount from about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the polymer of an amino acid is present in an amount of about 0.01 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the polymer of an amino acid is present in an amount of at least about 0.01 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, the polymer of an amino acid is present in an amount of at most about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %.
[0246] In some embodiments, the composition further comprises collagen. In some cases, the collagen in human collagen. In some cases, the collage is vegan human collagen (e.g., HumaColl21®). In some embodiments, the collagen is in a solid form. In some embodiments, the collagen is in a gel form. In some embodiments, the collagen is in a liquid form. In some embodiments, the collagen in present in an amount from about 0.01 % to about 0.2 %. In some embodiments, the collagen is present in an amount from about 0.01 % to about 0.02 %, about 0.01 % to about 0.03 %, about 0.01 % to about 0.05 %, about 0.01 % to about 0.1 %, about 0.01 % to about 0.15 %, about 0.01 % to about 0.2 %, about 0.02 % to about 0.03 %, about 0.02 % to about 0.05 %, about 0.02 % to about 0.1 %, about 0.02 % to about 0.15 %, about 0.02 % to about 0.2 %, about 0.05 % to about 0.1 %, about 0.05 % to about 0.15 %, about 0.05 % to about 0.2 %, about 0.1 % to about 0.15 %, about 0.1 % to about 0.2 %, or about 0.15 % to about 0.2 %. In some embodiments, the collagen is present in an amount of about 0.01 %, about 0.02 %, about 0.03 %, about 0.04 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %. In some embodiments, the collagen is present in an amount of at least about 0.01 %, about 0.02 %, about 0.03 %, about 0.04 %, about 0.05 %, about 0.1 %, or about 0.15 %. In some embodiments, the collagen is present in an amount of at most about 0.02%, about 0.03 %, about 0.04 %, about 0.05 %, about 0.1 %, about 0.15 %, or about 0.2 %.
[0247] In some embodiments, the composition further comprises material to promote a desirable change in the skin, such as reducing darkness in one or more areas of the skin. In some embodiments, the material comprises one or more biological extracts. In some embodiments, the one or more biological extracts are natural extracts or synthetic extracts. In some embodiments, the one or more biological extracts comprises a carbohydrate. In some embodiments, the carbohydrate comprises fucoidan. Examples of biological extracts comprise, but are not limitedto, an algae extract, a marine extract, a biotechnology extract, or a flower extract (e.g., Seanactiv, Shadownyl Clear, Eyedeline, Eye’fective, or Meiview). In some embodiments, the biological extract comprises Jasminum Sambac (Jasmine) Flower Extract. In some embodiments, the biological extract comprise Crataegus Monogyna Flower Extract.
[0248] In some embodiments, the additional components comprise purified water. In some embodiments, purified water is present in an amount of about 50% to 80% (w / w). In some embodiments, purified water is present in an amount of about 50 % to about 55 %, about 50 % to about 60 %, about 50 % to about 65 %, about 50 % to about 70 %, about 50 % to about 75 %, about 50 % to about 80 %, about 55 % to about 60 %, about 55 % to about 65 %, about 55 % to about 70 %, about 55 % to about 75 %, about 55 % to about 80 %, about 60 % to about 65 %, about 60 % to about 70 %, about 60 % to about 75 %, about 60 % to about 80 %, about 65 % to about 70 %, about 65 % to about 75 %, about 65 % to about 80 %, about 70 % to about 75 %, about 70 % to about 80 %, or about 75 % to about 80 %. In some embodiments, purified water is present in an amount of about 50 %, about 55 %, about 60 %, about 65 %, about 70 %, about 75 %, or about 80 %. In some embodiments, purified water is present in an amount of at least about 50 %, about 55 %, about 60 %, about 65 %, about 70 %, or about 75 %. In some embodiments, purified water is present in an amount of at most about 55 %, about 60 %, about 65 %, about 70 %, about 75 %, or about 80 %.Exemplary Compositions for Delivery of Unmodified Peptides
[0249] Provided below are exemplary compositions for the delivery of one or more peptides. In some embodiments, the one or more peptides are unmodified. In some embodiments, the one or more peptides comprise dipeptides, tripeptides, tetrapeptides, pentapeptides, hexapeptides, heptapeptides, octapeptides, or any combination thereof. In some embodiments, the exemplary compositions deliver one, two, three, four, five, six, seven, or eight peptides. The embodiments below may further comprise other ingredients or components, such as those provided herein. In some embodiment, the other ingredients or components may be an anionic polymer material. In some embodiments, the anionic polymer material may be hyaluronic acid. In some embodiments, the hyaluronic acid may be entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof.
[0250] Peptide Composition 1: In one aspect, provided herein, is a lipid vesicle composition comprising(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids, wherein the vesicle forming lipids are present in an amount of from about 5% to about 20%;(b) an oil-in-water emulsion entrapped in the lipid vesicles, stabilized by one or more surfactants; and(c) one or more peptides in an amount of from about 0.1 mg / mL to about 50 mg / mL entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof, wherein the composition further comprises: a fatty amide derived propylene glycol-diammonium phosphate ester in an amount of from about 1% to about 10%; and a non-ionic surfactant in an amount of from about 0.1% to about 3%.
[0251] In some embodiments, the oil component is present in an amount of from about 2.5% to about 20 %.
[0252] In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL. In some embodiments the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0253] In some embodiments, the one or more peptides of (c) comprises a tetrapeptide, pentapeptide, a hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises at least two, three, four, five, or six peptides each with an amino acid sequence at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of SEQ ID NO: 37.
[0254] In some embodiments, the composition further comprises a fatty acylated amino acid in an amount of from about 0.5 % to about 3%. In some embodiments, the fatty acylated amino acid is monoloauryl lysine.
[0255] In some embodiments, the lipid vesicle composition further comprises viscosity enhancing agents in an amount of from about 0.5% to about 5%. In some embodiments, the viscosity enhancing agents comprise one or more of a fatty alcohol, a wax, a fatty ester of glycerol, or any combination thereof.
[0256] In some embodiments, the non-ionic surfactant comprises a PEG ether of a fatty alcohol.
[0257] Peptide Composition 2: In one aspect, provided herein, is a lipid vesicle composition comprising(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids, wherein the vesicle forming lipids are present in an amount of from about 2% to about 20%;(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants;(c) one or more peptides in an amount of from about 0.1 mg / mL to about 50 mg / mL entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof, wherein the composition further comprises: a PEG fatty acid ester in an amount of from about 0.1% to about 2%; a polysorbate in an amount of from about 0.5 % to about 3%; and a sorbate ester in an amount of from about 0.1% to about 2%.
[0258] In some embodiments, the oil component is present in an amount of from about 2.5% to about 20 %.
[0259] In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL. In some embodiments the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0260] In some embodiments, the one or more peptides of (c) comprises a tetrapeptide, pentapeptide, hexapeptide, or a combination thereof. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises at least two, three, four, five, or six peptides each with an amino acid sequence at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of SEQ ID NO: 37.
[0261] In some embodiments, the lipid vesicle composition further comprises viscosity enhancing agents in an amount of from about 0.5% to about 5%. In some embodiments, the viscosity enhancing agents comprise one or more of a fatty alcohol, a wax, a fatty ester of glycerol, or any combination thereof.
[0262] In some embodiments, the PEG fatty acid ester comprises PEG4-dilaurate. In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the sorbate ester is sorbitan palmitate.
[0263] Peptide Composition 3: In one aspect, provided herein, is a lipid vesicle composition comprising(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids, wherein the vesicle forming lipids are present in an amount of from about 5% to about 20%;(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants;(c) one or more peptides in an amount of from about 0.1 mg / mL to about 50 mg / mL entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof, wherein the composition further comprises: and a fatty amide derived propylene glycol-diammonium phosphate ester in an amount of from about 1% to about 10%; a PEG ether of a fatty alcohol in an amount of from about 0.1% to about 3%; a polysorbate in an amount of from about 0.5 % to about 3%; and a sorbate ester in an amount of from about 0.1% to about 2%.
[0264] In some embodiments, the oil component is present in an amount of from about 2.5% to about 20 %.
[0265] In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL to about 0.5 mg / mL, about 0.1 mg / mL to about 1 mg / mL, about 0.1 mg / mL to about 2 mg / mL, about 0.1 mg / mL to about 3 mg / mL, about 0.1 mg / mL to about 4 mg / mL, about 0.1 mg / mL to about 5 mg / mL, about 0.1 mg / mL to about 10 mg / mL, about 0.1 mg / mL to about 20 mg / mL, about 0.1 mg / mL to about 50 mg / mL. In some embodiments the lipid vesicle composition comprises one or more peptides in an amount of about 0.1 mg / mL, about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 10 mg / mL, about 20 mg / mL, or about 50 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in an amount of about 1 mg / mL, about 2 mg / mL, about 3 mg / mL, about 4 mg / mL, or about 5 mg / mL.
[0266] In some embodiments, the one or more peptides of (c) comprises a tetrapeptide, pentapeptide, hexapeptide, or any combination thereof. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises at least two, three, four, five, or six peptides each with an amino acid sequence at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of SEQ ID NO: 37.
[0267] In some embodiments, the lipid vesicle composition further comprises viscosity enhancing agents in an amount of from about 0.5% to about 5%. In some embodiments, the viscosity enhancing agents comprise one or more of a fatty alcohol, a wax, a fatty ester of glycerol, or any combination thereof.
[0268] In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the sorbate ester is sorbitan palmitate. In some embodiments, the PEG ether of the fatty alcohol is diethylene glycol monooleyl ether.
[0269] Peptide Composition 4 In one aspect, provided herein, is a lipid vesicle composition comprising:(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids, wherein the vesicle forming lipids are present in an amount of from about 5% to about 20%;(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants;(c) one or more peptides in an amount of from about 0.001 % to about 0.05 % entrapped in the lipid bilayer, the oil-in-water emulsion, or a combination thereof, wherein the composition further comprises: a fatty amide derived propylene glycol-diammonium phosphate ester in an amount of from about 1% to about 20%; a PEG ether of a fatty alcohol in an amount of from about 0.5% to about 2%; a polysorbate in an amount of from about 0.4 % to about 1%; and a glyceryl stearate in an amount of from about 0.5% to about 2%.
[0270] In some embodiments, the lipid vesicle composition comprises one or more peptides each of the one or more peptides in an amount of about 0.001 mg / mL, about 0.005 mg / mL, about 0.01 mg / mL, about 0.02 mg / mL, about 0.05 mg / mL, about 0.08 mg / mL, or about 0.1 mg / mL. In some embodiments, the lipid vesicle composition comprises one or more peptides in total in an amount of about 0.001 mg / mL, about 0.005 mg / mL, about 0.01 mg / mL, about 0.02 mg / mL, about 0.05 mg / mL, about 0.08 mg / mL, about 0.1 mg / mL, about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, or about 0.5 mg / mL.
[0271] In some embodiments, the one or more peptides of (c) comprise tetrapeptides, pentapeptides, hexapeptides, or any combination thereof. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises at least two, three, four, five, or six peptides each with an amino acid sequence at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 1-51. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 21-40. In some embodiments, the one or more peptides comprises at least two, three, four, five, or six peptides each with an amino acid sequence at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 21-40. In some embodiments, the one or more peptides comprises an aminoacid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of any one of SEQ ID NO: 21, 24, 31, 36, 37, 39, or 40. In some embodiments, the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of SEQ ID NO: 37. In some embodiments, the one or more peptides comprises an amino acid sequence identical to the amino acids of SEQ ID NO: 37. In some embodiments, the lipid vesicle composition comprises one, two, three, four, five, or six peptides with amino acid sequences of any one of SEQ ID NO: 21-40.
[0272] In some embodiments, the lipid vesicle composition further comprises viscosity enhancing agents in an amount of from about 0.5% to about 10%. In some embodiments, the viscosity enhancing agents comprise one or more of a fatty alcohol, a wax, a fatty ester of glycerol, or any combination thereof.
[0273] In some embodiments, the polysorbate is polysorbate 80. In some embodiments, the glyceryl stearate is a glyceryl monostearate. In some embodiments, the PEG ether of the fatty alcohol is diethylene glycol monooleyl ether.Methods of Use of Lipid Vesicle Compositions Provided Herein
[0274] The lipid vesicle compositions provided herein are contemplated for cosmetic uses in a subject, for indications including but not limited to the prevention or temporary improvement of the appearance of one or more of: skin wrinkles; skin laxity; moderate to severe glabellar lines associated with corrugator and / or procerus muscle activity; moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow’s feet lines); and moderate to severe forehead lines associated with frontalis muscle activity.
[0275] The lipid vesicle compositions provided herein are contemplated for pharmaceutical use in a subject, for indications including but not limited to: prevention or temporary improvement of the appearance of one or more of skin wrinkles, e.g., in the face, skin laxity, moderate to severe glabellar lines associated with corrugator and / or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow’s feet lines), and moderate to severe forehead lines associated with frontalis muscle activity.
[0276] In some embodiments, the subject is a mammal. In specific embodiments, the mammal is a human. In some embodiments, the human subject is a pediatric or adult subject, of any age.
[0277] Methods for Using Cosmetic or Pharmaceutical Compositions
[0278] The present disclosure also relates to methods for using cosmetic or pharmaceutical compositions comprising one or more peptides or an anionic polymer material such as hyaluronic acid. In some embodiments, the disclosure relates to methods for using the cosmetic or pharmaceutical composition to prevent or temporarily improve the appearance in a subject of one or more of skin wrinkles, e.g., in the face or neck, skin laxity, moderate to severe glabellar lines associated with corrugator and / or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow’s feet lines), and moderate to severe forehead lines associated with frontalis muscle activity, comprising applying an effective amount of the cosmetic or pharmaceutical composition to the skin of the subject.
[0279] In some embodiments, the lipid vesicle composition is topically applied to a subject. Topical application as referred to herein can refer to application onto one or more surface, e.g., keratinous tissue. In some embodiments, the topical composition is applied to the skin of a subject. In some embodiments, the skin is the facial skin of the subject. In some embodiments, the skin comprises the neck of the subject. In some embodiments, the skin comprises the skin around the eyes of the subject. Topical application may relate to direct application to the desired area. A topical cosmetic or pharmaceutical composition or preparation can be applied by, e.g., pouring, dropping, or spraying, when present as a liquid or aerosol composition; smoothing, rubbing, spreading, and the like, when in ointment, lotion, cream, gel, or a like composition; dusting, when a powder; or by any other appropriate means.
[0280] In some embodiments, the lipid vesicle composition is formulated in a form suitable for topical administration. In some embodiments, the lipid vesicle composition is formulated as a cream, a lotion, a suspension, or an emulsion. In some embodiments, the lipid vesicle composition is formulated as a cream. In some embodiments, the lipid vesicle composition is formulated as a lotion. In some embodiments, the lipid vesicle composition is formulated as a suspension.
[0281] In some embodiments, topical composition is applied to a subject or the skin of the subject with an effective amount of the lipid vesicle composition one or more times, e.g., 1-3 times per day, 1-21 times per week, 1 time per day, 2 times per day, or 3 times per day. In some embodiments, the topical composition is applied to a subject or the skin of the subject with an effective amount of the lipid vesicle composition about 1 time per week to about 12 times per week. In some embodiments, the topical composition is applied to a subject or the skin of the subject with an effective amount of the lipid vesicle composition at least about 1 time per week. In some embodiments, the topical composition is applied to a subject or the skin of the subject with an effective amount of the lipid vesicle composition at most about 12 times per week. In some embodiments, the topical composition is applied to a subject or the skin of the subject withan effective amount of the lipid vesicle composition about 1 time per week to about 2 times per week, about 1 time per week to about 3 times per week, about 1 time per week to about 4 times per week, about 1 time per week to about 5 times per week, about 1 time per week to about 6 times per week, about 1 time per week to about 7 times per week, about 1 time per week to about 8 times per week, about 1 time per week to about 9 times per week, about 1 time per week to about 10 times per week, about 1 time per week to about 11 times per week, about 1 time per week to about 12 times per week, about 2 times per week to about 3 times per week, about 2 times per week to about 4 times per week, about 2 times per week to about 5 times per week, about 2 times per week to about 6 times per week, about 2 times per week to about 7 times per week, about 2 times per week to about 8 times per week, about 2 times per week to about 9 times per week, about 2 times per week to about 10 times per week, about 2 times per week to about 11 times per week, about 2 times per week to about 12 times per week, about 3 times per week to about 4 times per week, about 3 times per week to about 5 times per week, about 3 times per week to about 6 times per week, about 3 times per week to about 7 times per week, about 3 times per week to about 8 times per week, about 3 times per week to about 9 times per week, about 3 times per week to about 10 times per week, about 3 times per week to about 11 times per week, about 3 times per week to about 12 times per week, about 4 times per week to about 5 times per week, about 4 times per week to about 6 times per week, about 4 times per week to about 7 times per week, about 4 times per week to about 8 times per week, about 4 times per week to about 9 times per week, about 4 times per week to about 10 times per week, about 4 times per week to about 11 times per week, about 4 times per week to about 12 times per week, about 5 times per week to about 6 times per week, about 5 times per week to about 7 times per week, about 5 times per week to about 8 times per week, about 5 times per week to about 9 times per week, about 5 times per week to about 10 times per week, about 5 times per week to about 11 times per week, about 5 times per week to about 12 times per week, about 6 times per week to about 7 times per week, about 6 times per week to about 8 times per week, about 6 times per week to about 9 times per week, about 6 times per week to about 10 times per week, about 6 times per week to about 11 times per week, about 6 times per week to about 12 times per week, about 7 times per week to about 8 times per week, about 7 times per week to about 9 times per week, about 7 times per week to about 10 times per week, about 7 times per week to about 11 times per week, about 7 times per week to about 12 times per week, about 8 times per week to about 9 times per week, about 8 times per week to about 10 times per week, about 8 times per week to about 11 times per week, about 8 times per week to about 12 times per week, about 9 times per week to about 10 times per week, about 9 times per week to about 11 times per week, about 9 times per week to about 12 times per week, about 10 times per week to about 11 times per week, about 10 times perweek to about 12 times per week, or about 11 times per week to about 12 times per week. In some embodiments, the topical composition is applied to a subject or the skin of the subject with an effective amount of the lipid vesicle composition about 1 time per week, about 2 times per week, about 3 times per week, about 4 times per week, about 5 times per week, about 6 times per week, about 7 times per week, about 8 times per week, about 9 times per week, about 10 times per week, about 11 times per week, about 12 times per week, about 13 times per week, or about 14 times per week.
[0282] In some embodiments, one or more layers of a lipid vesicle composition of the disclosure is applied to the skin of the subject at a given time. In some embodiments, a subsequent layer may be applied after a previous layer of the lipid vesicle composition is fully absorbed into the skin of the subject. In some embodiments, the lipid vesicle composition may take a couple of seconds (e.g., one second, two seconds, three second, five seconds, ten seconds, fifteen seconds, thirty seconds, etc.) to fully absorb into the skin of the subject. In some embodiments, one, two, three, four, five, six, or seven layers of the lipid vesicle composition is applied to the skin of the subject at a given time. In some embodiments, the lipid vesicle composition is applied to the skin of the subject one or more times a day (e.g., 1-3 times per day, 1 time per day, 2 times per day, 3 times per day, etc.). In some embodiments, the lipid vesicle composition is applied to the skin of the subject one or more times a week (e.g., 1-21 times per week, 1-14 times per week, 1-7 times per week, etc.). In some embodiments, the lipid vesicle composition is applied to the skin of the subject daily. In some embodiments, one or more layers of the lipid vesicle composition is applied to the skin of the subject once a day for one or more days. In some embodiments, two or more layers of the lipid vesicle composition is applied to the skin of the subject once a day for one or more days. In some embodiments, three or more layers of the lipid vesicle composition is applied to the skin of the subject once a day for one or more days. In some embodiments, one or more layers of the lipid vesicle composition is applied to the skin of the subject twice a day for one or more days. In some embodiments, two or more layers of the lipid vesicle composition is applied to the skin of the subject twice a day for one or more days. In some embodiments, three or more layers of the lipid vesicle composition is applied to the skin of the subject twice a day for one or more days. In some embodiments, the lipid vesicle composition is applied to the skin of the subject for at least one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, two months, three months, six months, one year. In some embodiments, the lipid vesicle composition is applied to the skin of the subject for more than one day, two days, three days, four days, five days, six days, one week, two weeks, three weeks, one month, two months, three months, six months, nine months, or one year. In some embodiments, one or more layers of the lipid vesicle composition is applied to the skin of the subject twice aday for several days, and thereafter is applied three times a day. In some embodiments, five layers of the lipid vesicle composition is applied to the skin of the subject twice a day for five days (e.g., morning and night), and thereafter one to three layers of the lipid vesicle composition is applied to the skin of the subject three times a day (e.g., morning, noon and night).
[0283] In some embodiments, a lipid vesicle composition of the disclosure is applied to the skin of a subject, for indications including but not limited to: prevention or temporary improvement of the appearance of the skin, including, but not limited to, one or more of skin wrinkles on the face or the neck, e.g., skin laxity, moderate to severe glabellar lines associated with corrugator and / or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow’s feet lines), and moderate to severe forehead lines associated with frontalis muscle activity.
[0284] In some embodiments, a lipid vesicle composition of the disclosure is applied to a subject, for indications including but not limited to: temporary improvement of the appearance of the skin of the face. In some embodiments, a lipid vesicle composition of the disclosure is used with other skincare products, including, but not limited to sunscreen, moisturizers, face creams (e.g., BB cream, CC cream, night cream, etc.), mists, foundations, concealers, highlighters, primers, etc.
[0285] In some embodiments, a topical composition of the disclosure is self-applied by a subject. In some embodiments, a topical composition of the disclosure is not self-applied by a subject. In some embodiments, the topical composition is a topical cosmetic composition.Methods of Making Lipid Vesicle Compositions Provided Herein
[0286] Also provided herein are method of making lipid vesicle compositions. In some embodiments, compositions of the disclosure as describe...
Claims
CLAIMSWHAT IS CLAIMED IS:
1. A lipid vesicle composition comprising:(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids,(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants, wherein the oil-in-water emulsion comprises one or more viscosity enhancing agents, wherein the one or more viscosity enhancing agents comprises a fully hydrogenated oil; wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof comprises one or more peptides, wherein the one or more peptides comprises an amino acid sequence:Xaa 1 -Xaa2-Xaa3 -Xaa4-Xaa5 -Xaa6-Xaa7 -Xaa8 wherein:Xaal is absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Gly, Lys, Pro, Tyr, or Vai;Xaa2 is absent or selected from: Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, or Vai;Xaa3 is absent or selected from: Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, or Vai;Xaa4 is absent or selected from: Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Vai;Xaa5 is absent or selected from: Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Vai;Xaa6 is absent or selected from: Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Vai and a derivative of Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Vai;Xaa7 is selected from: Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Vai;Xaa8 is selected from: Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Vai and a derivative of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Vai.
2. A lipid vesicle composition comprising:(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids,(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants, wherein the oil-in-water emulsion comprises one or more viscosity enhancing agents, wherein the one or more viscosity enhancing agents comprises a fully hydrogenated oil; wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof comprises one or more peptides, wherein the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to any one of SEQ ID NOs: 1-51.
3. A lipid vesicle composition comprising:(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids,(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants, wherein the oil-in-water emulsion comprises a biological extract composition in an amount of about 0.01 % to about 3 %; wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof comprises one or more peptides, wherein the one or more peptides comprises an amino acid sequence:Xaa 1 -Xaa2-Xaa3 -Xaa4-Xaa5 -Xaa6-Xaa7 -Xaa8 wherein:Xaal is absent or selected from Ala, Arg, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Gly, Lys, Pro, Tyr, or Vai;Xaa2 is absent or selected from: Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Cys, Gly, He, Lys, Pro, Tyr, or Vai;Xaa3 is absent or selected from: Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Phe, Pro, Tyr, or Vai;Xaa4 is absent or selected from: Ala, Arg, Glu, Gly, Lys, Pro, Tyr, Vai and a derivative of Ala, Arg, Glu, Gly, Lys, Pro, Tyr, or Vai;Xaa5 is absent or selected from: Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Gin, Gly, Lys, Leu, Met, Pro, Thr, Tyr, or Vai;Xaa6 is absent or selected from: Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, Vai and a derivative of Ala, Arg, Asp, Gin, Gly, His, Lys, Phe, Pro, Ser, Thr, Tyr, or Vai;Xaa7 is selected from: Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, Vai and a derivative of Ala, Arg, Asn, Asp, Cys, Gly, His, Lys, Phe, Pro, Thr, Tyr, or Vai;Xaa8 is selected from: Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, Vai and a derivative of Ala, Arg, Cys, Glu, Gly, His, Lys, Phe, Pro, Ser, Thr, Trp, Tyr, or Vai.
4. A lipid vesicle composition comprising:(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids,(b) an oil-in-water emulsion entrapped in the lipid vesicles, and stabilized by one or more surfactants, wherein the oil-in-water emulsion comprises a biological extract composition in an amount of about 0.01 % to about 3 %; wherein the lipid bilayer, the oil-in-water emulsion, or a combination thereof comprises one or more peptides, wherein the one or more peptides comprises an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to any one of SEQ ID NOs: 1-51.
5. The lipid vesicle composition of any one of claims 1-4, wherein the one or more peptides are entrapped in the lipid bilayer, the oil-in-water emulsion, or in the combination thereof.
6. The lipid vesicle composition of any one of claim 1-5, wherein the one or more peptides are unmodified.
7. The lipid vesicle composition of any one of claim 1-6, wherein the one or more peptides are present at a concentration of from about 0.001 mg / mL to about 10 mg / mL.
8. The lipid vesicle composition of any one of claim 1-7, wherein the one or more peptides comprises a tetrapeptide, a pentapeptide, a hexapeptide, or a combination thereof.
9. The lipid vesicle composition of claim 1 or 3, wherein the one or more peptides comprise an amino acid sequence at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% sequence homology to the amino acid sequence of any one of SEQ ID NOs: 1-51.
10. The lipid vesicle composition of any one of claim 1-9, wherein the one or more peptides comprise an amino acid sequence identical to the amino acid sequence of any one of SEQ ID NOs: 1-51.
11. The lipid vesicle composition of any one of claim 1-10, wherein one or more peptides have an amino acid sequence consisting of an identical sequence to the amino acid sequence of any one of SEQ ID NO s: 1-51.
12. The lipid vesicle composition of any one of claim 1-11, wherein the one or more peptides have an amino acid sequence consisting of an identical sequence to the amino acid sequence of SEQ ID NO: 31, 36, or 37.
13. The lipid vesicle composition of any one of claim 1-12, wherein the one or more peptides have an amino acid sequence consisting of an identical sequence to the amino acid sequence of SEQ ID NO: 31.
14. The lipid vesicle composition of any one of claim 1-13, wherein the one or more peptides have an amino acid sequence consisting of an identical sequence to the amino acid sequence of SEQ ID NO: 36.
15. The lipid vesicle composition of any one of claim 1-14, wherein the one or more peptides have an amino acid sequence consisting of an identical sequence to the amino acid sequence of SEQ ID NO: 37.
16. The lipid vesicle composition of any one of claims 1-15, wherein the lipid bilayer, the oil- in-water emulsion, or the combination thereof further comprises an anionic polymer material.
17. The lipid vesicle composition of any one of claim 1-16, wherein the anionic polymer material is entrapped in the lipid bilayer, the oil-in-water emulsion, or in a combination thereof.
18. The lipid vesicle composition of any one of claim 1-16, wherein the anionic polymer material comprises an anionic polysaccharide.
19. The lipid vesicle composition of any one of claim 1-16, wherein the anionic polymer is present in an amount of about 0.05 mg / mL to about 10 mg / mL of the composition.
20. The lipid vesicle composition of any one of claim 1-16 , wherein the anionic polysaccharide comprises hyaluronic acid, or a salt thereof.
21. The lipid vesicle composition of any one of claims 16-20, wherein the anionic polymer material has a molecular weight of from about 5kDa to about 500 kDa.
22. The lipid vesicle composition of any one of claims 16-21 , wherein the anionic polymer material comprises a first and a second anionic polymer material, each anionic polymer material having a different molecular weight.
23. The lipid vesicle composition of claim 22, wherein the first and the second anionic polymer material are the same material.
24. The lipid vesicle composition of claim 22 or 23, wherein the first anionic polymer material has a molecular weight of up to about 75 kDa and the second anionic polymer material has a molecule weight of greater than about 75 kDa.
25. The lipid vesicle composition of any one of claim 22-24, wherein the first anionic polymer material has a molecular weight of from about 5 kDa to about 50 kDa, and wherein the second anionic polymer material has a molecular weight of from about 100 kDa to about 500 kDa.
26. The lipid vesicle composition of any one of claims 22-25, wherein the vesicle forming lipids comprise phospholipids, glycolipids, lecithins, ceramides, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, cerebroside, or any combination thereof.
27. The lipid vesicle composition of any one of claims 1-26 , wherein the vesicle forming lipids comprise phospholipids.
28. The lipid vesicle composition of any one of claims 1-27, wherein the composition comprises vesicle forming lipids in an amount of from about 0.5 % to about 25 % (w / w) of the composition.
29. The lipid vesicle composition of any one of claims 1-28, wherein the oil-in-water emulsion comprises a triglyceride in the oil component.
30. The lipid vesicle composition of claim 29, wherein the triglyceride comprises a mediumchain triglyceride.
31. The lipid vesicle composition of claim 29 or 30, wherein the triglyceride is present in an amount of from about 1 % to about 35 % (w / w) of the composition.
32. The lipid vesicle composition of any one of claims 1-31, wherein the composition comprises a sterol.
33. The lipid vesicle composition of claim 32, wherein the sterol is present in an amount of from about 1 % to about 5 % (w / w) of the composition.
34. The lipid vesicle composition of any one of claims 1-33, wherein the composition comprises propylene glycol.
35. The lipid vesicle composition of claim 34, wherein the propylene glycol is present in an amount of from about 1 % to about 25 % (w / w) of the composition.
36. The lipid vesicle composition of claims 3 or 4, wherein the oil-in-water emulsion comprises one or more viscosity enhancing agents, wherein the one or more viscosity enhancing agents comprises a fully hydrogenated oil.
37. The lipid vesicle composition of any one of claims 1-36, wherein the fully hydrogenated oil comprises jojoba wax.
38. The lipid vesicle composition of any one of claims 1-37, wherein the one or more viscosity enhancing agents are present in an amount of from about 0.1 % to about 10 % (w / w) of the composition.
39. The lipid vesicle composition of any one of claims 1-38, further comprising one or more penetration enhancing agents.
40. The lipid vesicle composition of claim 39, wherein the one or more penetration enhancing agents comprises a non-ionic surfactant or a combination of non-ionic surfactants.
41. The lipid vesicle composition of claim 40, wherein the non-ionic surfactant or a combination of non-ionic surfactants is selected from polyethylene glycol ethers of fatty alcohols, sorbitan esters, polysorbates, sorbitan esters and polyethylene glycol fatty acid esters and combinations thereof.
42. The lipid vesicle composition of claim 41, wherein the polyethylene glycol ethers of fatty alcohols comprise a C8-C22 fatty alcohol and a polyethylene glycol group having from about 2 to about 8 ethylene glycol subunits.
43. The lipid vesicle composition of claim 41 or 42, wherein the polyethylene glycol ethers of fatty alcohols comprise diethylene glycol hexadecyl ether, 2-(2-octadecoxyethoxy)ethanol, diethylene glycol monooleyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene (3) oleyl ether, or polyoxyethylene (5) oleyl ether, or any combination thereof.
44. The lipid vesicle composition of any one of claims 41-43, wherein the sorbitan esters comprise sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, or sorbitan isostearate, or any combinations thereof.
45. The lipid vesicle composition of any one of claims 41-44, wherein the polyethylene glycol fatty acid ester comprises PEG-8 dilaurate, PEG-4 dilaurate, PEG-4 laurate, PEG-8 dioleate, PEG-8 distearate, PEG-8 distearate, PEG-7 glyceryl cocoate, and PEG-20 almond glycerides, or any combination thereof.
46. The lipid vesicle composition of any one of claims 41-45, wherein the polysorbate comprises polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 85, or any combination thereof.
47. The lipid vesicle composition of any one of claims 40-46, wherein the non-ionic surfactant or a combination of non-ionic surfactants has a hydrophobic-lipophilic balance (HLB) of about 10 or less.
48. The lipid vesicle composition of any one of claims 40-46, wherein the non-ionic surfactant or a combination of non-ionic surfactants is present in an amount of from about 0.5 % to about to about 10 % (w / w) of the composition.
49. The lipid vesicle composition of any one of claims 40-48, wherein at least one non-ionic surfactant is present in the oil-in-water emulsion.
50. The lipid vesicle composition of any one of claims 40-49, wherein at least one non-ionic surfactant is present in the lipid bilayer.
51. The lipid vesicle composition of any one of claims 40-50, wherein the one or more penetration enhancing agents comprises a combination of a sorbitan ester, a polysorbate, and a polyethylene glycol fatty acid esters.
52. The lipid vesicle composition of any one of claims 39-50, wherein the one or more penetration enhancing agents comprises a combination of a polyethylene glycol ether of a fatty alcohol, a sorbitan esters, and a polysorbate.
53. The lipid vesicle composition of any one of claims 39-50, wherein the one or more penetration enhancing agents comprises monolauroyllysine or dipalmitoyllysine, or a combination thereof.
54. The lipid vesicle composition of any one of claims 1-53, wherein the composition comprises a cationic surfactant.
55. The lipid vesicle composition of claim 54, wherein the cationic surfactant is a monocationic surfactant.
56. The lipid vesicle composition of claim 54 or 55, wherein the cationic surfactant comprises a fatty amide derived propylene glycol-diammonium phosphate ester.
57. The lipid vesicle composition of any one of claims 54-56, wherein the cationic surfactant is present in an amount of from about 1 % to about 20 % (w / w) of the composition.
58. The lipid vesicle composition of any one of claims 54-56, wherein the cationic surfactant is present in an amount of from about 1 % to about 10 % (w / w) of the composition.
59. The lipid vesicle composition of claim 54, wherein the cationic penetration enhancing agent comprises a di -cationic penetration enhancing agent.
60. The lipid vesicle composition of claim 59, wherein the di-cationic penetration enhancing agent is a gemini cationic surfactant.
61. The lipid vesicle composition of claim 59 or 60, wherein the cationic penetration agent comprises a cationic polymer.
62. The lipid vesicle composition of any one of claims 59-61, wherein the cationic penetration enhancing agent is present in an amount of from about 0.01 % to about 1 % (w / w) of the composition.
63. The lipid vesicle composition of any one of claims 39-62, wherein the penetration enhancing agent comprises a salicylate ester or a nicotinate ester.
64. The lipid vesicle composition of claim 63, wherein the ester is a Ci-Ce alkyl ester or a benzyl ester.
65. The lipid vesicle composition of claim 63 or 64, wherein the penetration enhancing agent comprises methyl salicylate or benzyl nicotinate.
66. The lipid vesicle composition of claim 1 or 2, further comprising a biological extract composition.
67. The lipid vesicle composition of any one of claims 1-66, wherein the biological extract composition is present in an amount of from about 0.01 % to about 3 % (w / w).
68. The lipid vesicle composition of any one of claims 1-67, wherein the biological extract composition comprises a flower extract.
69. The lipid vesicle composition of claim 68, wherein the flower extract is present in an amount of at most 0.1 % (w / w).
70. The lipid vesicle composition of any one of claims 1-65, further comprising one or more additional agents.
71. The lipid vesicle composition of claim 66, wherein the additional agents comprise one or more of a thickener, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial, , or any combination thereof.
72. The lipid vesicle composition of any one of claims 1-71, wherein the composition is formulated for topical application to the skin of a subject.
73. The lipid vesicle composition of any one of claims 1-72, wherein the composition is formulated to deliver the anionic polymer to a specified layer of the skin of a subject.
74. The lipid vesicle composition of any one of claims 1-73, wherein the composition if formulated to deliver the one or more peptides to a specified layer of the skin of a subject.
75. The lipid vesicle composition of any one of claims 1-74, wherein the composition is formulated as a cream, a lotion, a suspension, or an emulsion.
76. A method of preparing a lipid vesicle composition of any one of claims 1-75, comprising a) preparing an oil-in-water emulsion comprising the one or more peptides by mixing oil components of the oil-in-water emulsion with aqueous components of the oil-in-water emulsion, wherein the oil components and / or the aqueous components of the oil-in-water emulsion comprises the one or more surfactants; b) solubilizing vesicle forming lipids in an acceptable solvent other than water; c) adding the oil-in-water emulsion to the solubilized vesicle forming lipids; and d) mixing the oil-in-water emulsion and the solubilized vesicle forming lipids under mixing conditions effective to form the lipid vesicles comprising a lipid bilayer comprising vesicle forming lipids, and an oil-in-water emulsion entrapped in the lipid vesicles.
77. A method of claim 76, wherein (a) further comprises the anionic polymer material.
78. A method of producing one or more cosmetic effects by delivering a cosmetic agent below a skin surface of a subject, comprising applying to the skin surface a lipid vesicle composition according to any one of claims 1-77.
79. The method of claim 78, wherein the cosmetic agent is the anionic polymer material.
80. The method of claim 78 or 79, wherein the cosmetic agent is delivered to the dermis of the subject.
81. The method of claim 78, wherein the cosmetic agent is the one or more peptides.
82. The method of claim 81, wherein the one or more cosmetic effect comprises prevention or temporary improvement of the appearance of one or more of skin wrinkles.
83. The method of claim 82, wherein the one or more skin wrinkles comprises moderate to severe glabellar lines associated with corrugator and / or procerus muscle activity, moderate to severe lateral canthal lines associated with orbicularis oculi activity (crow’s feet lines), or moderate to severe forehead lines associated with frontalis muscle activity.
84. A composition comprising a peptide comprising an amino acid sequence of SEQ ID NO: 37.
85. The composition of claim 84, further comprising one or more additional agents.
86. The composition of claim 85, wherein the one or more additional agents comprise one or more of a thickener, a preservative, a moisturizer, an emollient, a humectant, an antimicrobial, a biological extract composition, a viscosity enhancing agent, or any combination thereof.
87. The composition of claim 86, wherein the biological extract composition is present in an amount of from about 0.01 % to about 3 % (w / w).
88. The composition of claim 87, wherein the biological extract composition comprises a flower extract.
89. The composition of claim 88, wherein the flower extract is present in an amount of at most 0.1 % (w / w).
90. The composition of any one of claims 86-89, wherein the one or more viscosity enhancing agents comprises a fully hydrogenated oil.
91. The composition of claim 90, wherein the fully hydrogenated oil comprises jojoba wax.
92. The composition of any one of claims 86-91, wherein the one or more viscosity enhancing agents is present in an amount of from about 0.1 % to about 10 % (w / w) of the composition.
93. The composition of any one of claim 85 to 92, wherein the one or more additional agents comprises an anionic polymer material.
94. The composition of any one of claims 84 to 93, wherein the composition is formulated to deliver the one or more peptides to a specified layer of the skin of a subject.
95. The composition of any one of claims 84 to 94, wherein the composition is formulated for topical application to the skin of a subject.
96. The composition of any one of claims 84 to 95, wherein the composition is formulated as a cream, a lotion, a suspension, or an emulsion.
Citation Information
Patent Citations
Nano-soft-sensitive detoxifying cream
CN107137319A
Anti-wrinkle repair type eye cream and preparation method thereof
CN112206184A
Hyaluronic acid composition, liposome and preparation method and application thereof
CN114288413A
A cosmetic or dermatological composition comprising a combination of honey and a peptide.
DE102011001150A1
Compounds useful in the treatment and / or care of the skin and their cosmetic or pharmaceutical compositions
EP2792684A1
